Innovent
信达生物制药

環境、社會及管治報告 · 2025

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Innovent Biologics, Inc. 信達生物製藥 | Stock Code 股份代號：1801

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司)

CONTENTS

About This Report

Overview

This Report is the eighth Environmental, Social and Governance ("ESG") report ("ESG Report" or "Report") issued by Innovent Biologics, Inc. ("Innovent", "the Company", "we" or "us"), which focuses on the disclosure of information on the environmental, social and governance performance of the Company for the period from 1 January 2025 to 31 December 2025 (the "Reporting Period"), with some content tracing back to earlier years or extending into 2026 to ensure the completeness of information.

Basis of Preparation

This Report has been prepared in accordance with the Appendix C2 "Environmental, Social and Governance Reporting Code" of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Stock Exchange" or the "HKEX"), the Implementation Guidelines for Climate Disclosures under the HKEX ESG reporting framework. Also, this Report has been prepared with reference to the GRI Sustainability Reporting Standards (GRI Standards), the relevant disclosure requirements of the Sustainability Accounting Standards Board (SASB), and Morgan Stanley Capital International ("MSCI") ESG Ratings.

This Report was prepared according to relevant procedures, including: identifying and prioritizing important stakeholders and major ESG issues, formulating the ESG Report's coverage, collecting relevant materials and data, preparing the Report based on up-to-date information and examining report data, for the purpose of ensuring the integrity, substance, authenticity and balance of the report's contents.

Reporting Scope and Boundaries

The scope and boundaries of this Report is consistent with the annual report. The entities included in the scope of this Report include Innovent Biologics (Suzhou) Co., Ltd. (信達生物製藥(蘇州)有限公司), Innovent Biologics Technology (Suzhou) Co., Ltd. (蘇州信達生物科技有限公司), Jiangsu Zhongxu Biopharmaceuticals Co., Ltd. (江蘇眾煦醫藥有限公司), Innovent Biologics Technology Co., Ltd. (信達生物科技有限公司), Innovent Cells Pharmaceuticals (Suzhou) Co., Ltd. (信達細胞製藥(蘇州)有限公司), Innovent Biologics (Hangzhou) Co., Ltd. (信達生物製藥(杭州)有限公司), Altruist Biotechnology (Hangzhou) Co., Ltd. (夏爾巴生物技術(杭州)有限公司), Altruist Biotechnology (Suzhou) Co., Ltd. (夏爾巴生物技術(蘇州)有限公司), Innovent Biopharmaceutical Technology (Hangzhou) Co., Ltd. (信達生物醫藥科技(杭州)有限公司), Hangzhou Aide Pharmaceutical Co., Ltd. (杭州愛澤醫藥有限公司), Suzhou Xincheng Private Equity Fund Management Co., Ltd. (蘇州信成私募基金管理有限公司), Suzhou Xinhui Boan Enterprise Management Co., Ltd. (蘇州信惠博安企業管理有限公司), Shanghai Xin Heng Ying Feng Enterprise Management Co., Ltd. (上海信恒盈峰企業管理有限公司), Suzhou Xin Cheng Bo Kang Yi Hao Venture Capital Partnership (Limited Partnership) (蘇州信成博康壹號創業投資合夥企業(有限合夥)), Suzhou Xin Cheng Bo Kang Yi Hao Enterprise Management Partnership (蘇州信成博康壹號企業管理合夥企業(有限合夥)), Suzhou Xinhe Guoqing Venture Capital Partnership (Limited Partnership) (蘇州信禾國清創業投資合夥企業(有限合夥)), Xinda Rongchuang (Suzhou) Investment Co., Ltd. (信達融創(蘇州)投資有限公司), Zhongxi Pharmaceutical Technology (Suzhou) Co., Ltd. (眾熙醫藥科技(蘇州)有限公司), Innovent Biologics, Inc., Innovent Biologics (HK) Limited, Fortvita Biologics (USA), Inc., Fortvita Biologics (Europe) Limited, Innovent Cells Inc., Innovent Cells (HK) Limited, Fortvita Biologics Inc., Fortvita Biologics (Ireland) Limited, Fortvita Biologics (Singapore) Pte. Ltd., Fortvita Biologics International Inc., Fortvita Biologics Limited, Innovent Biopharmaceuticals Inc., Innovent Biopharmaceuticals (HK) Limited, Innovent Biologics Capital, Inc., InnoPinnacle Fund Management Pte. Ltd., InnoPinnacle International I Inc., InnoPinnacle Fund I L.P. and Oriza Xinda International Limited. The newly added entities are mainly newly established companies of the group.

Data Source and Reliability Assurance

The data and cases in this Report are mainly from the statistical reports and relevant documents of Innovent. Monetary values in this Report are in RMB unless otherwise stated. We undertake that this Report contains no false or misleading statements, and are responsible for the truthfulness, accuracy and completeness of its contents.

Confirmation and Approval

As confirmed by the management, this ESG Report was approved by the Board of Directors (the "Board") on 26 March 2026.

Availability of and Feedback to This Report

This Report is available in Traditional Chinese and English. The electronic version of the Report is available on the Stock Exchange's website (https://www.hkexnews.hk), and on Innovent's website (https://www.innoventbio.com).

We value the opinions of the stakeholders and welcome readers to contact us through the following contact details. Your feedback will help us further improve Innovent's overall ESG performance.

Email: ir@innoventbio.com
Mailing address: 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, China

Chairman's Statement

De-Chao Michael Yu, Ph.D.

Chairman of the Board, Executive Director and Chief Executive Officer

To Our Colleagues and Business Partners:

In 2025, the global biopharmaceutical industry landscape underwent profound restructuring. Technological iteration and regulatory transformation advanced in tandem, with sustainable development evolving from a broad industry consensus into a core competitive factor. At this historical juncture, Innovent has remained committed to its mission to "empower patients worldwide with affordable, high-quality biopharmaceuticals, and adhered to its development strategy of building on innovation while pursuing a global path". With a global perspective, we examine our corporate responsibilities and deeply integrate ESG principles into strategic decision-making and the entire operational chain, establishing a dynamic balance between innovation breakthroughs and sustainable development, making responsibility the intrinsic driving force for the Company's progress. From Suzhou to Silicon Valley, from biologics to combination drug-device products, we continuously expand the meaning and boundaries of 'high quality and affordable', making sure that every innovation embodies respect for life and responsibility to society. Here, I am honored to share with you our journey over the past year in translating ESG principles into concrete actions and creating tangible value for all stakeholders.

Governance lays the foundation for steady progress and long-term development. We continue to refine our ESG governance system. In 2025, Innovent maintained an MSCI ESG Rating of AAA, positioning the Company among the top performers in the global biotechnology industry. As the highest authority responsible for ESG matters, the Board has integrated ESG considerations into its governance and decision-making frameworks, conducting regular reviews of ESG strategies and performance to ensure the Company's continued advancement in this area. We continuously strengthen ESG management practices and deepen collaborative compliance efforts with regulatory authorities, jointly building a new model of government-enterprise cooperative compliance. We have established a comprehensive anti-corruption & anti-bribery audit system. The coverage rate for business ethics training for staff and directors reached 100%, and the signing rate of the "Integrity Practice Commitment" (<合規承諾書>) by suppliers and partners also reached 100%. These measures have solidified a governance culture characterized by integrity and transparency. Meanwhile, the Company has established an information security protection system covering all business scenarios and an intellectual property management system spanning the entire R&D lifecycle to comprehensively safeguard the Company's assets and the rights and interests of relevant stakeholders. These efforts lay a solid foundation for the high-quality development of the Company.

Innovation as wings, inclusion without borders. We are committed to improving global accessibility and affordability of medications for patients, ensuring that the achievements of innovation benefit more lives. As the first IGF-1R antibody drug in China and the second globally approved for the treatment of thyroid eye disease, SYCUME® (teprotumumab N01 injection) fills a 70-year clinical treatment gap in this field domestically. Its pricing is approximately 1/17 that of similar imported products. It was successfully included in the National Reimbursement Drug List ("NRDL") in December 2025, enabling more patients to afford and access this innovative drug. As the world's first approved dual GCG/GLP-1 receptor agonist, Mazdutide has been approved for weight management in adults with obesity or overweight and for glycemic control in type 2 diabetes. It has been recognized by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025. As of the end of the Reporting Period, our product portfolio expanded to 18 marketed products, including 12 products listed on the NRDL, making us the enterprise in China with the largest number of approved antibody drugs. Over 3,000 patients benefit from Innovent's therapies every day, and to date, more than 6 million patients have benefited. We put the concept of inclusive healthcare into practice through concrete actions. As of now, our Patient Assistance Program (PAP) has benefited over 238,000 patients, with the total value of donated medications reaching RMB 4 billion. We are actively expanding our global footprint by officially establishing a research and development center in the core area of Silicon Valley, California. We have also reached global strategic partnerships with companies such as Eli Lilly, Takeda and Roche. Three of our candidate drugs have entered or are preparing to enter global Phase III clinical trials, accelerating the delivery of innovative therapies to more patients worldwide and enabling Chinese-origin innovations to reach a global audience.

Quality builds trust, life comes first. We regard high quality as the key to fulfilling our corporate mission, consistently uphold the highest standards and adhere to the quality philosophy of 'doing the right things and getting them right the first time'. We have established a quality management system covering the entire lifecycle of pharmaceutical products. All production bases operated by the Company within China have obtained GMP certification, safeguarding patient medication safety with superior quality. During the Reporting Period, we obtained the ISO 13485 medical device quality management system certification, extended our quality management capabilities to combination drug-device products, and continued to improve our pharmacovigilance ("PV") system, ensuring global compliance in PV. We successfully passed inspections and audits by regulatory authorities in China, the European Union and Mexico, as well as by global partners including Takeda, Roche, Sun Pharma, and Incyte. We uphold stringent standards to ensure product quality and patient safety. Furthermore, we have established a comprehensive ethical review mechanism for experimental animals and implemented a quality and ethical review system covering the entire clinical trial process, prioritizing the health and safety of trial subjects. These measures reflect our commitment to the principle of 'putting life first' and demonstrate the scientific and humanistic values at the heart of our work. We deeply integrate the concept of sustainable development into supply chain management, implementing a dual-source supply strategy for all self-produced commercialized products and continuously conducting supplier quality and ESG-related audits. These efforts effectively ensure supply chain quality and stability, contributing to the building of a sustainable industrial ecosystem.

People first, uniting for shared growth. We have assembled a team of leading talents positioned at the forefront of global industry technology, possessing international vision and capabilities, to establish a high-end biopharmaceutical R&D and industrialization talent team with internationally advanced standards, providing solid talent support for enterprise innovation and development. In 2025, the Company's female employee ratio reached 51%, achieving the employee diversity goal and demonstrating our inclusive and equitable corporate culture. We have established a systematic talent development framework. Through tiered and categorized training programs, scientific performance management, and clear career advancement pathways, we provide comprehensive support to staff across diverse roles and stages of their professional growth. Total employee learning hours for the year reached 317,694 hours, with a training coverage rate exceeding 98% and an average learner satisfaction score of 98.95%, reflecting the emphasis we placed on employee growth. We continuously optimize employee communication mechanisms and benefits systems, launched "health testing stations" for employees in all operation sites to safeguard their physical and mental well-being. Meanwhile, we have implemented a systematic occupational health and safety risk management mechanism across all operational sites. All production sites in operation have received ISO 45001 occupational health and safety management system certification, enabling every employee to thrive in a safe and healthy working environment and fostering the mutual growth of both the Company and its employees.

Building a sustainable ecosystem for a greener future. We continue to practice the concept of green sustainable development, having established an environmental, health and safety ("EHS") governance structure with the Board-level Audit Committee as the ultimate supervisory body. This structure ensures the effective implementation of environmental policies and systems, providing a solid governance foundation for the Company's green development. We actively address climate change and ecological environmental challenges by setting scientific carbon reduction targets. Through carefully planned emission reduction pathways, the application of energy-saving technologies, and the utilization of renewable energy, we actively promote low-carbon development, contributing to the achievement of China's 'Dual Carbon' goals. In addition, we actively advance clean energy projects such as photovoltaic power generation. The Shanghai R&D Center generates approximately 30,000 kWh renewable electricity annually, contributing to the energy transition through tangible and concrete actions. We continue to reduce resource consumption and pollutant emissions, thereby mitigating the environmental impact of our daily operations. In 2025, the Company achieved its interim targets ahead of schedule, with energy consumption per unit of product decreasing by 28%, freshwater usage per unit of product dropping by 42%, hazardous waste generation per unit of product reduced by 44%, and greenhouse gas emissions per unit of product reduced by 2% compared to 2024, demonstrating our firm commitment and significant achievements in environmental sustainability. In terms of environmental compliance, all production bases have obtained ISO 14001 environmental management system certification, demonstrating the Company's commitment to green and sustainable development and contributing to the cultivation of a healthy ecological environment.

Looking ahead, Innovent will continue to uphold its mission of empowering patients worldwide with affordable, high-quality biopharmaceuticals. Driven by the dual engines of 'sustainable development and global innovation', we will further deepen our global R&D, clinical, and commercial footprint to ensure that innovative achievements originating from China benefit a broader patient population worldwide. We recognize that only by deeply integrating business aspirations with social responsibility and advancing alongside like-minded partners can we navigate a transformative era with stability and long-term success. Guided by our belief in 'Creating Boundless Value for Life', we will join hands with all stakeholders to write a new chapter in the high-quality development of the biopharmaceutical industry, create sustainable value for society, and strive to ensure that every life can equally benefit from the health outcomes brought by technological progress.

De-Chao Michael Yu, Ph.D.
Chairman of the Board, Executive Director and
Chief Executive Officer



About Innovent

Profile

Inspired by the spirit of "Start with Integrity, Succeed through Action", Innovent's mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals. Established in 2011, Innovent is committed to discovering, developing, manufacturing, and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, cardiovascular and metabolic (CVM), and eye diseases to enhance the quality of life for patients worldwide. On 31 October 2018, Innovent was listed on the Main Board of the Stock Exchange under the stock code: 01801.

Innovent places high importance on new drug research and development as well as the construction of related technology platforms. Innovent has developed a fully-integrated multi-functional platform encompassing early-stage R&D, clinical development, production, and commercialization. Through integration and optimization, we have built an efficient operational system, laying a solid foundation for a steady pipeline of innovative drugs.

Our commercial stage portfolio contains a total of 18 marketed products: TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection), PEMAZYRE® (pemigatinib), Olverembatinib, Cyramza® (ramucirumab), Retsevmo® (selpercatinib), FUCASO® (Equecabtagene Autoleucel), SINTBILO® (tafolecimab injection), Dupert® (fulzerasib), DOVBLERON® (taletrectinib adipate), JAYPIRCA® (pirtobrutinib), limertinib, SYCUME® (teprotumumab N01 injection), mazdutide, PECONDLE® (picankibart injection) and TABOSUN® (Ipilimumab N01 injection). Meanwhile, we have 5 assets in Phase 3 or pivotal clinical trials and 14 molecules in early clinical stage.

In 2025, 7 of our innovative products have been included in the updated 2025 NRDL. This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection), Limertinib, DUPERT® (fulzerasib), DOVBLERON® (taletrectinib adipate), Retsevmo® (selpercatinib), and Jaypirca® (pirtobrutinib). The updated NRDL took effect on 1 January 2026, covering major disease areas such as oncology, CVM and ophthalmology, thereby effectively enhancing patient access to and affordability of medications. As of the end of the Reporting Period, the Company has included 12 products in the NRDL. The Company will continue to promote the research and development and accessibility of high-quality biopharmaceuticals, support the implementation of medical insurance policies, and benefit more patients.

The Company has established more than 30 strategic partnerships with international collaborators, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, and MD Anderson Cancer Center. While continuously developing innovative drugs through in-house research and pursuing its own growth, the Company adheres to the development philosophy that economic construction must center on the people. For many years, we have remained committed to scientific benevolence and steadfastly upheld the principle of 'patient-centeredness,' caring for patients and their families while actively fulfilling our social responsibilities. The Company has successively initiated and participated in multiple public welfare assistance programs for pharmaceuticals, enabling an increasing number of patients to benefit from advancements in life sciences through access to high-quality, affordable biopharmaceuticals. As of now, the Company's PAP has benefited over 238,000 patients, with a total drug donation value of RMB 4 billion. The Company maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

Corporate Culture

Innovent's mission, to empower patients worldwide with affordable, high-quality biopharmaceuticals, guides our corporate culture and informs our development strategy, which is to discover new medicines through innovation and deliver them through our global platforms. In addition to offering high-quality biopharmaceuticals that are accessible to providers and patients, we aim to be an inclusive, transparent and diverse place of work and education for our staff. We hope that by working together with all relevant parties, we can make Innovent a driver of progress in "saving lives and improving quality of life".

Mission	To empower patients worldwide with affordable, high-quality biopharmaceuticals
Vision	To be a premier global biopharmaceutical company
Strategy	To discover new medicines through innovation and deliver them through our global platforms
Core Values	Integrity, Learning agility, Dedication, Cooperation

Board Statement

Responsibilities of the Board of Directors	The Board serves as the highest accountable body for ESG issues and is responsible for leading, coordinating, and overseeing the Company's ESG work. It authorizes the audit committee of the Company ("Audit Committee") to manage ESG-related strategies, targets, and overall implementation.
ESG Leading Group	The ESG Leading Group, formed by senior management of the Company, is in charge of reviewing and providing insights and resource support for ESG work. This group also facilitates coordination and ensures effective execution of ESG efforts.
ESG Risk Management	The Company regularly analyzes ESG risks and opportunities in light of external trends, environmental changes, stakeholder feedback, and internal strategic development. Based on this analysis, relevant plans and initiatives are formulated to establish and implement a robust internal control and risk management system that supports effective execution of the ESG strategy.
Priority ESG Topics	We identify, evaluate, and follow up on key ESG issues raised by stakeholders. During the Reporting Period, a materiality assessment was conducted, and the materiality matrix was updated accordingly.

Milestones during the Reporting Period

January 2025

- Innovent enters into exclusive global license agreement with Roche for novel DLL3 antibody drug conjugate. This collaboration aims to bring innovative treatment options to patients with advanced small cell lung cancer ("SCLC").
- Innovent announces the approval from the National Medical Products Administration of China ("NMPA") of Limertinib, a third-generation EGFR TKI, in-licensed from Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), for the treatment of lung cancer in adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC").

March 2025

- Innovent announces the NMPA approval of SYCUME® (teprotumumab N01 injection), China's first and the world's second approved IGF-1R monoclonal antibody, for the treatment of thyroid eye disease ("TED"). As the first new drug approved in China for TED in the past 70 years, SYCUME® is expected to redefine the standard of care for TED.

May 2025

- *New England Journal of Medicine* ("*NEJM*") published the Phase 3 clinical study of mazdutide in Chinese adults with overweight or obesity (GLORY-1). It is the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in *NEJM*.

June 2025

- Innovent announces the NMPA approval of Mazdutide, the world's first and the only approved dual GCG/GLP-1 receptor agonist, for chronic weight management in adult patients with obesity or overweight. With the core benefits of dual-target weight reduction, fat burning, and liver protection, it has been recognized as one of the top ten most anticipated drugs globally in 2025.
- Eight oral presentations at the 2025 American Society of Clinical Oncology ("ASCO") Annual Meeting showcased breakthrough clinical data of IBI363 (PD-1/IL-2$^{\alpha\text{-bias}}$), IBI343 (CLDN18.2 ADC) and other novel drug candidates, highlighting the strength and global competitiveness of our R&D.
- Multiple oral and poster presentations were featured at the American Diabetes Association's ("ADA") 85th Scientific Sessions, showcasing DREAMS-1 and exploratory mechanism-of-action ("MoA") analyses of mazdutide, as well as a preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate ("APC")).

July 2025

- *Nature Medicine* published the Phase 1 clinical results of IBI343 (CLDN18.2 ADC) in patients with advanced gastric/gastroesophageal junction adenocarcinoma.

September 2025

- Innovent announces the NMPA approval of Mazdutide, the world's first dual GCG/GLP-1 receptor agonist, for glycemic control in adults with type 2 diabetes ("T2D"). Mazdutide is expected to support disease management for a broad population of patients with diabetes in China by delivering multiple benefits in glycemic control, weight management, and liver, cardiovascular and renal health indicators.

October 2025

- Innovent enters into global strategic partnership with Takeda Pharmaceutical Company Limited (TSE: 4502, NYSE: TAK) ("Takeda") to accelerate the global development and commercialization of our next-generation IO and ADC therapies, including the global partnership on IBI363 (PD-1/IL-2$^{\alpha\text{-bias}}$) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).
- *Cancer Cell* published the Phase 1b results of TABOSUN® (Ipilimumab N01 injection) plus TYVYT® (sintilimab injection) as neoadjuvant treatment in locally advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) colon cancer.

November 2025

- Innovent announces the NMPA approval of PECONDLE® (picankibart injection), China's first domestically developed next-generation potent IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. PECONDLE® (picankibart injection) is a preferred biologic therapy for the long-term management of psoriasis.

December 2025

- Innovent announces that 7 of its innovative products have been included in the updated 2025 NRDL. This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection), Limertinib, DUPERT® (fulzerasib), DOVBLERON® (taletrectinib adipate), Retsevmo® (selpercatinib) and Jaypirca® (pirtobrutinib).
- Innovent announces the NMPA approval of TABOSUN® (ipilimumab N01 injection), China's first domestic anti-CTLA-4 monoclonal antibody. It is indicated in combination with TYVYT® (sintilimab injection) for neoadjuvant treatment of patients with resectable stage IIB-III MSI-H/dMMR colon cancer. Furthermore, this regimen represents the world's first and only dual-immunotherapy approach approved for neoadjuvant treatment of colon cancer.
- *Nature* published back-to-back results of two Phase 3 clinical studies of mazdutide in Chinese adults with T2D (DREAMS-1, DREAMS-2). Mazdutide is the first China-developed innovative drug with two clinical studies simultaneously published in *Nature* and the only GCG/GLP-1-based therapy ever to achieve top-tier publications in both *Nature* and *NEJM*.

February 2026

- Innovent announces the NMPA approval of Jaypirca® (pirtobrutinib) for a new indication for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma ("CLL/SLL") after at least one line of systemic therapy including a Bruton tyrosine kinase ("BTK") inhibitor.

Key Performance during the Reporting Period

Excellent Governance

AAA
MSCI ESG rating maintained, positioning us at the forefront of biotechnology industry

100%
of staff and the Board participated in business ethics and anti-corruption training

100%
of suppliers and partners have signed the "Integrity Practice Commitment" (<合規承諾書>)

Enjoying Good Health

18 marketed products in our product pipeline, including **12** products listed on the NRDL

7
drugs or assets granted for orphan drug designation

13
orphan drug designations granted

430
million in total value of newly donated drugs

38,400
additional patients benefited

over **238,000**
patients reached through patient assistant programs

High Quality as Key

100%
of production sites in operation have been GMP certified

All in-house commercialized products have implemented a dual source of supply

100%
of staff have completed responsible marketing training

People First

51%
female representation among staff worldwide

45.2%
female in management

97.1%
employee satisfaction rate achieved

100%
production sites in operation received the ISO 45001 occupational health and safety management system certification

Embracing Ecology

100%
production sites in operation received ISO 14001 environmental management system certification

2
internal environmental management system audits implemented

2
external environmental management system audit implemented

21
environmental impact tests and environmental impact assessments completed

51,100
tons of water recycled in total

100%
of staff received training on hazardous waste management and environmental protection knowledge

Compared to the previous reporting period (per unit of product)

Energy consumption reduced by **28%**

Water consumption reduced by **42%**

Hazardous waste generation reduced by **44%**

Greenhouse gas emission reduced by **2%**

an average annual decrease compared to 2022 (per unit of product)

Hazardous waste generation reduced by **17.67%**

Waste gas emissions reduced by **4%**

72.7%
greenhouse gas emission reduced compared with 2020 (per unit of production)

Awards and Recognitions

Excellent Governance

AAA
MSCI ESG Rating

"Huashan Award" (Best Innovative Growing Biopharma)
Medical Community

2025 China Top 50 Innovative Companies
Forbes China

Top 100 Chinese Pharmaceutical Enterprises
China National Pharmaceutical Industry Information Center

2025 Excellent Cases of China's Pharmaceutical R&D Pipeline Industrial Enterprises
China National Pharmaceutical Industry Information Center

2024-2025 Pharmaceutical Industry Information Statistics: Top 50 Enterprises by Growth Rate in the Pharmaceutical Sector
China Chamber of Commerce for Pharmaceutical Industry

2024-2025 Pharmaceutical Industry Information Statistics – Top 50 Enterprises in Independent Innovation within the Pharmaceutical Industry
China Chamber of Commerce for Pharmaceutical Industry

2024-2025 Pharmaceutical Industry Information Statistics – Top 100 Enterprises by Operating Revenue in the Pharmaceutical Manufacturing Sector
China Chamber of Commerce for Pharmaceutical Industry

Top 200 Jiangsu Private Enterprises
Jiangsu Federation of Industry and Commerce

Top 100 Jiangsu Private Enterprises by R&D Investment
Jiangsu Federation of Industry and Commerce

2025 Jiangsu Province Advanced-Level Smart Factory
Industry and Information Technology Department of Jiangsu

Top 100 Suzhou Private Enterprises
Suzhou Federation of Industry and Commerce

Top 20 Sci-tech Enterprises by R&D Investment
Suzhou Municipal People's Government

14th Five-Year Plan Outstanding Contribution Enterprise – Suzhou Enterprise with Significant Achievements in Scientific and Technological Innovation and Development
Suzhou Municipal People's Government

Suzhou Top 20 Manufacturing Enterprises by Output Value
Suzhou Municipal People's Government

14th Five-Year Plan Outstanding Contribution Enterprise – Suzhou Top 20 Manufacturing Enterprises by Contribution
Suzhou Municipal People's Government

Suzhou Top 20 Manufacturing Enterprises by Profit

Suzhou Municipal People's Government

Suzhou Certified Smart Factory

Suzhou Municipal Bureau of Industry and Information Technology

Enjoying Good Health

China Innovative Drugs Decade Honor Roll – Industry-Leading Biotech Companies

Pharma Cube

2025 China Pharmaceutical Innovation Index Top 3

IDEA Pharma

First Prize of the 2024 Jiangsu Province Science and Technology Progress Award (sintilimab injection)

People's Government of Jiangsu Province

2025 Suzhou Top Ten Industrial Science and Technology Achievements – GCG/GLP-1 Dual Receptor Agonist Weight-Loss Drug (Mazdutide Injection)

Suzhou Science and Technology Bureau

People First

2025 Human Resources AI Application Pioneer Award

Beisen Cloud Computing

Extraordinary Employer

Liepin

Embracing Ecology

2025 Annual Letter of Appreciation for Ecological Environmental Protection

Emergency Management Bureau of SIP's Suzhou Dushu Lake Sci-Edu Innovation District

01
EXCELLENT GOVERNANCE

Innovent has always regarded integrity as the core cornerstone of corporate development. We firmly believe that an excellent corporate governance system and a comprehensive compliance management mechanism are the key guarantees for the Company to achieve high-quality development. Through continuous optimization of the governance structure, we have continuously enhanced our risk response capabilities to lay a solid foundation for the Company's long-term and stable operations. In terms of business ethics practices, we align with leading management practices by integrating compliance requirements into every aspect of daily operations. At the same time, we have established a multi-level stakeholder engagement mechanism. Through transparent and open dialogue channels, we work with partners to build an integrity-based and mutually beneficial business ecosystem. In the future, we will continue to deepen ESG governance practices and promote the synergistic growth of corporate and social value.

This chapter is in response to the sustainable development goals (SDGs) of the United Nations

1.1 ESG Governance

As a leading enterprise in China's biopharmaceutical industry, Innovent continued to deepen its ESG strategic practices in 2025, comprehensively integrating the concept of sustainable development into the core of corporate operations. Facing increasingly severe climate change and public health challenges, we drive development through innovation and have established an ESG management system covering the three dimensions of ESG. By continuously optimizing the implementation pathways of our five strategic pillars, we not only ensured robust business growth but also remain committed to creating sustainable value for stakeholders. Innovent will continue to enhance its ESG management capabilities and drive the industry's green transformation, contributing corporate efforts toward achieving the United Nations Sustainable Development Goals.

Innovent's Five ESG Strategic Pillars

1.1.1 Board Diversity

We continue to deepen the diversification of our Board by strictly adhering to the "Board Diversity Policy" (<董事會成員多元化政策>). We conduct systematic assessments across key dimensions, including gender balance, cultural background, industry experience, and professional expertise, to cultivate a diverse composition of Board members. By incorporating diverse perspectives and complementary expertise, we have established a more inclusive and representative governance structure. As of the end of the Reporting Period, Innovent had a total of 9 directors, comprising 3 executive directors and 6 independent non-executive directors, of whom 2 are female.

The Board has established 4 committees: the Audit Committee, the Nomination Committee, the Remuneration Committee, and the Strategic Committee. Each committee includes at least one female chair or member.

1.1.2 ESG Governance Structure

To further embed the concept of sustainable development into the Company's strategic decision-making and daily operations, the Board has integrated ESG considerations into its decision-making mechanism. At the same time, we have refined a four-tier ESG governance system comprising the Board, the Audit Committee, the ESG Leading Group, and the ESG Working Group. This structure ensures the implementation of ESG strategic goals through clear allocation of responsibilities and efficient reporting and decision-making mechanisms, promoting systematic, standardized, and routine operations of the Company's ESG management.

- Takes ultimate responsibility for ESG matters as the highest decision-making body for ESG management
- Integrated ESG consideration into decision-making mechanism
- Reviews and approves ESG-related strategies, targets, policies, and approaches
- Monitors and reviews ESG performance and the progress of goals
- Reviews and evaluates ESG-related opportunities, risks, and materiality issues
- Reviews and approves disclosures of ESG information

- Assists the Board in guiding and formulating the Company's ESG-related strategies, goals, and policies
- Monitors and reviews the progress of ESG implementation
- Reviews and supervises ESG information disclosure
- Regularly reports to the Board

- Composed of senior management members from all relevant departments
- Identifies and reviews ESG-related opportunities and risks, provides insights on key ESG issues, and ensures ESG strategic objectives are closely integrated with the Company's strategic objectives
- Provides decision-making and resource support on ESG-related issues to ensure the implementation of ESG objectives and policies
- Reports to the Audit Committee and conducts external communication

- Drafts key ESG issues and objectives
- Undertakes the implementation of ESG issues
- Collects and organizes ESG information and compiles disclosure ESG report
- Identifies and manages ESG-related risks
- Reports to the ESG Leading Group

Innovent's ESG Governance Structure

1.1.3 Stakeholder Engagement

Innovent has established an Investor Relations (IR) management system directly led by the Chief Financial Officer (CFO). Through diversified channels such as investor hotlines, earnings presentation, and ESG-specific communication sessions, the Company maintains frequent interactions with 6 key stakeholders: shareholders, consumers and customers, employees, government, suppliers and partners, as well as the community and public. Based on systematically collected feedback, we have incorporated stakeholder expectations into the ESG strategic upgrade plan, continuously optimizing the Company's ESG management to meet stakeholders' expectations. The CFO regularly reports to the Board on investor relations matters and is subject to the guidance and oversight of the Board.

Stakeholders	Focus Issues	Communication Channels and Mechanisms
Shareholders	• Research & Development ("R&D") Innovation • Compliance Operations • Risk Management • Corporate Governance • Business Ethics and Anti-Corruption • Product Quality and Safety	• Investor Relations Calendar • Strengthen Online Interaction • Conduct Offline Activities • Convene General Meeting and the Earnings Presentation • Regular Information Disclosure • Enhance Global R&D and Innovation Capabilities • Optimize the Cooperation Platform
Consumers and Customers	• Product Quality and Safety • Customer Privacy Protection • Intellectual Property Protection • Customer Service	• Establish and Improve a Quality Management System • Conduct Customer Satisfaction Surveys • Customer Seminar • Strictly Protect Intellectual Property Rights • Implement Responsible Marketing
Staff	• Employment Policy • Staff Training and Development • Staff Compensation and Benefits • Staff Care • Occupational Health and Safety	• Emphasizing Employee Diversity and Belonging • Improve the Employee Communication Mechanism • Fair Recruitment • Strengthen Employee Training and Talent Development • Optimize the Compensation System • Equity Incentives and Employee Benefits • Safeguarding Employee Health and Safety
Government	• Compliant Operation • Business Ethics and Anti-Corruption • Emissions Management • Energy Consumption • Water Consumption • Industry Development Promotion • Response to Climate Change	• Government Symposium • Government and Business Correspondence • Implement Relevant Policies • On-site Inspection and Work Reporting • Regular Information Disclosure
Suppliers and Partners	• Sustainable Supply Chain Management • Compliant Operations • Business Ethics and Anti-Corruption	• Supplier Assessment • Supplier Training and Support • Industry Exchange Meeting • Hospital-Enterprise Matching Conference
Community and Public	• Public Welfare and Charity • Inclusive Healthcare • R&D Innovation • Emission Management	• Strengthen Cooperation Between Enterprises and Educational Institutions • Conduct Social Welfare and Volunteer Activities • Community Environmental Activities

1.1.4 ESG Materiality Issue Analysis

Innovent continues to refine its materiality assessment mechanism for ESG issues, systematically identifying key ESG management areas and responding to the core concerns of all stakeholders. Grounded in the Company's medium- and long-term Strategic Planning, benchmarking against international best practices and policy directions, we identified 22 ESG material issues through multi-dimensional stakeholder engagement, expert consultation, and industry trend analysis. Based on a dual assessment of the enterprise impact and stakeholder impact of each issue, we have developed the 2025 ESG Materiality Issues Matrix to provide a scientific basis for decision-making regarding the Company's sustainable development strategy.



Materiality Issues Matrix of Innovent

Five Strategic Pillars	Issues of high importance	Issues of medium importance	Issues of low importance
Excellent Governance	Compliance Operations Business Ethics and Anti-Corruption Risk Management Corporate Governance	Customer Privacy Protection Intellectual Property Protection	None
Enjoying Good Health	Inclusive Healthcare R&D Innovation	Public Welfare and Charity	Industry development promotion
High Quality as Key	Product Quality and Safety Customer Service	Sustainable Supply Chain Management	None
People First	Occupational Health and Safety Employee Training and Development	Staff Care Staff Remuneration and Benefits Employment Policy	None
Embracing Ecology	Responding to Climate Change	Use of Energy Emissions Management	Use of Water Resources

Innovent's Material Issues

1.2 Compliance Operations

Innovent has always regarded integrity and compliance as the cornerstone of corporate development, dedicated to building a systematic and sound governance system. Guided by high standards of business ethics and compliance principles, the Company actively responds to concerns raised by various stakeholders, continuously strengthens its compliance operational capabilities, and ensures that all business processes adhere to applicable laws, regulations, and industry standards. Building on this foundation, the Company continues to shape and enhance its corporate reputation and brand value, fostering an open, integrity-based, and healthy business ecosystem. This initiative aims to collaborate with partners for shared progress, mutual benefits, and the co-creation of a sustainable long-term future.

1.2.1 Our Governance

Innovent strictly complies with relevant laws and regulations, including the "Anti-Unfair Competition Law of the People's Republic of China"(<中華人民共和國反不正當競爭法>) and the "Anti-Money Laundering Law of the People's Republic of China"(<中華人民共和國反洗錢法>), while continuously improving its compliance management system to ensure the Company's stable operations. We have established policies such as the "Code of Conduct" (<合規行為準則>), the "Conflict of Interest Policies"(<利益衝突政策>), the "Code of Business Conduct" (<商業行為準則>) and the "Code of Ethics and Business Conduct" (<商業道德準則>)[1] to provide compliance guidance for business operations. These policies apply to all staff, as well as stakeholders including customers, suppliers, and partners. During the Reporting Period, we updated policies including the "Code of Business Conduct" (<商業行為準則>), the "Guidelines for Promotion and Educational Materials" (<推廣和教育材料流程指引操作規程>), and the "Special Approval for Academic Activities" (<學術活動管理審批>) to refine compliance standards based on the latest business requirements.

We have established a compliance management structure led by the Board to supervise the compliance of all business operations from top to bottom, ensuring adherence to applicable laws, regulations, and internal policies.

Board of Directors	• Approves business ethics and compliance targets and policies, and supervises their implementation
Audit Committee	• Reviews policies and objectives related to business ethics and compliance operations and monitors implementation
	• Oversees the rectification of medium/high-risk items and issues
	• Debriefs the report made by the management team in terms of business ethics and compliance operations every six months and reports to the Board
Compliance and Discipline Management Committee	• Spearheaded by senior management, including the Chief Executive Officer, and composed of the heads of compliance, audit, and legal departments
	• Establishes policies and objectives for business ethics and compliance operations
	• Reviews the enforcement of pivotal policies and targets
	• Handles whistleblowing, investigations, and pursuits, conducts compliance audits, and facilitates corrective actions
	• Diagnoses potential compliance risks, manages risks and problem items, and takes preemptive actions
	• Reports to the Audit Committee on a half-yearly basis

Compliance Operation Governance Structure

1 Please refer to Innovent's ESG website for "Code of Ethics and Business Conduct" (<商業道德準則>).

1.2.2 Our Objectives

Innovent upholds the concept of sustainable development by establishing clear ethical standards and goals to ensure the effective implementation and continuous improvement of ethical standards across all stages of the value chain. During the Reporting Period, 100% of the Company's staff and directors received business ethics and anti-corruption training, while 100% of suppliers and partners signed the "Integrity Practice Commitment" (<合規承諾書>) and confidentiality agreement.

Business ethics targets	Ensure 100% of staff and directors participate in training for business ethics and anti-corruption each year
	Ensure 100% of suppliers sign the "Integrity Practice Commitment" (<合規承諾書>) each year

1.2.3 Our Actions

Construction of the Compliance System

Innovent continues to refine its compliance governance framework by establishing a routine internal audit mechanism and engaging external authoritative institutions to conduct external audits. This systematic approach enhances the effectiveness of compliance management and establishes Innovent as a benchmark for compliance within the biopharmaceutical industry.

During the Reporting Period, with respect to cross-border data transfer compliance, the Company continued to advance a dedicated internal compliance initiative for the cross-border transfer of clinical data, conducting a comprehensive review and assessment of outbound data transfer scenarios to ensure that all cross-border transfers of personal information comply with the "Personal Information Protection Law of the People's Republic of China" (<中華人民共和國個人信息保護法>) and applicable data protection laws in relevant jurisdictions. The Company has continuously enhanced its data compliance management system and optimized processes and control measures for cross-border data transfers to strengthen its overall compliance standards and risk management capabilities. Under the PRC legal framework, Innovent has completed the filing of several Standard Contractual Clauses (SCCs) for the outbound transfer of personal information, and has completed the required filings with the Cyberspace Administration of China for transferring relevant personal information to certain overseas recipients in key business scenarios such as commercial due diligence and transaction negotiations, clinical research, and PV, thereby fulfilling its compliance obligations under the Personal Information Protection Law. Looking ahead, the Company will continue to monitor evolving data protection laws and regulations both domestically and internationally and will further strengthen its compliance framework for cross-border data transfers, upholding a responsible approach to safeguarding the legitimate rights and interests of patients, trial participants, and business partners.

Strengthening the Compliance System through External Collaboration

In December 2025, the Company held a signing ceremony for cooperation on compliance system construction with the Enforcement Corps of the Shanghai Municipal Administration for Market Regulation and jointly signed the "Memorandum of Guidance on Compliance System Construction" (<合規體系建設指導備忘錄>). Both parties will focus on the Company's compliance governance, carrying out systematic cooperation in five key areas: drug promotion and commercial marketing, management of academic exchanges and risk prevention, drug pricing behavior and strategy formulation, distributor management and policy establishment, and strengthening capabilities for trade secret protection.

This collaboration marks progress in the Company's development of a new model for compliance construction through government-enterprise coordination, providing clear policy guidance and risk prevention support for the Company's business operations.

Signing Ceremony for Cooperation on Compliance System Construction

Anti-Corruption and Anti-Bribery Audit

Innovent conducts comprehensive compliance audits annually across all operational sites and business units to evaluate the effectiveness of anti-corruption policies and management measures. The Company also reviews the business ethics behavior of all staff (including board members, senior management, and part-time staff) as well as our business partners. The audit scope primarily covers risk points such as potential benefit transfers, commercial bribery, misappropriation of funds, and illegal misappropriation of the Company's assets during operations. We dynamically identify high-risk partners through monthly data analysis and implement precise supervision supplemented by regular and irregular on-site audits. In addition, we conduct at least one special audit annually for high-risk departments including procurement, sales, the Key Account (KA) management team, marketing department, and medical department.

During the Reporting Period, we comprehensively reviewed and upgraded our internal audit processes and standard operating procedures ("SOP(s)"). We abolished 6 outdated policies and updated 5 core policies to ensure the timeliness and authority of our audit basis. To address emerging risk points and key links in business development, we have newly established 3 specialized audit SOPs: the Import and Export Business Audit SOP, the Tax Special Audit SOP, and the Pre-Launch Policy and Omnichannel Audit SOP for New Products. These measures continuously deepen the Company's capability to conduct standardized and in-depth audits of complex business operations.

In engineering project management, we developed the "Engineering Audit Guidelines" (<工程審計指南>) to comprehensively cover key stages throughout the entire project lifecycle, including initiation, bidding, construction, and acceptance. These guidelines facilitate effective audit operations at each stage of the project, strengthen mechanisms for preventing violations, and help ensure the integrity and efficiency of the entire project process.

Regarding issues identified during the audit process, the internal audit department will report directly to the Audit Committee to ensure that significant audit findings are addressed and rectified in a timely and effective manner.

Scope	Audit Frequency	Audit Content
Suzhou operations center	At least once each year	Conduct specialized audits by procurement category, including bidding and tendering audits, tax audits, molecule delivery audits, production cost management audits, interview and recruitment process audits, asset management audits, R&D expense audits, information security audits, and import/export business audits.
Global R&D center in Shanghai	At least once per month	Engineering tracking and settlement audit.
	Once per year	Conduct specialized audit, bidding and tendering audit, asset management audit, expense expenditure audit, and information security audit by procurement category.
Hangzhou factory	At least once per month	Engineering settlement audit.
	Once per year	Conduct procurement audit, bidding and tendering audit, asset management audit, expense expenditure audit, and information security audit for all categories.
Beijing sites	At least once per month	Engineering tracking audit.
	Once per year	Asset management audit, expense expenditure audit, information security audit
Overseas Business	Once per year	Conduct special audits, expense audits, information security audits, and import/export business audits by procurement categories.
Commercial Team	At least once each year	Production, supply and sales audit, distributor and pharmacy audit, sales expense audit, assistance project and sample requisition audit, foundation project audit, inventory audit, channel diversion audit.

Whistleblowing and Complaint Procedures

Innovent has established a comprehensive internal whistleblowing and investigation management system. In accordance with the "Policy and Procedures for Internal Reporting and Investigation Handling" (<內部舉報與調查管理規程>), the Company has systematically standardized the management of reporting matters, departmental coordination mechanisms, and investigation and disposal processes. Upon receiving feedback from stakeholders such as staff, clients, suppliers, and partners, all departments must promptly transfer the information to the Company's internal audit department for centralized handling. The Company commits to responding promptly to all reported matters and providing feedback to whistleblowers regarding the progress and final outcomes of their handling.

Monthly, we distribute the "Announcement on Complaint and Whistleblowing Channels" (<信達生物製藥集團投訴舉報方式公告>) and the "Whistleblower Protection Policy"(<舉報人保護政策>)[2] to all staff via email. Additionally, complaint and whistleblowing notice boards are displayed in all office locations to ensure that every employee is aware of the reporting channels for violations. We continuously encourage internal and external parties to supervise and report violations, thereby strengthening our prevention and corrective mechanisms.

Mailing address: Audit Department, Innovent Biologics, Office of the Innovent Biologics A1-4F Audit Department, No. 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu Province

Hotline: 400-606-3130

Email: IA@innoventbio.com

DingTalk channel: DingTalk → Workbench → Complaints and Reports → Anti-fraud Reports

Social media platform: WeChat official account "Sunshine Innovent"

Innovent's Reporting Channel

During the Reporting Period, Innovent did not experience any significant compliance violations. All internal and external reports concerning potential non-compliance were thoroughly investigated, verified, and addressed in accordance with established procedures, including result feedback and rectification implementation. All related matters have been properly resolved.

2 Please refer to Innovent's ESG website for "Whistleblower Protection Policy"(<舉報人保護政策>).

Whistleblower Protection

Innovent maintains a zero-tolerance stance toward any form of retaliation. The Company has established the "Whistleblower Protection Policy" (<舉報人保護政策>) to clarify information handling procedures during investigation cases. By coordinating with legal, audit, human resources, and finance departments, the Company thoroughly investigates all cases while comprehensively safeguarding the legitimate rights and interests of whistleblowers and witnesses.

During the reporting process, reporters may freely choose to report violations anonymously, under a pseudonym, or using their real name. We will strictly keep confidential the reporter's personal information and the materials provided. Unless explicitly authorized by the whistleblower or under special circumstances such as statutory disclosure requirements, we commit to not disclosing the whistleblower's information in any form. In cases where disclosure is legally required, we will adhere to the principle of minimum necessity, strictly control the scope of information disclosure, and ensure it is limited only to personnel with a legitimate need to know.

Punishment and Accountability Process of Regulatory Violations

Relevant departments of the Company will strictly enforce policies such as the "Disciplinary System" (<違紀懲處制度>) and impose sanctions on involved personnel based on the nature and severity of the incident, while continuing to provide supervision and education to ensure that similar incidents do not occur.

During the Reporting Period, Innovent and its staff were not involved in any corruption litigation cases.

Compliance and Business Ethics Training and Promotion

Innovent continues to advance the construction of an integrity culture by delivering commercial ethics and compliance training to all personnel, including full-time staff, part-time staff, and members of the Board. Through customized training for departments, we continuously disseminate the Company's compliance policies and procedures, effectively enhancing the business ethics awareness of staff as well as their capabilities in preventing compliance risks.

Compliance Training for the Commercial Team

In January 2025, we convened the annual conference for our commercial team. The agenda covered regulatory trends in the pharmaceutical industry, a review of the compliance performance of the commercial team in 2024, and compliance management requirements for 2025. This initiative effectively strengthened the compliance awareness of the commercial team and systematically deployed compliance management work for the new year.

Compliance Presentation for the Annual Commercial Team Conference

In 2025, the Compliance Department conducted a total of 192 compliance-themed training sessions, covering 28,277 participants. Annual compliance training covered all staff, with a completion rate of 100%. The annual conflict of interest training also achieved a 100% completion rate, and the signing rate for "Integrity Practice Commitment" (<合規承諾書>) reached 100%.

The legal department conducted training on anti-corruption and anti-bribery laws and regulations for staff to comprehensively prevent violations such as corruption and fraud. It also conducted 189 anti-corruption training sessions, with a total of 8,236 participants and a 100% participation rate.

The Company's audit department strengthen staff's understanding of the definition and boundaries of business ethics through training, dissemination, and business meetings. During the Reporting Period, the audit department conducted 24 systematic onboarding training sessions, covering nearly 3,000 new staff. The training topics encompassed core compliance issues including the Company's code of ethics, anti-bribery and anti-corruption measures, information security, and conflict of interest.

Business Cycle Meeting

The audit department regularly conducts business cycle meetings centered on "Notification of Audit Findings" and "Interpretation of the Next Year's Audit Plan". Drawing lessons from cases, these meetings clarify regulatory priorities, transform audit supervision pressure into self-improvement momentum within business units, and achieve a closed loop for risk warning and management. During the Reporting Period, we conducted 8 periodic business briefings, covering a total of 3,073 participants.

Commercial Ethics Standards and Integrity Culture Promotion

During the Reporting Period, Innovent conducted multiple integrity culture awareness campaigns for all staff. Prior to traditional festivals such as Spring Festival, Dragon Boat Festival, and Mid-Autumn Festival, reminder notices on "integrity during holidays" were issued via thematic posters, continuously consolidating the corporate cultural atmosphere of "self-discipline and clean conduct".

Integrity Promotion Poster

Business Ethics Management for Partners

Innovent has established a systematic compliance access and management mechanism for business partners. All new business partners must complete an anti-corruption and anti-bribery assessment questionnaire, sign compliance documents including the "Supplier Integrity Commitment" (<供應商廉潔承諾書>) and Non-Disclosure Agreement. Additionally, all new and existing business partners are required to complete annual compliance training and sign an Annual Compliance Commitment Letter to ensure strict adherence to relevant laws and regulations on anti-monopoly and anti-unfair competition. In 2025, the annual compliance commitment re-signing rate for Innovent's business partners reached 100%.

We reserve the right to conduct due diligence on partners to ensure that all business operations uphold its commitment to a fair business environment. During the Reporting Period, we engaged an independent professional firm to conduct a systematic compliance review of key service suppliers. This is to ensure that all of our business operations strictly comply with applicable laws and regulations, industry standards and internal compliance policies, effectively prevent supply chain compliance risks, and safeguard the legality, security and sustainability of commercial operations.

Partner Compliance Training

During the Reporting Period, we conducted annual compliance training for key business partners. The training covered trends in pharmaceutical compliance, laws and regulations on anti-commercial bribery, the Company's compliance policies, and compliance standards. These initiatives helped our business partners to strengthen their compliance capabilities and jointly foster a culture of compliance excellence.

1.3 Risk Control

A sound risk prevention and control mechanism is the guarantee for the Company's steady and sustainable development. We have established a risk management framework covering the entire business process, including R&D, production, supply chain and commercialization. Through measures such as regular risk assessments and contingency plan formulation, we continuously enhance the Company's overall risk management capabilities.

1.3.1 Our Governance

Innovent has established a Risk Management Committee composed of department heads and key personnel from compliance, audit, and legal departments. Covering all business processes from early-stage R&D and product development to manufacturing and commercialization, the committee coordinates company resources to identify, mitigate, and respond to risks. The Risk Management Committee reports directly to the Audit Committee.

We have established a three-tier risk management structure with the Board and its subordinate Audit Committee serving as the highest oversight bodies, clearly defining responsibilities ranging from frontline operations to senior management. By clearly defining risk management responsibilities at each level, we have achieved collaborative risk management across the entire process, from business operations to strategic decision-making, providing a solid governance guarantee for the Company's sustainable development.

Board of Directors and Subordinate Audit Committee

3rd line of defense-Risk supervision department

- Coordinating in the supervision of internal control and risk management
- Receiving and consolidating reports, conducting independent audits, investigating and addressing serious violations of policies, rules, and regulations, including the implementation of appropriate disciplinary measures

2nd line of defense-Risk management department

- Organizing, leading, and coordinating specific work of internal control and risk management
- Risk control information disclosure/communication/training

1st line of defense-Risk-owning department

- Implementation of risk control measures

Three Lines of Defense in Risk Management

1.3.2 Our Actions

Risk Management

We have established a standardized risk assessment process to conduct comprehensive enterprise risk assessments on a regular basis and identify various risks throughout our operations. For identified significant risks, we have established a dynamic early warning mechanism and continuously optimize and adjust risk response plans to ensure timely and effective control of all types of risks.



Risk Management System



Risk Assessment Process

We conduct risk assessment work using multi-dimensional methods, including historical data analysis, probabilistic forecasting models, and expert consultation. During the risk quantification and assessment process, we focused on the Company's implementation effectiveness across the following four key dimensions:

Key control measures

- Assess the accessibility and operability of the current regulations

Systematized work procedures

- Place the critical control points for formal execution in a systematic work flow to ensure the implementation and enforcement of regulations

Training and support

- Implement training of business risks continuously and assess external trends and development risks

Monitoring and audits

- Formulate monitoring approach and plan, rectify and supervise key issues

Risk Quantification Metrics

For identified risk points, we continuously monitor and periodically assess, analyze potential issues, and identify optimization opportunities to consistently enhance risk management effectiveness, ensuring that the Company's operational risks remain within a controllable level.

Risk Monitoring and Inspection Process

Compliance Risk Review

During the Reporting Period, Innovent's compliance department collaborated with multiple departments to conduct a systematic compliance risk assessment. By establishing a compliance risk map, the Company performed a comprehensive risk review of high-risk business processes and implemented multi-level risk prevention measures, effectively enhancing the Company's compliance risk governance capabilities.



Compliance Risk Assessment Process

Business Risk Assessment

In 2025, the Company's audit department initiated a systematic risk identification and assessment process, establishing a dynamic risk assessment model that integrates business perspectives with professional audit judgment. Qualitative insights were obtained through interviews with frontline business managers. Combining historical audit findings and industry trends, a quantitative and qualitative analysis was conducted to assess the probability and impact of risks. Ultimately, risks were categorized into three levels: high, medium and low. We directly translate assessment results into management actions, prioritizing the allocation of audit resources to high-risk areas and driving business units to refine internal control processes addressing the root causes of risks. Meanwhile, the Company has established a regular risk communication and training mechanism, regularly reporting to senior management and conducting briefings for key personnel to effectively enhance the Company's overall risk prevention and control capabilities.

1.4 Customer Privacy Protection and Information Security

Innovent regards information security and data protection as the cornerstone of compliant corporate operations. The Company has established an independent Information Security Management Office and implemented a comprehensive information security management system covering all business scenarios to provide full protection for the Company's assets and the legitimate rights and interests of its stakeholders.

1.4.1 Our Governance

Innovent strictly complies with applicable domestic and international laws and regulations, including the "Network Security Law of the People's Republic of China"(<中華人民共和國網絡安全法>), the "Data Security Law of the People's Republic of China" (<中華人民共和國數據安全法>), the "Personal Information Protection Law of the People's Republic of China"(<中華人民共和國個人信息保護法>), and the "General Data Protection Regulation (GDPR)" (<歐盟通用數據保護條例>) of the European Union. Based on the ISO 27001 Information Security Management System standard, Innovent has established a comprehensive information security management system. The Company has formulated and implemented a series of policies, such as the "Information Security Management Manual" (<信息安全管理手冊>), the "Information Security Operation Procedures" (<信息安全運營操作規程>), and the "Business Information Security Management Procedures" (<業務信息安全管理規程>). These policies cover key areas including core business processes and supply chain management. Through systematic control measures, Innovent effectively mitigates information security risks and ensures operational compliance and data security.

In 2025, we reviewed and recompiled 14 information security policies across 6 key areas: business data security, supplier management, security operations, information security management system, application system development, and IT operations management. We also revised specific standards, including the "Operations and Maintenance Audit System (Bastion Host) Management Specification" (<運維審計系統(堡壘機)管理規範>), the "Application System Development and Construction Security Specification" (<應用系統開發建設安全規範>) and the "Information System Development Security Requirement Baseline Operational Procedures" (<信息系統開發安全需求基線操作規程>), to continuously safeguard the Company's operational information security.

During the Reporting Period, Innovent successfully passed the annual surveillance audit for its ISO 27001 Information Security Management System certification. The certification now covers all core business segments of the Company, including R&D, manufacturing, clinical trials and commercialization, as well as the corresponding business premises.

1.4.2 Our Actions

Information Security Protection Measures

To prevent information leakage to the greatest extent possible, we implemented an information classification management policy. Based on staffs' roles, ranks, and work function, access rights to information were categorized into three levels: Red Zone, Blue Zone, and Green Zone. Clear management rules and regulations regarding the use of facilities and equipment and access rights for each tier have been established. During the Reporting Period, we reassessed our existing business secret confidentiality management system. Based on asset and threat analyses, we quantified potential risks and completed comprehensive rectification measures. We implemented end-to-end encryption for key positions within core business department. During the Reporting Period, no data leakage incidents occurred at the Company.

In daily operations, we continuously strengthen proactive prevention measures by upgrading technologies across technical protection, infrastructure enhancement, vulnerability scanning, access control, and active monitoring. These efforts are supported by a normalized audit mechanism to comprehensively defend against data breaches. During the Reporting Period, based on business scenarios, we implemented a series of information security improvement initiatives:

- **Overseas Data Security Compliance:** To meet the operational requirements of our U.S. business, we have deployed dedicated security policies covering all staff in the United States to ensure the security of information transmission and storage in overseas business scenarios.

- **SDDS Paperless Project Security Construction:** Security assessment requirements are integrated during the planning and design phases of all project modules. Specialized security testing is completed prior to system go-live, followed by refined access control implementation post-launch to ensure end-to-end security.

- **ELN System Security Deployment:** We implemented security solutions in the R&D and production departments, define baseline security requirements, design permission matrices and blueprint-level security architectures, complete 100% vulnerability scanning prior to go-live, and issue a specialized security assessment report.

- **Online Security Operations Capability Building:** Online transformation of security processes in Suzhou, Hangzhou and Shanghai has been completed, with operational decision-making supported through data-driven approaches. A unified department dashboard has been established, and four key processes, including bastion host application and vulnerability scanning application, have been launched. This initiative has reduced manual processing time by approximately 30% and significantly improved overall response efficiency.

- **Security Control of R&D Computing Platform:** Building upon the protective measures implemented in 2024 for the WeMol computing platform and AI intelligence repository, a security baseline for the ELN system has been added to comprehensively cover the R&D computing environment, ensuring that genetic data does not leak during project workflows. During the Reporting Period, R&D data leaks had never occurred.

Building on proactive defense measures, the Company continues to refine its information security incident response processes to minimize the impact of incidents when the incident happens.

Information Security Incident Handling Process

Internal and External Information Security Risk Assessment

Innovent regularly conducts systematic reviews of internal and external information security risks to ensure the timely identification and response to significant potential risks.

During the Reporting Period, we conducted a systematic security assessment of 588 key assets across our three major operational bases in Suzhou, Shanghai and Hangzhou. This assessment covered 10 core systems, including IT infrastructure, clinical R&D, and commercial operations. Through the implementation of specialized vulnerability scanning and penetration testing, all identified optimization recommendations have been fully addressed to close the loop, ensuring the continuous enhancement of the Company's information system security protection capabilities.

Information Security Culture Construction

Innovent has established a comprehensive information security training mechanism. The Company organizes mandatory annual specialized training for all staff on information security and trade secret protection and ensures training effectiveness through online assessments. Concurrently, we established a normalized information security communication mechanism. Through regular email dissemination and case sharing, we continuously enhance staff's awareness of information security prevention, effectively mitigating risks related to data breaches and commercial fraud. We conduct at least one specialized emergency drill for information security annually to ensure that the Company can rapidly restore data and services when facing unexpected incidents such as potential data breaches or system failures, thereby safeguarding business continuity. During the Reporting Period, we conducted 2 online training sessions for all staff and held 6 offline information security training sessions specifically for high-risk departments.

Information Security Drill

In December 2025, we organized and implemented a specialized information security emergency drill. This drill simulated a "LockBit ransomware attack" scenario to systematically verify the Company's emergency response capabilities within its information security risk management system. The drill adopted a three-tier response management structure (Leadership Decision Group, Technical Support Group, and Expert Group), strictly adhering to the requirements of the "Information Security Risk Management Procedure", ultimately achieving the goal of a 100% business system backup recovery success rate.

This emergency drill significantly enhanced the technical team's operational proficiency and achieved full coverage of core business scenarios. The successful drill validated the effectiveness of the 'full + incremental' backup mechanism, reducing emergency response time by 30% compared to industry standards. This significantly enhanced Business Continuity Management (BCM) capabilities and provided robust support for safeguarding critical data security.

Information Security Awareness and Promotion

In 2025, we conducted multiple company-wide information security awareness campaigns via email. The content covered physical intrusion prevention, personnel data leakage prevention, commercial espionage prevention, office security, and virus protection. Utilizing comic illustrations, we vividly disseminated information security knowledge to continuously enhance staff's information security awareness. During the Reporting Period, we distributed a total of 23 illustrated information security tips.

Information Security Awareness Email

Information Security Audit

We conduct information security audits on a regular basis to ensure the effectiveness of information security management. During the Reporting Period, we conducted a special audit of the Company's digital systems. The sampling covered 56 systems, with a primary focus on those related to research and development and commercialization. Upon completion of the audit, a special audit report was issued, and 100% of all high-risk vulnerabilities have been fully remediated. At the same time, we fully implemented the principle of least privilege to eliminate the risk of bulk data leakage from a systemic perspective.

1.5 Intellectual Property Protection

Innovent has established an intellectual property ("IP") management system covering the entire R&D lifecycle to continuously enhance IP management capabilities and provide a solid foundation for R&D innovation.

1.5.1 Our Governance

Innovent strictly complies with intellectual property protection laws and regulations such as the "Patent Law of the People's Republic of China"(<中華人民共和國專利法>) and the "Trademark Law of the People's Republic of China" (<中華人民共和國商標法>) and actively fulfills international treaties and initiatives including the "Patent Cooperation Treaty (PCT)" (<專利合作條約(PCT)>), the "Madrid Agreement Concerning the International Registration of Marks" (<商標國際註冊馬德里協定>), the "WIPO Copyright Treaty" (<世界知識產權組織版權條約>), the "Paris Convention for the Protection of Industrial Property" (<保護工業產權巴黎公約>), the "Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement)"(<與貿易有關的知識產權協議>), and the "Doha Declaration on the TRIPS Agreement and Public Health"(<多哈健康宣言>).

We have established intellectual property management policies, including the "Patent Infringement Risk Management and Control Measures" (<專利侵權風險管理控制辦法>), the "Risk Patent Monitoring Procedures" (<風險專利監控程序>), and the "Guidelines for Patent Due Diligence in Introduced Projects" (<引進項目專利盡職調查指南>). We continuously conduct monitoring to prevent external patent infringement and ensure the global compliance and asset security of innovative achievements through full-process management. During the Reporting Period, we updated the "Operating Procedures for Determining Inventors of Molecular Patents" (<分子專利發明人確定操作規程>) to standardize the fundamental process for determining inventors of molecular patents and further strengthen the protection of patent rights and interests. We have also updated the "Overseas Patent Portfolio Strategy" (<境外專利佈局策略>), integrating our international patent portfolio with the Company's global strategy by taking into account project priorities, patent categories, and patent examination standards of different countries and regions.

Benefiting from the well-established intellectual property management system, we obtained the GB/T 29490-2023 Intellectual Property Compliance Management System certification during the Reporting Period.


知识产权合规管理体系认证证书

证书号码：165IP250671R0L

兹证明

信达生物制药（苏州）有限公司

统一社会信用代码：91320594581020 64XX

注册地址：苏州工业园区东平街 168 号

经营地址：江苏省苏州市苏州工业园区东平街 168 号

知识产权合规管理体系符合标准：

GB/T29490-2023

通过认证的范围如下：

抗体类、蛋白类、小分子类药物的研发，资质范围内抗体类生物制品、蛋白类生物制品、小分子类药品的生产、销售的知识产权管理

注：认证注册范围不包括未获得有效的国家规定的相关行政许可、资质许可的产品/服务范围

初次发证日期：2025 年 12 月 31 日　　有效期至：2028 年 12 月 30 日

本证书有效期三年，证书有效性通过年度监督确认保持。证书有效信息可登陆国家认证认可监督委员会官方网站 www.cnca.gov.cn 或中知（北京）认证有限公司官方网站查询。

签发：

中知认证

本次发证日期：2025 年 12 月 31 日

中知（北京）认证有限公司

地址：北京市海淀区花园路5号133幢3层302室（100088）

http://www.zzbjrz.com

GB/T 29490-2023 Certificate of Conformity for Intellectual Property Compliance Management System

1.5.2 Our Actions

In intellectual property management, we have established an intellectual property risk prevention and control system spanning the entire R&D lifecycle. By implementing rigorous patent searches, risk assessments, and infringement early-warning mechanisms, we ensure that all R&D innovation activities are conducted within a compliant framework, effectively safeguarding the legitimate rights and interests of the Company's innovation achievements.

Intellectual Property Management Stages

Innovent has integrated IP protection into its contract management system. It formulates differentiated IP protection clauses tailored to the characteristics of different business types and continuously optimizes them in accordance with the laws and regulations of its operating locations. All contracts must undergo comprehensive compliance review prior to execution to effectively mitigate potential infringement and ownership risks. We conducted an in-depth review of the Company's various agreements, including Confidential Disclosure Agreements (CDAs), Material Transfer Agreements (MTAs), and License Agreements (LAs), as well as performed specialized intellectual property audits on procurement contracts and clinical agreements. Meanwhile, the IP Department ensures the achievement of the Company's long-term strategic objectives through formulating effective IP terms in cooperation and licensing negotiations. This includes drafting key IP terms for both In-License and Out-License arrangements and finalizing a checklist for intellectual property due diligence.

At different stages of R&D projects, we conduct patent risk assessments and formulate response measures for identified risks respectively.

Scenario	Process	Purpose
Conduct FTO searches according to different stages at the time of project establishment, provide IP support, and promote the project team to make decisions.	Continuously track risky patents and patents of competing companies according to the continuous advancement of R&D to ensure zero risk of product IP.	Eliminate IP risks for future products and establish a solid patent protection mechanism.

Patent Risk Assessment and Exclusion

To continuously strengthen staff's awareness of IP protection and enhance the capabilities of relevant personnel in this area, we regularly conduct specialized intellectual property training sessions for all staff. In 2025, we organized 20 specialized training sessions on intellectual property using a flexible hybrid format combining online and offline delivery. The content covered global patent examination standards, patent portfolio strategies, search and analysis techniques, interpretation of laws and regulations, end-to-end management of In/Out Licenses, and cutting-edge areas such as AI agent applications. We specifically invited internationally renowned intellectual property legal experts to conduct special lectures, providing an in-depth analysis of patent protection strategies in key overseas markets. These systematic training programs effectively enhanced the professional competence of the intellectual property team and R&D teams, ensuring that staff stay current with the latest technological developments and practical operational standards.

Invite international renowned intellectual property legal experts to conduct thematic lectures

02

ENJOYING GOOD HEALTH

Innovent believes that a company's true value should not be limited solely to its own development. Corporate value becomes most meaningful when viewed within the broader context of industrial progress, social well-being, national development, and the advancement of human civilization.

Guided by the principle of "science for good", the Company advances its independent drug R&D while strengthening its overall capabilities. We remain consistently patient-centered, actively promote more inclusive healthcare, and take our social responsibilities seriously, with the goal of enabling more patients to benefit from advances in life sciences through accessible, affordable, high-quality biopharmaceuticals. We are committed to collaborating with partners to enhance the overall capabilities of China's biopharmaceutical industry, contributing to the "Healthy China" initiative and supporting the development of a global community for health.

This chapter is in response to the sustainable development goals (SDGs) of the United Nations

2.1 Inclusive Healthcare

With the mission of empowering patients worldwide with affordable, high-quality biopharmaceuticals, Innovent adheres to a development strategy integrating innovation-driven growth, global collaboration, and patient accessibility. The Company is committed to addressing unmet clinical needs and providing safer and more effective treatment options by focusing on cutting-edge research and development. We consistently prioritize drug affordability as a key objective, promote the equitable sharing of medical resources, and accelerate the global dissemination of innovative outcomes through deepened international cooperation. Ultimately, we are committed to realizing our long-term vision of safeguarding patient health and well-being while fulfilling our social responsibilities.

2.1.1 Our Governance

Innovent has integrated inclusive healthcare into the core of its corporate sustainable development strategy. As the highest decision-making authority, the Board holds overall responsibility for overseeing inclusive healthcare initiatives, with a dedicated Audit Committee established to conduct regular supervision and evaluation of significant issues. On this basis, the Company's management is responsible for the specific organization, leadership and execution of inclusive healthcare initiatives to ensure that all measures are effectively implemented and continuously promoted.

2.1.2 Our Actions

Enhance healthcare accessibility

Product Pipeline

Innovent is committed to science-driven innovative research, focusing on major disease areas such as cancer, CVM, autoimmune and eye disease. The Company advances drug development and production centered on unmet medical needs. As of the end of Reporting Period, the Company has 18 approved products, 5 assets are in Phase III or pivotal clinical trials, and an additional 14 molecules are in early clinical stage.

18
marketed products

5
assets in Phase III or pivotal clinical trials

14
molecules in early clinical stage

Therapeutic Areas	Product Pipeline	Marketing Status
Oncology	TYVYT® (sintilimab injection) BYVASDA® (bevacizumab injection) HALPRYZA® (rituximab injection) PEMAZYRE® (pemigatinib) Olverembatinib CYRAMZA® (ramucirumab) Retsevmo® (selpercatinib) FUCASO® (equecabtagene autoleucel) DUPERT® (fulzerasib) Jaypirca® (pirtobrutinib) DOVBLERON® (taletrectinib adipate) Limertinib TABOSUN® (ipilimumab N01 injection)	Marketed
	IBI343 IBI363 IBI354	Clinical Phase III
	IBI3003	Clinical Phase II
	IBI3009 IBI3001 IBI3005 IBI3014 IBI3020 IBI3026	Clinical Phase I
CVM	Mazdutide SINTBILO® (tafolecimab injection)	Marketed
	IBI128	Clinical Phase III
	IBI3016 IBI3032	Clinical Phase I
Autoimmune	SULINNO® (adalimumab injection) PECONDLE® (picankibart injection)	Marketed
	IBI355 IBI356 IBI3002	Clinical Phase I
Ophthalmology	SYCUME® (teprotumumab N01 injection)	Marketed
	IBI302	Clinical Phase III
	IBI324	Clinical Phase I

We firmly believe that the ultimate value of innovation lies in effectively addressing patients' challenges. In 2025, the Company's multiple Core Products achieved milestone progress, spanning from R&D origins to clinical accessibility, comprehensively demonstrating our commitment to enhancing healthcare accessibility.

Ophthalmology

In the ophthalmology field, our independently developed SYCUME® (teprotumumab N01 injection), as the first IGF-1R targeted antibody drug in China and second globally, has filled a nearly 70-year treatment gap for TED in the country. Its therapeutic efficacy is comparable to international standards, while its pricing is approximately 1/17 that of similar products in the United States. This product was successfully included in the NRDL in December 2025. Through a combination of 'clinical efficacy + affordability + insurance coverage', it significantly reduced the financial burden on patients, ensuring that this breakthrough therapy truly benefits those who need it.

CVM

In the field of CVM, IBI362 (Mazdutide), the world's first approved GCG/GLP-1 dual receptor agonist, has been approved for weight management in adults with obesity or overweight, as well as for glycemic control in T2D. Its clinical studies have demonstrated significant weight loss and multiple metabolic improvement benefits, providing a potent new option for patients with moderate to severe obesity. This "first-in-class" product addresses a large patient population and aims to enhance treatment standards and accessibility through innovative mechanisms.

Immunology

In the field of autoimmune diseases, the novel IL-23p19 antibody PECONDLE® (picankibart injection) has been approved for the treatment of moderate-to-severe plaque psoriasis. The high PASI 90 response rate (surpassing 80%) in its Phase III clinical study validates its superior efficacy. Meanwhile, its 12-week dosing interval, the longest among its class, significantly reduces patient clinic visits and dosing frequency. This approach enhances treatment convenience and patients' quality of life while ensuring efficacy, thereby improving the accessibility and sustainability of long-term treatment.

Highlights of Innovent's Drug R&D Progress in 2025

While deepening its focus on major disease areas such as oncology, CVM, immunology, and ophthalmology, Innovent is also actively expanding its global portfolio in rare disease drug development. The Company is committed to addressing unmet clinical needs worldwide, ensuring that innovative therapies better benefit patients with rare diseases. As of the end of the Reporting Period, the Company has cumulatively obtained 13 Orphan Drug Designations and 1 listing in the Rare Disease Catalog for a total of 7 drugs, with 2 of them remaining in clinical development.

TYVYT® (sintilimab injection)	• Obtained 2 Orphan Drug Designations from the U.S. Food and Drug Administration ("FDA") for two indications: T-cell lymphoma and esophageal cancer. • Obtained 1 Orphan Drug Designation from the European Medicines Agency ("EMA") for peripheral T-cell lymphoma.
PEMAZYRE® (Pemigatinib)	• Obtained 1 Orphan Drug Designation from the U.S. FDA for the indication of cholangiocarcinoma. • Obtained 1 Orphan Drug Designation from the Ministry of Health, Labor and Welfare (MHLW) of Japan for the Indication of cholangiocarcinoma.
Olverembatinib	• Obtained 4 Orphan Drug Designations from the U.S. FDA for four indications: chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, and gastrointestinal stromal tumor. • Obtained 1 Orphan Drug Designation from the European EMA for the indication of chronic myeloid leukemia.
Retsevmo® (selpercatinib)	• Obtained 1 Orphan Drug Designation from the U.S. FDA for the indication of metastatic non-small cell lung cancer (NSCLC).
FUCASO® (Equecabtagene Autoleucel)	• Obtained 1 Orphan Drug Designation from the U.S. FDA for the indication of relapsed/refractory multiple myeloma.
IBI343	• Obtained 1 Orphan Drug Designation from the U.S. FDA for the indication of pancreatic cancer.
IBI363	• One of the indications is melanoma, a disease included in the "Second Batch of Rare Disease Catalog" issued by the National Health Commission of China.

R&D Platform

As an innovation-driven biopharmaceutical company, Innovent continues to deepen its R&D capabilities and is committed to providing accessible and high-quality innovative treatment solutions for patients worldwide. We continue to increase investment in cutting-edge technology platforms and actively build a high-caliber talent team with a global perspective and innovation capabilities. This injects sustained momentum into drug R&D and solidifies the Company's core competitiveness for long-term development. The Company has established a high-value technology platform system that spans the entire lifecycle of biologic innovative drugs. This system covers key stages from R&D to manufacturing and quality management, clinical development, and commercial operations, and provides a strong foundation for the consistent delivery of globally competitive therapies.



Innovent Fully Integrated Drug Platform Construction

During the Reporting Period, based on strategic planning and business development needs, the Company leveraged its established technology platform system covering the entire process from drug R&D to commercialization. It focused on advancing digital transformation and intelligent upgrades to build a globally leading new paradigm for digital R&D.

Intelligent Upgrade of the R&D System: Building an AI Drug Development (AIDD) Platform

In 2025, Innovent continued to advance the intelligent upgrade of its R&D system, accelerating the deep integration of artificial intelligence technologies across the entire drug development chain. Centered on Innovent Academy as its core platform, the Company systematically advanced the online and structured governance of R&D data while achieving laboratory process automation, thereby establishing an AI-driven R&D system covering "discovery, optimization, and decision-making".

On this basis, we have established multiple industry-leading intelligent platforms. Among them, the 'AI+NGS' wet-dry closed-loop antibody discovery platform has been applied to multiple internal projects, significantly shortening the antibody screening cycle and improving the efficiency of discovering high-quality candidate molecules. Meanwhile, the Company has developed an AI-driven *de novo* design closed-loop system dedicated to small protein drug development. This system enables intelligent iteration across the entire workflow, from target elucidation to molecular optimization, demonstrating a magnitude-level improvement in hit rates and R&D iteration speed in internal projects.

As of the end of the Reporting Period, the Company has assembled a high-end talent team of nearly 8,000 personnel, including approximately 1,200 R&D professionals. Over 91% of the early-stage R&D team are holding master's or doctoral degrees, while more than 35% of the clinical development team have attained master's or doctoral qualifications. Their core leaders all possess dual backgrounds from top-tier global industrial and academic sectors, providing solid talent support for cutting-edge innovation and global development.

Promoting Global Presence

During the Reporting Period, Innovent continued to expand its global presence and strengthen strategic partnerships:

We entered into global strategic partnership with Takeda to accelerate the global development and commercialization of our next-generation IO and ADC therapies, including the global partnership on IBI363 (PD-1/IL-2$^{\alpha\text{-bias}}$) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC). We entered into the seventh partnership with Eli Lilly to advance novel medicines in oncology and immunology, establishing a new model for Innovent to accelerate the global development of our innovative pipeline. We entered into a collaboration and exclusive global license agreement with Roche for IBI3009 (DLL3 ADC). We entered into a joint development agreement with Ollin Biosciences for IBI324 (VEGF/ANG2). In February 2026, Ollin announced positive topline data of IBI324 from a head-to-head Phase Ib JADE clinical study versus faricimab (Vabysmo®). IBI324 demonstrated superiority in terms of faster and greater retinal drying in DME and numerically greater BCVA improvements in both DME and wAMD.

Approvals were obtained from the Pharmaceutical Administration Bureau ("ISAF") of the Macau Special Administrative Region of China ("Macau") for mazdutide (GCG/GLP-1), DUPERT® (fulzerasib), SINTBILO® (tafolecimab injection) and BYVASDA® (bevacizumab injection). We continued collaborating with regional partners to expedite the registrational process of our products such as TYVYT® (sintilimab injection) and BYVASDA® (bevacizumab injection) in Southeast Asian and Latin American markets.

The Company is committed to enabling more patients globally to access high-quality, affordable innovative treatments. During the Reporting Period, we provided free investigational drugs for two clinical trials in India and Africa. In the future, we will further strengthen our layout in emerging markets and low- to middle-income countries. We will actively collaborate with local governments, partners, and non-governmental organizations to jointly improve drug accessibility, respond to broader health needs, and contribute to building a sustainable and inclusive global health ecosystem.

To further accelerate the accessibility of pharmaceutical products in overseas markets, the Company actively expanded localized partnerships during the Reporting Period. Five collaborations have been established with enterprises in Colombia, Mexico, Brazil, India, and Indonesia, covering biosimilars and innovative drugs, with a particular focus on the oncology sector. We collaborate with local partners to jointly build local capabilities in pharmaceutical R&D, production, and pharmacovigilance, addressing the urgent clinical needs of the market.

As of the end of the Reporting Period, the Company's products have been developed or launched in multiple countries/regions (including EU, US, Japan, Australia etc. Asian regions and South American regions), 1 product achieved approval and on market in ex-China, another 4 products are either in pivotal studies or NDA (or MAA/BLA) stage, deepening the Company's global footprint.

Enhance Medication Affordability

Fair Pricing

Innovent has always been committed to improving the affordability of innovative drugs and upholding its corporate promise to develop high-quality biologics that are accessible to the general public. The Company has established the *"Fair Pricing Policy"* (<公平定價政策>)[3], committing to adhere to the World Health Organization's definition of "fair pricing" and formulating pricing strategies based on the World Bank's national income classification standards. A scientific and structured global differentiated pricing system has been established.

When formulating global pricing strategies, we systematically evaluate five core dimensions based on conditions in different countries and regions: healthcare systems and payment capabilities, regulatory and pricing policies, market competition and the generic drug environment, market access, and payer needs. By integrating global price references and system management, we actively align with local medical insurance and health policies to achieve a multi-dimensional balance among drug value, patient accessibility, and the sustainability of healthcare systems.

▶ Healthcare system and payment capacity

- Per capita GDP level
- National health expenditure scale
- Per capita health expenditure
- Health insurance system coverage

▶ Regulatory and Pricing Policies

- National Drug Pricing Policy
- Pharmaceutical Subsidy Status
- Government Intervention

▶ Market Competition and Generic Drug Environment

- Price Structure of Competing Originator Drugs
- Competitive Intensity and Pricing of Generics/Biosimilars
- Market Penetration Rate in Key Therapeutic Areas

▶ Global Price Referencing and System Management

- Price Referencing and Alignment Across Key Global Markets
- Internal Pricing Decision-Making and Coordination Mechanisms

▶ Market Access and Payer Needs

- Cost-effectiveness and Budget Impact Analysis Standards, and Partner Negotiations

Key Factors in Innovent's Fair Pricing Considerations

In China market, leveraging continuous R&D innovation and scaled production, we have significantly lowered the treatment threshold for high-quality biopharmaceuticals. For example, the Company's PD-1 inhibitor is priced at approximately 1/30 of similar products in the United States; the price of its Core Product SYCUME® (teprotumumab N01 injection) is also only 1/17 of imported comparable products. In overseas emerging markets, we adopt a cost-based pricing strategy, referencing pharmaceutical prices in local or comparable middle-income countries to ensure that our pricing is significantly lower than that of similar originator drugs. This initiative aims to provide high-quality and cost-effective treatment options for patients in emerging markets, thereby fulfilling our mission to benefit a broader patient population.

3 Please refer to Innovent's ESG website for "Fair Pricing Policy" (<公平定價政策>).

The Implementation of Medical Insurance

Innovent actively responds to national medical security policies and is committed to implementing the "Healthy China 2030" strategy, striving to advance public health development through the development of affordable innovative therapies. We have significantly enhanced the accessibility and affordability of medicines by continuously incorporating innovative drugs into the NRDL and expanding market coverage.

During the Reporting Period, seven innovative products of the Company were successfully included in the "*National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition)* (<國家基本醫療保險、工傷保險和生育保險藥品目錄(2025版)>)", also known as National Reimbursement Drug List and NRDL. The updated catalog is effective from 1 January 2026, further enhancing drug accessibility and affordability to benefit more patients in China. As of the end of the Reporting Period, 12 of the Company's products have been included in the NRDL, covering key therapeutic areas including oncology, CVM, autoimmune, and eye disease.

2025 NRDL Update: Inclusion of Innovent's Products

- **TYVYT® (Sintilimab injection)** has been included in the NRDL with a new, eighth approved indication: in combination with fruquintinib capsules for the treatment of patients with advanced mismatch repair proficient (pMMR) endometrial cancer who have progressed on prior systemic anti-tumor therapy and are not candidates for curative surgery or radiotherapy. This inclusion addresses a significant unmet medical need for patients who have limited response to traditional therapies.
- **SYCUME® (Teprotumumab N01 injection)** has been newly included in the NRDL for the treatment of moderate-to-severe TED. This drug is the only non-invasive breakthrough therapy approved in China capable of reversing TED, filling a 70-year clinical treatment gap in this disease area. The inclusion of this treatment in the national medical insurance scheme will align the therapeutic approach for patients with TED in China with international standards and maximize the accessibility and affordability of innovative drugs.
- **Limertinib** has been newly included in the NRDL for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR sensitizing mutations (first-line therapy), as well as patients who have developed an EGFR T790M mutation following EGFR TKI treatment. Its unique structure effectively penetrates the blood-brain barrier, significantly reducing the risk of disease progression in patients with brain metastases and providing a superior treatment option for patients with EGFR-mutated NSCLC.
- **DUPERT® (fulzerasib)** has been newly included in the NRDL for the treatment of adult patients with advanced NSCLC harboring KRAS G12C mutations who have received at least one prior systemic therapy. This drug is a novel KRAS G12C inhibitor. Its inclusion in the national medical insurance scheme fills the clinical gap in targeted therapy for this mutant lung cancer.
- **DOVBLERON® (Taletrectinib Adipate)** has been newly included in the NRDL for the treatment of adult patients with ROS1-positive locally advanced or metastatic NSCLC. This drug is a next-generation ROS1 TKI. Its inclusion in the national medical insurance program will benefit patients with advanced lung cancer positive for ROS1.
- **Retsevmo® (selpercatinib)** has been newly included in the National Reimbursement Drug List for the treatment of patients with RET fusion-positive advanced NSCLC, RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer. This drug is the first globally approved highly selective RET inhibitor and will further benefit patients with RET-mutated tumors.
- **Jaypirca® (pirtobrutinib)** has been newly included in the NRDL for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior systemic therapies, including BTK inhibitors. This drug is the world's first and only approved non-covalent (reversible) BTK inhibitor. It will provide new treatment options for patients who have failed BTK inhibitor therapy, effectively addressing unmet clinical needs.

Empowering the enhancement of medical standards

As an industry-leading biopharmaceutical company, Innovent adheres to the strategic theme of 'Building a Healthy China through Joint Construction and Shared Benefits' for national health. The Company has long focused on and supported the development of medical and health services across various regions. Through continuous professional training, resource matching, and exchanges and cooperation, it is gradually narrowing the gaps in basic health services and health levels between urban and rural areas, different regions, and diverse population groups.

Training of local medical personnel

During the Reporting Period, we continued to implement the 'Comfortable and Reliable Patient Assistance Project', consolidating and expanding comprehensive support for patients with malignant tumors. The project leverages the tiered diagnosis and treatment system to continuously promote multidisciplinary collaboration and full-process management, while steadily strengthening healthcare professionals' professional capabilities in immunotherapy. At the same time, we continue to collaborate with pharmacies, professional institutions, and medical personnel across various regions to optimize service processes and patient education, thereby further enhancing the accessibility of high-quality medical services and fulfilling the Company's commitment to 'empowering patients with affordable and high-quality biopharmaceuticals'.

Assist local partners in enhancing pharmaceutical manufacturing standards

Innovent has long paid close attention to and actively participated in building pharmaceutical manufacturing capabilities in developing countries. Through technical training, system optimization, and resource alignment, we support local partners in enhancing their capabilities in pharmaceutical procurement, warehousing, logistics, and quality management. We are committed to building a more efficient, stable, and accessible pharmaceutical supply network to advance the realization of global health equity and accessibility goals through concrete actions. In addition, Innovent actively responds to the initiative to enhance drug manufacturing capabilities in developing countries and collaborates with various parties to support healthcare standards in less developed regions.

Assist Local Manufacturers in Mexico to Enhance Pharmaceutical Manufacturing Standards

Innovent has entered an in-depth strategic collaboration with Saya Biologics, a local biopharmaceutical company in Mexico, for the BYVASDA® (bevacizumab injection) project. In this collaboration, leveraging its professional expertise and international experience in the biopharmaceutical sector, the Company provided its Mexican partner with systematic support, including technical training and process guidance. This collaboration enabled the successful establishment and operation of an internationally compliant sterile drug production and quality control (QC) system, thereby enhancing the local supply of high-quality pharmaceuticals.

Supporting the Indonesian Partner in Establishing a Pharmacovigilance System

Innovent's product BYVASDA® (bevacizumab injection) has been approved for marketing in Indonesia. To better ensure global PV compliance, we have signed a pharmacovigilance agreement with our Indonesian partner PT Etana Biotechnologies Indonesia (Etana), to support the partner in improving its pharmacovigilance system.

To ensure that the pharmacovigilance system and relevant activities comply with regulatory requirements, both parties have clarified and defined their respective responsibilities and divisions of labor across all PV processes, including but not limited to the processing and submission of safety information, safety signal monitoring and risk management, as well as periodic risk-benefit evaluations. As the global safety database holder for this product, Innovent is assisting its partner in establishing a rigorous and comprehensive pharmacovigilance system, thereby effectively ensuring medication safety for patients in Indonesia.

Promote industry development

Innovent is committed to leading biopharmaceutical industry progress. We deeply engage in industry standards development to drive sectoral standardization; participate actively in international conferences to advance industry-academia-research-medicine integration; establish innovation funds to boost upstream-downstream industrial collaboration. Innovent has been leveraging original innovation to deliver technological breakthroughs and empowering the sustainable development of the medical and health ecosystem.

Innovent led the dual-currency "InnoPinnacle Fund" establishment, focusing on innovative drugs, biotechnology, and upstream industrial chain companies. Leveraging its industrial strengths, Innovent empowers next-generation biopharmaceuticals and breakthrough technologies to address unmet medical needs.

In 2025, Innovent actively engaged in top-level design to accelerate both the market approval of innovative drugs and the formulation of national standards. Through in-depth involvement in the development of technical guidelines, national drug standards and reference standards, we proactively fulfilled our industry responsibilities and advanced the establishment and refinement of multiple key technical specifications and national standards. To establishing technical guidance and principles, the Company participated in "*Technical Guidance on Single-Arm Clinical Trials in Support of Regular Approval for Marketing Applications of Anti-tumor Drugs*" (<單臂臨床試驗用於支持抗腫瘤藥物常規上市申請技術指導原則>) issued by the National Medical Products Administration's Center for Drug Evaluation. The Company also promoted the formal release of this guideline in December 2025. In addition, the Company participated in preliminary discussions and solicited opinions on 6 technical guidance regarding "post-approval variations to biological products, CMC documents written for recombinant proteins and antibody drugs, and segmented production of chemical drugs". These efforts contributed to clarifying relevant technical requirements and fostering industry consensus. During the development of national drug standards, the Company participated in revising the pharmacopeial monographs for three biosimilars – SULINNO® (adalimumab injection), BYVASDA® (bevacizumab injection), and HALPRYZA® (rituximab injection) – for inclusion in the "*Pharmacopoeia of the People's Republic of China*" (<中國藥典>). This involved multiple rounds of technical communication with professional institutions. In the field of reference standards, the Company supported the collaborative calibration of national candidate of reference standards for the 3 above biosimilar products, focusing on applicability assessments of the biological activities, we dedicated to providing technical support for the improvement of the national QC system.

List of Draft Technical Guidelines for Comment Participated by Innovent

- *"Technical Guidelines for the Drafting and Evaluation of Post-Approval Pharmaceutical Change Management Plans for Therapeutic Biological Products"* (<治療用生物製品批准後藥學變更管理方案起草及評價技術指導原則>)
- *"Guidelines for Drafting the Manufacturing and Testing Specifications for Recombinant Monoclonal Antibody Biologics"* (<重組表達單克隆抗體類生物製品製造及檢定規程撰寫指南>)
- *"Guidelines for Drafting the Quality of Summary for Marketing Authorization Applications of Therapeutic Recombinant Protein Drugs"* (<治療用重組蛋白藥物上市許可申請質量綜述資料撰寫指導原則>)
- *"Guidelines for Drafting the Quality of Summary for Marketing Authorization Applications of Biosimilars"* (<生物類似藥上市許可申請質量綜述資料撰寫指導原則>)
- *"Guidelines for Drafting the Quality of Summary for Marketing Authorization Applications of Antibody-Drug Conjugates"* (<抗體偶聯藥物上市許可申請質量綜述資料撰寫指導原則>)
- *"Technical Guidelines for Pharmaceutical Research on Segmented Manufacturing of Innovative Chemical Drugs"* (<化學藥品創新藥分段生產藥學研究技術指導原則>)

Hosted the Inaugural Weight Management Industry Conference, Joining Forces with the Industry to Foster a New Weight-loss Ecosystem

On 10 August 2025, as part of the ongoing national "Weight Management Year" initiative, the "Shaping Health—2025 Weight Management Industry Conference" was successfully held in Suzhou. The conference was guided by the National Center for Technology Innovation in Biopharmaceuticals and hosted by Innovent. The conference brought together over 800 attendees from various sectors, including government bodies, medical institutions, research organizations, industry representatives. Discussions centered on the evolving role of weight management within the Healthy China strategy, emphasized the importance of localized innovative solutions, and called for cross-sector collaboration to enhance public awareness of obesity science, standardize treatment practices, and jointly build a healthier weight management ecosystem.

Innovent Hosted the first "Shaping Health – 2025 Weight Management Industry Conference

Sharing of Cutting-Edge Trends at Renmin University of China

In 2025, Dr. Li Li, Director of the Statistics and Information Department at Innovent, was invited as a keynote speaker for the 'Statistics Grand Lecture' at the School of Statistics, Renmin University of China. Titled 'Evolution of Statistical Analysis Frameworks in Clinical Trials: A Case Study of GLP-1 Drug Development,' she systematically reviewed the evolution of trial design and statistical methodologies for such drugs, drawing on her extensive cross-domain R&D experience, and outlined emerging trends including real-world evidence and decentralized trials in the era of artificial intelligence. This sharing reflects Innovent's professional accumulation in the field of pharmaceutical data science and its continuous efforts to promote academic exchange within the industry and build a talent ecosystem.

Innovation Seminar on Clinical Research at the First Affiliated Hospital of Henan University of Science and Technology

In December 2025, Dr. Qian Lei, Chief Research Officer of Innovent, led a team to the First Affiliated Hospital of Henan University of Science and Technology for academic exchange. Focusing on the publication of the IBI362 GLORY-1 study in *"The New England Journal of Medicine"* (<新英格蘭醫學雜誌>), both parties conducted in-depth discussions on topics including clinical trial design, statistical methodologies, and manuscript preparation. This exchange strengthened the collaboration between medical and pharmaceutical enterprises, laying a pragmatic foundation for enhancing regional clinical research capabilities and promoting the transformation of research outcomes.

Participated in the 4th China Obesity Conference (COC 2025)

From 15 to 17 August 2025, Innovent participated in the 4th China Obesity Conference (COC 2025). The Company successfully hosted the "New Advances in Pharmacological Treatment for Obesity" forum and officially launched the SMART multicenter clinical study supported by Innovent. This study involved more than 20 medical centers nationwide and aimed to explore the therapeutic efficacy of IBI362 (Mazdutide), a dual GCG/GLP-1 receptor agonist, when used in combination with sleeve gastrectomy.

Concurrently, the conference presented breakthrough data from the Phase III trial of Mazdutide, GLORY-1: significant weight reduction, a reduction in waist circumference of approximately 11 centimeters, and a liver fat content reduction exceeding 80%. These findings offer a novel therapeutic option for patients with obesity and support the implementation of the "Healthy China 2030" strategy.

Innovent Participated in the 4th China Obesity Conference

Participated in the 2025 Annual Meeting of the Chinese Diabetes Society (CDS)

From 20 to 22 November 2025, Innovent showcased its key products in the endocrine and metabolic portfolio – IBI362 (Mazdutide), SYCUME® (teprotumumab N01 injection), and SINTBILO® (tafolecimab injection) – at the 2025 Annual Meeting of the Chinese Diabetes Society (CDS). The Company successfully hosted two specialized sessions: "Co-management of Obesity, Metabolic Disorders, and Fatty Liver Disease" and "Targeted Therapy for TED," systematically exploring cutting-edge advancements in metabolic diseases. The Company established an exhibition booth at the conference to introduce its pipeline and products. It hosted 'Innovent Mini-Lectures' to analyze the GCG receptor mechanism and TED treatment strategies, attracting over 300 physicians for interactive engagement. A liver elastography experience zone was also set up to strengthen clinical communication. Leveraging China's largest academic gathering in endocrinology, the Company continues to advance its academic influence.

Innovent Participated in the 2025 Annual Meeting of the Chinese Diabetes Society

We actively promote academic research. During the Reporting Period, multiple high-quality R&D data points from the Company were published in top-tier scientific journals and conferences:

- *"The New England Journal of Medicine"* (<新英格蘭醫學雜誌>) has published the Phase III pivotal trial (GLORY-1) of Mazdutide in Chinese adults with overweight or obesity. This marks the first publication in this prestigious journal for a major independently developed therapy from China in the field of endocrinology and metabolism.

- *"Nature"* (<自然>) published the results of two Phase III (Pivotal/Registrational) clinical trials (DREAMS-1 and DREAMS-2) evaluating Mazdutide in adult patients with T2D in China in a back-to-back format. Mazdutide is the first innovative drug developed in China to have two clinical studies published at the same time in Nature. It is also the only GCG/GLP-1 therapy ever to be published in both *Nature* and *The New England Journal of Medicine*.

- *"Nature Medicine"* (<自然•醫學>) published the results of a Phase I (Dose Escalation/Expansion) clinical study on IBI343 (CLDN18.2 ADC) in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

- *"Cancer Cell"* (<癌細胞>) has published Phase 1b results of the neoadjuvant regimen combining TABOSUN® (ipilimumab N01 injection) and TYVYT® (sintilimab injection) for locally advanced MSI-H/dMMR colon cancer.

- At the 2025 Annual Meeting of the ASCO, the Company presented eight oral reports showcasing breakthrough clinical data for IBI363 (PD-1/IL-2$^{\alpha\text{-bias}}$), IBI343 (a CLDN18.2 ADC), and other novel candidate drugs, further demonstrating the Company's R&D capabilities and global competitiveness.

- At the 85th Scientific Sessions of the ADA, the Company presented its research through multiple oral and poster presentations showcasing data from the DREAMS-1 trial of Mazdutide, an exploratory analysis of its mechanism of action, and preclinical data on IBI3030 (a PCSK9-GCG antibody-peptide conjugate).

Oral presentation at the 2025 ASCO Annual Meeting



Oral presentation at the 85th ADA Scientific Sessions

Mazdutide (GCG/GLP-1) Phase III Clinical Study Published in Top-Tier International Journals, Marking a Milestone for Academic Achievements in China's Metabolic Field

Mazdutide (GCG/GLP-1) has achieved a series of landmark academic milestones. Multiple key clinical studies have been published in top-tier international academic journals, garnering significant attention and recognition within the field. In May 2025, the results of its Phase III (Pivotal/Registrational) clinical trial for obesity indication (GLORY-1) were published in full as an original article in *"The New England Journal of Medicine (NEJM)"* (<新英格蘭醫學雜誌>). This marks the first innovative drug Phase III clinical trial in China's metabolic disease field to be published in this journal. Subsequently, in December 2025, the papers for its two Phase III studies targeting T2D (DREAMS-1 and DREAMS-2) were published back-to-back in *"Nature"* (<自然>). This marks the first time since the founding of *"Nature"* (<自然>) that two Phase III (Pivotal/Registrational) clinical trials have been published in this format within the field of metabolic and endocrine diseases. At this point, Mazdutide has become the first GCG/GLP-1 drug to publish Phase III (Pivotal/Registrational) clinical research in both *"The New England Journal of Medicine (NEJM)"* (<新英格蘭醫學雜誌>) and *"Nature"* (<自然>), two comprehensive academic journals with the highest reputation.

2.1.3 Our Performance

Innovent adheres to the philosophy of supporting business development through R&D investment. The Company has continuously strengthened its internal R&D capabilities and expanded its product pipeline through diversified deployment, achieving multiple key milestones.

Key Performance Indicators

- Commercialization of Products: Successfully launched 18 drugs, making the Company the enterprise in China with the largest number of marketed antibody drugs.
- NRDL: Currently, 12 drugs have been included in the NRDL of China, significantly enhancing patient access to medications.
- Key Clinical Studies: 5 additional new drug molecules are in Phase III or pivotal clinical study stages.
- Clinical Pipeline Reserve: Several new drug candidates are in early clinical development stages, forming a sustainable innovation pipeline.
- Orphan Drug Designation: The Company has cumulatively obtained 13 Orphan Drug Designations for 7 drugs, demonstrating its R&D differentiation and international potential.

Innovent was ranked among the Top 3 in IDEA Pharma's 2025 China Pharmaceutical Innovation Index

2.2 Public Welfare and Charity

Innovent has always remained true to its original aspiration of 'being a kind company'. Leveraging our comprehensive advantages in resources, technology, and products, we actively give back to society, earnestly fulfill corporate responsibilities, and contribute to the common development of the community. We have long focused on key areas such as improving patients' quality of life, enhancing access to healthcare, supporting rural education, and volunteer services. We continue to advance various public welfare practices and fulfill our commitment to society through concrete actions.

2.2.1 Our Actions

Public Welfare Drug Assistance

Developing high-quality biologics that are affordable for the general public is Innovent's original aspiration and mission. While continuously developing innovative drugs through in-house research and pursuing its own growth, the Company adheres to the development philosophy that economic construction must center on the people. For many years, we have consistently upheld scientific benevolence and remained committed to the principle of 'patient-centeredness,' caring for patients and their families while actively fulfilling our social responsibilities. As of now, Innovent's Patient Assistance Program has benefited approximately 238,000 patients, with the total value of drug donations exceeding RMB 4 billion. In 2025 alone, the Company's drug donations were valued at approximately RMB 430 million, providing support to over 38,000 patients.

SYCUME® (teprotumumab N01 injection) - Bethune Patient Care Program

On 13 April 2025, the national launch ceremony for SYCUME® (teprotumumab N01 injection) was successfully held simultaneously in eight cities across China. SYCUME® (teprotumumab N01 injection) is the first IGF-1R antibody drug approved in China and the second globally for the treatment of TED. The event was co-chaired by Dr. Xianqun Fan, Academician of the Chinese Academy of Engineering (Eye Institute, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine) and Professor Teng Weiping (Director of the Endocrinology Research Institute, China Medical University). It attracted over 500 experts and scholars from the fields of ophthalmology and endocrinology nationwide.

In partnership with the Beijing Bethune Charitable Foundation, Innovent launched the "Bright Vision – Bethune Patient Care Program," which is being implemented across 73 cities in 28 provinces. The program not only provides charitable access to SYCUME® (teprotumumab N01 injection) for TED patients to improve treatment availability but also establishes a specialized patient follow-up management system and carries out public education campaigns. These initiatives aim to raise awareness of TED among the public and patients, thereby helping to improve standardized diagnosis and treatment.

On 20 March 2026, marking the first anniversary of the product's launch, an offline patient-doctor exchange event was held by the Company. The event began with a speech titled *"A Letter to Thyroid Eye Disease Patients"* by Mr. Ruili Wei, director of the Ophthalmology Department at Changzheng Hospital. It invited patients from across the country to share their treatment experiences, engage in face-to-face consultations with clinical experts, and discuss disease management. Secretary-General Liu Jing of the Beijing Bethune Foundation, the initiator of the Bright Vision Patient Care Program, also attended and presented commemorative banners to experts and company representatives in recognition of their contributions.

As of the end of the Reporting Period, nearly 2,000 patients had benefited from the program.

SYCUME® (teprotumumab N01 injection) – Bethune Patient Care Program (Continued)

Project Achievement Showcase

Photo from the "Letter to Thyroid Eye Disease Patients" event

DOVBLERON® (taletrectinib adipate) – New Lease on Life Patient Assistance Program

In January 2025, with the support of Innovent, the Quzhou Medical Health and Community Development Foundation launched the "New Lease on Life" (樂達新生) project, providing innovative solutions and long-term, sustainable treatment support for patients with ROS1-positive lung cancer, significantly alleviating their financial burden.

Since its launch, the project has provided medication assistance to patients across the country, effectively reducing the financial strain on their families and raising awareness of long-term treatment adherence. As of the end of the Reporting Period, the project had benefited over 500 patients, with cumulative donations exceeding 3,000 boxes of medication.

Limertinib – Aoran New Life Patient Assistance Program

To help patients with EGFR-positive non-small cell lung cancer better control disease progression, receive more precise and effective treatment, alleviate financial burden, and improve treatment accessibility, the Quzhou Medical Health and Community Development Foundation launched the "Aoran New Life Medical Aid Public Welfare Project" with the support of Innovent through directed donations on 10 March 2025. As of the end of the Reporting Period, the project had benefited over 1,000 patients, with cumulative donations exceeding 3,000 boxes of medication.

DUPERT® (fulzerasib) – "New Life Blessings" Medical Aid Public Welfare Project

In 2025, Innovent continued to support the "New Life Blessings" project, aimed at reducing the financial burden for adult patients with KRAS G12C mutated advanced NSCLC who have received at least one prior systemic therapy, and consistently benefiting eligible patients. Meanwhile, the project provided "Compassionate Care Services for Patients with Rare Target Tumors," offering long-term support such as disease education and regular follow-up reminders to help patients strengthen their confidence and return to normal life with greater optimism.

As of the end of the Reporting Period, the project had cumulatively benefited over 3,000 patients, with total donations exceeding 10,000 treatment boxes.

2.2.2 Patient Care

Innovent has always placed patients at the center of its operations. Collaborating with various partners across multiple regions, the Company conducts patient education and public welfare support activities aimed at helping patients better understand their diseases and treatment plans. These initiatives seek to improve treatment adherence and quality of life, empowering patient groups to actively manage their conditions.

In 2025, Innovent actively responded to the 'Year of Weight Management' initiative and promoted the enhancement of public health literacy through diverse forms. The Company innovatively launched the public service MV 'Weight Loss Is No Hard Task' (減重無難事) and the public service short film 'Weight Down, Life Up' (體重向下、人生向上), disseminating scientific management concepts through vivid content. At the same time, we support the publication of professional educational materials such as *"Popular Science Handbook for Thyroid Eye Disease"* (<甲狀腺眼病科普教育手冊>) and "*Doctor-Guided Scientific Weight Loss"* (<醫生教你科學減重>).

Innovent Supports "Healthy China • Weight Management Year": Using a Popular Science Book as a Bridge to Bring Scientific Weight Loss into Communities

Responding to the call of the "Weight Management Year" initiative jointly launched by 16 departments including the National Health Commission, Innovent Biologics, as a caring supporting enterprise, fully supported the "Healthy China • Weight Management Year" themed science promotion and Healthy China Action community event in Beijing on 28 September 2025. The event was jointly organized by the People's Medical Publishing House and the Health News. During the activity, the popular science book – *"Doctor-Guided Scientific Weight Loss"* (<醫生教你科學減重>) – supported by Innovent and created by the Health News in collaboration with 88 authoritative medical experts – reached deep into communities, serving as a core vehicle for disseminating scientific weight management concepts. This demonstrated Innovent's corporate practice of empowering public health through science education.

"Healthy China • Weight Management Year" Themed Science Promotion and Healthy China Action Community Event

The book stood out in the 2025 New Era Health Science Popularization Works Collection Activity and was awarded the Excellent Work Prize in the Popular Science Graphics and Text category. This authoritative accolade further establishes "Doctor-Guided Scientific Weight Loss" (<醫生教你科學減重>) as a comprehensive guide for the daily health management of overweight/obesity patients. It not only provides professional and authoritative knowledge guidance for the vast number of overweight/obese patients and their families in China but also gives them confidence and strength for scientific weight loss, helping to build a solid public defense for healthy weight management.

"Caring for Employee Health" Series of Activities

In terms of health promotion, the Company actively encourages staff to embrace healthy lifestyles. Health testing stations have been established in office locations across Suzhou, Shanghai, Beijing, and Hangzhou to provide convenient health monitoring services. The Company organized a 28-day scientific weight-loss challenge to encourage staff to manage their weight through scientific methods. Concurrently, the 'Healthy Canteen' initiative was advanced by optimizing dietary structures to foster a healthy workplace environment. These initiatives not only expanded the scope of the Company's public welfare practices – from oncology to broader public health issues such as metabolic health and endocrine diseases – but also marked Innovent's gradual establishment of a full-spectrum healthcare support system encompassing financial assistance, diagnostic and treatment support, and upstream health education and science communication. This drives the professionalization, systematic development, and sustainability of its public welfare actions.

Guide for Employee Health Testing Stations

Public Welfare Exhibition on Obesity Education

In 2025, Innovent continued to carry out the series of public welfare science popularization activities focused on abdominal obesity in the Chinese population, promoting the dissemination of health concepts through multi-stage and widely covered innovative formats. In September 2025, the Company held its inaugural public welfare exhibition at Wujiang Road in Shanghai. Leveraging the traffic of this internet-famous landmark, the event attracted over 4,000 offline participants and achieved a total online exposure of 39 million. From October to November 2025, the tour was upgraded to a national circuit covering 17 cities, extending science popularization content to more regions and reaching over 70,000 people offline. In December 2025, in response to the demand during the year-end health checkup season, we launched the "No Belly Stress" campaign in Beijing and Shanghai. This initiative precisely addressed the health anxieties of the working population, achieving over 5,000 offline participants and 37 million impressions. The series of events held throughout the year reached over 80,000 on-site attendees and generated more than 100 million impressions across all online platforms. Through innovative interactive formats, we effectively enhanced public awareness of abdominal obesity, demonstrating the Company's commitment to fulfilling its social responsibility for health education through concrete actions.

Public Welfare Exhibition on Obesity Education

Innovent participated in hosting the "Lower Body Weight, Higher Quality of Life: Early Screening and Treatment Management Action Plan for Obesity and Fatty Liver Disease"

Innovent actively responded to the "Healthy Weight Management Year" initiative. Centered on the theme "Lower Body Weight, Higher Quality of Life", the Company conducted a series of activities including expert-led public welfare education, screening and free clinics for fatty liver diease, and engaging knowledge-based interactive sessions. This public welfare initiative aimed to promote the concepts of scientific weight loss and liver health in the workplace and among the general public from the perspectives of market engagement and public education. It sought to enhance health management awareness and provides a reference case for the industry to fulfill corporate social responsibility and conduct health promotion activities.

Display of Fatty Liver Model

During the event period, two expert science popularization lectures were held daily on schedule. From a professional perspective, these sessions deconstructed the mechanisms for reversing fatty liver and systematically explained the hazards of abdominal obesity. They provided the public with scientific guidance on weight loss and liver protection, facilitating evidence-based and precisely targeted fat reduction efforts.

TYVYT® (sintilimab injection) - Shuxin Keda Wechat Platform Patient Education

In 2025, leveraging the "Shuxin Keda" WeChat public platform, Innovent systematically conducted a series of online thematic live broadcasts for cancer patient education. As of the end of the Reporting Period, 86 sessions had been successfully held, cumulatively reaching over 500,000 views. The activities brought together over 100 clinical experts, covering prevalent cancer types such as lung cancer, liver cancer, gastric cancer, esophageal cancer, and gynecological tumors. In-depth interpretations were also provided on related therapies, offering patients continuous and authoritative disease knowledge and treatment guidance.

Volunteer Service

Innovent actively advocates for and organizes employee participation in volunteer services. By establishing a three-tier linkage mechanism comprising "volunteer management layer – representatives – members," the Company effectively mobilizes staff from various divisions and departments to engage in public welfare activities, such as free medical consultations and voluntary blood donations, thereby giving back to society through concrete actions. As of the end of the Reporting Period, the Company's volunteer team had grown to 312 members, having cumulatively provided 2,120 hours of volunteer service.

2.2.3 Our Performance

Innovent will integrate corporate social responsibility deeply into its operational and development strategies, actively supporting and participating in community co-construction. Leveraging its professional resources in the healthcare sector, the Company has continuously carried out social public welfare practices through donations of medical resources and organization of professional volunteer services. Focusing on empowering grassroots health and green pharmaceutical operations, the Company is committed to creating sustainable social value. During the Reporting Period, the Company was awarded the Charitable Award by the Cancer Foundation of China and the Torch of Dedication Award by Beijing Bethune Charitable Foundation.

Annual Charity Initiative: Charitable Award from the Cancer Foundation of China

Beijing Bethune Charitable Foundation – Torch of Dedication Award

03

HIGH QUALITY AS KEY

Quality is the lifeline of Innovent and a key element in fulfilling the Company's mission. To this end, we have established a control system covering the entire lifecycle of pharmaceutical products, continuously optimizing production processes and enhancing operational efficiency to provide patients with safer, more reliable, high-quality products. At the same time, we are building a sustainable supply chain, deepening service delivery and responsible marketing, and fully safeguarding patient health and rights.

This chapter is in response to the sustainable development goals (SDGs) of the United Nations

3.1 Product Quality and Safety

We consistently prioritize Patient Safety and drug quality as core considerations. Strictly adhering to internationally quality management standards and relevant laws and regulations, we have established a quality management system covering the entire product lifecycle – from research and development and clinical trials to manufacturing and market launch. Through high-standard QC and management systems, we ensure that every product is safe, effective, and reliable.

3.1.1 Our Governance

Quality Management Structure

Innovent has established a Product Development Platform (PDP) Quality Committee responsible for coordinating quality resources across relevant departments, identifying and assessing key risks, regularly reviewing quality data, evaluating the effectiveness of the management system, and promoting quality culture. Our Production Quality Management Committee regularly reviews key performance indicators and quality incident trends for factory operations to identify relevant quality improvement plans and projects. Additionally, the Committee discusses and addresses quality incidents reported to senior management by participating in real-time management meetings. The Audit Committee regularly supervises and reviews key initiatives and performance regarding the Company's quality control and responsible marketing to ensure the safe and stable operation of the quality control system.

Optimization of the Quality Management Policy

To ensure the quality management system remains current and progressive, we are committed to continuously improving our internal quality policies, thereby further enhancing the scientific rigor and effectiveness of the quality management system. During the Reporting Period, we introduced the *"Standard Operating Procedure for Shortage Drug Management"* (<短缺藥品管理標準操作規程>) to standardize the full-process management of shortage drug production and supply, as well as the reporting of production suspension information. Concurrently, we completed the iterative upgrades of policy documents such as the *"Recall Management Procedure"* (<召回管理規程>), *"Deviation Management Procedure"* (<偏差管理規程>) and *"Product Quality Complaint Management Procedure"* (<產品質量投訴管理規程>) to ensure quality and safety throughout the full lifecycle of pharmaceutical products, from R&D to production and post-market launch.

3.1.2 Our Actions

Quality Management System Certification

Building upon the continuous optimization of its full-lifecycle quality management system, Innovent systematically advanced the certification and scope expansion of its quality management system in 2025, closely aligning with its strategies for product diversification and internationalization. The Company not only continues to consolidate its compliance foundation for pharmaceutical Good Manufacturing Practice (GMP) but also significantly expands the breadth and depth of international system certifications centered on ISO standards. It has successfully extended high-standard quality management capabilities from pharmaceuticals to combination drug-device products, from domestic regulations to international certifications, achieving a comprehensive upgrade in quality control capabilities.

In the core area of pharmaceutical production quality, the Company has passed the Good Manufacturing Practice (GMP) supervision inspection conducted by the Shanghai Municipal Medical Products Administration. This outcome directly reflects the regulatory authority's recognition of the effectiveness of the Company's quality management system.

Advance the ISO 13485 Certification Process

As the business gradually expanded into the field of drug-device combination products such as auto-injectors and auto-injection pens, the Company completed the gap analysis, system establishment, and operational optimization of the ISO 13485 medical device quality management system based on its existing GMP management framework, and successfully obtained certification in April 2025. During the Reporting Period, the scope of certification has expanded from one product to three products. This marks that the Company has established a comprehensive quality control mechanism covering key links such as design and development, manufacturing, warehousing and logistics, and after-sales service for multiple drug-device combination products, providing strong assurance for product quality stability and compliant operations. Building upon a solid foundation of domestic quality management and regulatory compliance, the Company is also actively advancing applications for foreign GMP certification for select production lines. This initiative aims to continuously elevate international quality management standards and create conditions for global market access.


TANZN

医疗器械

质量管理体系认证证书

注 册 号：69025MDQ0001R0S

统一社会信用代码：91320594581020 64XX

公司名称：信达生物制药（苏州）有限公司

注册地址：苏州工业园区东平街 168 号

经营地址：中国江苏省苏州市吴中区苏州工业园区东平街 168 号

建立的医疗器械质量管理体系符合

GB/T 42061-2022 / ISO 13485：2016

认证范围：自动注射笔（生物制品）研发和组装

发证日期：2025 年 04 月 21 日

有效日期：2028 年 04 月 20 日

TANZN

MDMS certification

Registration No：69025MDQ0001R0S

Organization code：91320594581020 64XX

Corporate name：INNOVENT BIOLOGICS(SUZHOU)CO. LTD

Registered address：168 DONGPING STREET, INDUSTRIAL PARK, SUZHOU CITY, JIANGSU PROVINCE, CHINA

Business address：168 DONGPING STREET, INDUSTRIAL PARK, SUZHOU CITY, JIANGSU PROVINCE, CHINA

MDMS Capability Achievement

GB/T 42061-2022 / ISO 13485：2016

Scope of certification：Research, Development and Assembly of Auto-injector (Biological Product)

Issue date：21-04-2025

Valid until：20-04-2028

ISO 13485 System Certification Certificate

R&D Quality Management Measures

Innovent has established a quality control system spanning the entire product lifecycle and continues to optimize quality management in the R&D phase. Centered on process standardization, standardized experimental data management, continuous daily monitoring, and a culture of full-staff participation, we systematically enhance the overall quality management level of the R&D phase.



Improvement Measures for R&D Quality Management

Production Quality Management Measures

To continuously improve the production quality management system, Innovent systematically enhanced its quality control capabilities in 2025 across three dimensions: target setting, process optimization, and strengthened supervision of suppliers.

Regarding quality objectives and performance management, the Company has established and monitors key quality performance indicators, including batch success rate, product quality complaint rate, and the number of CAPA revisions. During the Reporting Period, all indicators remained stably controlled with no instances of exceeding limits.

In optimizing internal management processes, the Company focused on the systematic upgrade of pollution control strategies. By implementing the iterated clean area control strategy and the process microbiological control strategy, we have significantly enhanced the precision of environmental and process control. This was achieved by establishing differentiated monitoring limits based on room functions and refining microbial and endotoxin control standards across the entire process chain.

To strengthen quality supervision of suppliers, the Company has established a dedicated supplier quality management team and implemented a comprehensive quality management mechanism covering the entire process from supplier management, technology transfer, and process validation to post-market changes. We provide technical and quality support at key project milestones and continuously optimize the partner's quality management system through quarterly risk assessments, regular quality reviews, and corrective and preventive actions. For key projects, process oversight is strengthened through a combination of monthly quality performance tracking, regular project meetings, and on-site guidance. During the Reporting Period, Innovent achieved multiple milestone advancements in collaboration with its suppliers:

Key Performance Indicators

- The active pharmaceutical ingredient (API) for Mazdutide Injection has been approved by the NMPA. The injection formulation has been commercially launched, with approvals obtained for both scale-up production and manufacturing site changes.
- DUPERT® (fulzerasib), China's first KRAS G12C inhibitor, has successfully obtained marketing approval and completed the post-approval variation declaration for second-generation processes, which has been approved by the NMPA.

Product Testing and Quality Control

Innovent places product testing and quality control capabilities at the core of end-to-end drug management, establishing a sound QC system. The Company is equipped with world-class testing instruments and equipment, establishing robust capabilities for material and product testing to provide a solid guarantee for quality management throughout the full lifecycle of pharmaceutical products. As of the end of the Reporting Period, all production bases of the Company are equipped with professional QC laboratories and dedicated testing teams. The laboratory's testing capabilities comprehensively cover key areas including instrumental analysis, biochemical testing, physicochemical inspection, and microbiological testing. The team strictly implements full-chain testing and supervision for every batch of products, covering raw material intake, in-process control, and finished product release. Continuous monitoring is conducted on the production cleanroom environment and utility facilities to systematically identify and manage potential quality risks, ensuring compliance with domestic and international regulations as well as the Company's stringent requirements throughout the entire process.

During the Reporting Period, the Company continued to implement enhanced controls on raw materials and packaging materials for projects entering the process performance qualification stage, such as increasing in-plant inspection controls for microbial limits, endotoxins, and insoluble particulates. We upgraded the microbial control strategy for intermediate production processes by enhancing microbial limits and endotoxin testing standards for non-sterile inner packaging materials (stopper). Additionally, we refined the clean area control strategy and the process microbial control strategy to strengthen full-process safety management of product quality, setting a benchmark for quality management systems in the industry.



Production Quality Control Process

To address quality issues arising from emerging challenges such as extreme heat, we continuously standardize management requirements across production processes, verification of storage and transportation conditions, abnormal alarm and response mechanisms, re-verification of alarm functions, and stability studies (including extreme-condition testing during development). This approach enables the proactive identification of potential emerging risks to product quality and safety and the formulation of corresponding control plans.

Production and Storage

- The production plant/warehouse facilities, equipment, and utility clean systems have been qualified to support cGMP manufacturing. All materials and products used in production are stored under the storage conditions specified in their quality standards.

Transportation

- The product transportation method has been validated and is subject to real-time temperature monitoring to ensure appropriate transport conditions and compliance with temperature requirements. In the event of temperature excursions, assessment is conducted in accordance with *the "Standard Operating Procedure for Temperature Excursion Handling"* (<超溫處理操作規程>). Based on temperature data and stability conclusions, the Quality Unit determines the appropriate disposition of the product.

Abnormal Alarm and Response Mechanism

- A *"Procedure for Equipment or System Alarm Management"* (<設備或系統報警管理規程>) has been established to standardize alarm management. It defines the principles for identifying critical alarms and the procedures for handling alarms, thereby ensuring the proper operation of equipment or systems.

Preventive Testing and Stability Studies

- Preventive testing and stability studies are conducted for products, including high-temperature stress testing and accelerated/long-term stability studies. These studies provide a scientific basis for establishing storage conditions and shelf-life standards. In the event of temperature excursions during storage or distribution, the results of stability studies offer scientific guidance and a basis for assessment.

Emerging Quality and Safety Assessment Requirements

Innovent strictly complies with all pharmaceutical laws and regulations in its target markets, closely monitors industry regulatory developments, and actively participates in industry capacity-building initiatives.

Inspection Personnel Participate in Proficiency Testing Assessments

During the Reporting Period, we continued to organize inspection personnel to actively participate in the drug testing capability verification program organized by the Jiangsu Provincial Medical Products Administration. Relying on our solid professional skills and rigorous work attitude, we successfully passed the verification.


能力验证证书

兹证明 信达生物制药（苏州）有限公司 参加了"JSIFDC-PT-006 药品比旋度测定"能力验证计划，取得满意结果。

2025 年 11 月 12 日

Certificate of Competency Verification Assessment for Inspection personnel

Quality Audit

Innovent strictly enforces a GMP quality system management covering the entire production cycle. Systematic quality reviews are conducted quarterly at production bases, encompassing core dimensions such as product quality performance, regulatory compliance, material and production controls, and internal and external audit results. Through in-depth analysis and trend assessment by the Quality Management Committee, the Company is able to promptly identify potential risks in system operations, formulate and implement targeted improvement measures, and continuously optimize quality management effectiveness. During the Reporting Period, the Company completed 185 batches of raw liquid production with a production success rate of 100%.

In 2025, Innovent achieved significant results in building its quality compliance system and systematically passed multiple important audits and inspections conducted domestically and internationally. At the domestic regulatory level, the Company successfully completed registration inspections and GMP compliance checks for key products including PECONDLE® (picankibart injection), Bevacizumab, and TABOSUN® (ipilimumab N01 injection). No critical findings were identified in any of these inspections. In the field of international cooperation, the Company successfully passed quality audits conducted by global partners such as Takeda, Incyte, Sun Pharma and Roche, demonstrating its strong capabilities in quality management and cross-border collaboration. At the same time, we also completed multiple audits by EU Qualified Persons (QP) and official PAI verifications in Mexico, laying a solid foundation for the Company's global product layout. These achievements fully demonstrate the Company's robust quality management system and continuous improvement mechanism, providing a solid guarantee for product quality and global supply.

2025 Quality Audit Overview (Selected)
In February 2025, the registration on-site inspection and GMP compliance inspection for PECONDLE® (picankibart injection) were conducted as a combined inspection.
In March 2025, Passed the EU QP audit via the IBI363 project.
In May 2025, Passed the on-site inspection of pharmaceutical production enterprises.
In May 2025, Quality audit conducted through partner Incyte.
In May 2025, Quality audit conducted through partner Sun Pharma.
In June 2025, Passed the GMP compliance inspection for Bevacizumab Injection.
In June 2025, Passed the combined on-site inspection for production site change and GMP compliance of Bevacizumab injection.
In June 2025, the registration on-site inspection and GMP compliance check for TABOSUN® (ipilimumab N01 injection) were conducted as a combined inspection.
In August 2025, Quality audit conducted by partner Roche.
In August 2025, On-site PAI inspection of Bevacizumab Injection in Mexico was successfully completed.
In September 2025, Quality audit conducted by Takeda.
In September 2025, Passed the EU QP audit for Sintilimab Injection.
In September 2025, On-site inspection for the addition of Category B to the Drug Production License was successfully completed.
In September 2025, Passed the 2025 Comprehensive Credit Risk Assessment for Pharmaceutical Production Enterprises in Shanghai.
In October 2025, Successfully passed the EU QP audit for projects IBI 343 and IBI 3009.
In November 2025, the Company successfully passed the combined on-site inspection for the change of production site for Mazdutide Injection and the GMP compliance inspection.
In December 2025, the Company successfully passed the combined on-site inspection for the change of production site for SINTBILO® (tafolecimab injection) and the GMP compliance inspection.

Supplier Quality Audit

In terms of supply chain quality control, we continue to refine our audit management system and have updated the "*Global Quality and Compliance Audit Master Process*" (<全球質量與合規審計主流程>), incorporating ESG-related topics and pharmacopoeia compliance into the quality and compliance audit procedures. In accordance with the *"Material Supplier Management Procedure"* (<物料供應商管理規程>), the Company has established a tiered evaluation and periodic audit mechanism. On-site audits are conducted for suppliers of raw materials, auxiliary materials, and inner packaging materials. Furthermore, quality supervision is extended to Tier-2 suppliers of strategic suppliers through contractual constraints and direct audits. In 2025, the Company planned to conduct 118 audits and completed 142, achieving an execution rate of 120%. The overall audit pass rate for suppliers was 99%, ensuring effective quality coverage across the entire supply chain and providing a solid foundation for the Company's business expansion and global operations.

Deepen Supplier Quality Management to Achieve Proactive Extension and Systematic Control over Tier-2 Service Providers

In 2025, Innovent extended its quality oversight beyond conventional boundaries during audits of its primary suppliers. In addition to auditing the main production sites, the Company conducted independent on-site audits of the tier-2 suppliers responsible for critical testing tasks. This approach expanded quality management supervision from the Marketing Authorization Holder (MAH) level to the "suppliers' suppliers," achieving full-chain quality oversight of active pharmaceutical ingredients—from production to testing—and effectively controlling risks at the source of the outsourced testing process.

Following the audit, Innovent systematized these practices by formally incorporating strategic suppliers' tier-2 suppliers into its supplier management system and establishing a fixed re-audit mechanism on a two-year cycle. This shift moves the management of such key tier-2 suppliers from isolated, post-event "project-based" audits to a closed-loop, normalized system that includes upfront qualification and periodic monitoring, significantly enhancing supply chain resilience and quality controllability.

Quality Risk Management

Throughout the entire lifecycle of biopharmaceuticals – from R&D to production and usage – quality, safety, and efficacy serve as our core foundation. To this end, the Company has established a quality management system spanning the full product lifecycle in accordance with the *"Quality Risk Management Procedure"* (<質量風險管理規程>) comprehensively integrating risk management into key quality activities including validation management, change management, deviation management, corrective and preventive actions (CAPA), and annual quality reviews. We systematically conduct risk identification, assessment, control, communication, and review audits, achieving closed-loop risk management through corrective and preventive actions. During the quality risk assessment process, the Company extensively employs internationally recognized risk management tools such as HACCP and FMECA to ensure comprehensive, scientific, and effective identification and control of quality risks.

Drug Development Phase	Technology Transfer Phase	Commercial Production	Market Exit Stage
• Guided by *the Quality Risk Management in Drug Development guidelines* (<藥物研發階段質量風險管理>), effective management is implemented for potential risks throughout the product development process. • Systematic training is provided to employees to ensure their thorough understanding of the product and its manufacturing process. • A comprehensive control strategy is established to adequately manage risks associated with critical quality attributes and to clearly define critical process parameters.	• Conduct risk assessment and management for process and product quality during the technology transfer stage, covering multiple aspects including technology transfer, multi-product campaigns, laboratory systems, system impact, component criticality, and computerized systems.	• Assess and manage quality risks during the commercial operation phase, and establish robust control strategies. • *"The Self-Inspection Standard Management Procedure"* (<自檢標準管理規程>) has been established, with regular self-inspections and management reviews of the quality management system conducted.	• Risk assessment is conducted for the product withdrawal phase to identify and manage risks associated with patient transition to alternative therapies.

Full-Process Product Quality Risk Management

During the Reporting Period, the Company conducted routine internal audits in accordance with the *"Self-Inspection Standard Management Procedure"* (<自檢標準管理規程>). In 2025, a total of 8 Group self-inspections were completed, covering quality systems, equipment validation, laboratory management, production activities, computerized systems, and data integrity across all processes at factories in Suzhou and Hangzhou. The coverage rate of self-inspection areas reached 100%. No critical-level deviations were identified during the annual internal audit, and the quality management system maintained robust operations.

Quality Culture Construction

Innovent upholds the quality philosophy of 'doing the right thing and getting it right the first time'. Systematically advancing quality culture construction from three dimensions – cultural concepts, cultural carriers, and cultural practices, the Company actively fosters an organizational atmosphere where everyone values quality and creates quality. To embed this concept deeply, the Company has elevated talent development in quality to a strategic priority. Aligned with the goal of upgrading the quality management system, it continues to refine its tiered and categorized training framework.



GMP Employee Training

Through centralized training, department-specific training, practical drills, and external exchanges, the Company systematically enhances all staff's quality awareness, professional capabilities, and compliance levels, providing a solid talent foundation for a high-quality culture. During the Reporting Period, the Quality Department organized 7 annual training sessions focused on core areas including deviations and change management, process technology transfer, aseptic standards, data integrity, equipment validation, GMP regulations, and microbial control. These sessions covered over 6,500 person-times in total, effectively strengthening personnel's foundational compliance and quality control capabilities. The pass rate for the written assessment after training reached 100%.

At the departmental execution level, each department organized technical experts to conduct over 650 offline thematic training sessions throughout the year for positions related to GMP. The content delves into critical topics including in-depth analysis of deviations and CAPA cases, SOPs, process knowledge, pharmaceutical circulation management, and aseptic control. Through continuous and in-depth professional instruction, consistency and compliance with quality protocols in actual operations are ensured.

Case Study: Series of Sharing Sessions on the Internationalization Project for Quality Management Systems

In 2025, Innovent launched a series of specialized training programs focused on the internationalization of its quality system. These initiatives targeted three key areas: interpretation of international regulations, mock audit drills, and industry exchange and learning. The programs systematically enhanced the quality team's understanding of international regulations and their practical response capabilities. The Company conducted specialized training sessions aligned with ICH Q series guidelines and regulatory requirements from the EU and FDA to help staff stay current on global regulatory dynamics and key review focus areas. Through simulated audit exercises, the Company strengthened capabilities in document preparation, on-site responses, and post-audit issue reviews. Additionally, by leveraging external visits and exchanges, the Company benchmarked against industry best practices to continuously enhance the team's professional perspective and international audit capabilities. These activities further solidified the Company's talent foundation in quality management and provided strong support for the internationalization of the quality system.

Innovent Launched Sharing Sessions on the Internationalization Project for Quality Management Systems

Monthly Star Selection

To better integrate quality awareness into staff's daily work, the Company has established a multi-channel quality feedback and incentive system. Management places high importance on employee suggestions. Relying on the improvement suggestion platform to collect opinions widely, it recognizes outstanding individuals and teams through mechanisms such as "Star of the Month" based on their performance in five dimensions: project quality, comprehensive quality, quality improvement skills, innovation capability, and team spirit, thereby stimulating the enthusiasm of all staff for quality improvement.

Partner Quality Exchange

Innovent places high importance on partner and supply chain quality management. It integrates key material suppliers, such as those for active pharmaceutical ingredients and intermediates, along with entrusted production partners, into a unified quality management system. The Company continuously refines a comprehensive quality management mechanism covering access assessment, agreement management, process supervision, capability enhancement, performance evaluation, and continuous improvement. This initiative extends quality requirements throughout the upstream and downstream supply chain, establishing a closed-loop quality management system from raw material sources to production endpoints. Through continuous optimization of management mechanisms and collaborative models, the Company has gradually established a quality collaboration pathway characterized by 'joint policy development, joint process management, joint capability enhancement, and continuous improvement'.

Innovent Supply Chain Quality Management Process

Based on a partner quality synergy mechanism of 'co-creating policies, jointly managing processes, and collectively enhancing capabilities', Innovent has continuously promoted the effective implementation of quality management in cooperation projects by focusing on key links such as clear accountability, process coordination, on-site supervision, and continuous optimization. This approach steadily improves the quality standards of partners and strengthens the overall resilience of the supply chain.

In terms of building the cooperation mechanism, the Company has established a multi-level and normalized quality communication platform with international partners such as Eli Lilly, Takeda and Incyte, strengthening quality collaboration and risk control during project advancement. For example, we hold regular global joint quality management committee meetings and weekly working group meetings with Eli Lilly to systematically review production, supply, and quality performance; conduct quarterly joint reviews of quality KPIs with Incyte; we hold regular meetings with Takeda, including technical exchanges, clinical drug supply-demand alignment meetings, and the Global Joint Manufacturing and Quality Working Group, to support the co-development of global drugs and ensure stable supply for future commercial launches. During the Reporting Period, the Company established a quality management and control system that meets internationally leading standards, covering the entire process from early-stage R&D and clinical development to production and commercialization. Through standardized and institutionalized quality management, the system ensures the smooth progress of collaborative projects.

In addition to building and strengthening its own capabilities, the Company remains committed to enhancing the overall quality management standards of the industry. It implements full lifecycle quality management for entrusted manufacturing partners, combining quality audits, contractual agreements, and on-site support to continuously strengthen quality safeguards in external collaborations. In 2025, the Company deployed on-site personnel for a cumulative total of over 4,000 hours. Through these deployments, the technical team conducted reviews, provided compliance guidance, and optimized processes to support partners in enhancing their on-site management capabilities and quality execution. Meanwhile, the Company implements quarterly KPI tracking and semi-annual performance assessments for high-risk suppliers. Through regular communication meetings, the Company promptly drives issue rectification and the implementation of corrective measures, continuously enhancing the stability and resilience of supply chain quality.

Customer Service

Optimization of the Customer Service System

During the Reporting Period, Innovent systematically optimized its *"Product Complaint Management Procedure"* (<產品投訴管理規程>) to further enhance the effectiveness of its customer complaint service policy framework.



Product Quality Complaint Management Process

Customer Satisfaction

In managing dealer relationships and enhancing customer satisfaction, Innovent has established a systematic quality management system. Innovent has established a dual-hundred quality objective: '100% drug quality compliance rate and 100% customer satisfaction,' and has formulated the *"Drug Sales and After-Sales Service Management Policy"* (<藥品銷售及售後服務管理制度>). In 2025, our satisfaction survey of 23 dealers showed a customer satisfaction rate of 94%, with an unsatisfaction rate of 6%. For customers who provided feedback of 'relatively satisfied', the Company proactively conducted special communications to deeply assess areas for quality improvement and continuously optimize service levels.

Regarding specific improvement measures, the Company has established the *"Drug Outbound Verification Operation Procedures"* (<藥品出庫覆核操作規程>), requiring verifiers to strictly check drug quantities, information, and quality status to ensure zero outflow of non-compliant drugs. Meanwhile, a comprehensive transportation management system was established. Operational procedures were standardized through the *"Entrusted Transportation Management Policy"* (<委託運輸管理制度>) and the *"Drug Transportation Operation Procedures"* (<藥品運輸操作規程>) while quality agreements were signed with carriers to ensure strict adherence to GSP requirements. The Logistics Department implements full-process supervision over the transportation process to ensure that medicines are safely delivered within the specified timeframe. This minimizes the impact of transportation on drug quality and effectively safeguards customer satisfaction.

Customer Complaint Response

Through policy optimization and the establishment of closed-loop processes, the Company has further strengthened its capabilities for unified intake, professional assessment, and tiered handling of complaint information. Upon confirmation of quality responsibility, it can leverage cross-departmental collaboration mechanisms to rapidly formulate and implement corrective and preventive actions. The continuous and standardized operation of this system provides robust support for the rapid response and fundamental resolution of product quality issues.

During the Reporting Period, with the launch of new products such as SYCUME® (teprotumumab N01 injection) and Mazdutide, the Company optimized and implemented relevant complaint management processes for these products. Against the backdrop of continuous business expansion, our product quality performance remained stable, although the total number of complaints has increased, the proportion of quality complaints attributable to the Company's responsibility has shown a significant downward trend.

Product Recall

Innovent has established a comprehensive product recall process. This year, we systematically revised and improved the *"Recall Management Procedure"* (<召回管理規程>) to further strengthen the product recall management system. The revision stipulates the requirement to issue defect batch alert communications to healthcare professionals during recall actions. It refines the mechanism allowing recalls to be initiated before the root cause of quality defects is fully identified. Additionally, it introduces procedures related to unblinding for clinical trial drug recalls and supplements recall plans with detailed information on affected markets and product return locations.



Product Recall Process

We assess the system's effectiveness through simulated recall drills every two years. As of the end of the Reporting Period, all marketed products of Innovent maintained an excellent quality record. No actual product recalls occurred during the year, there were no returns due to quality or safety issues, and no warnings or alert notices were received from drug regulatory authorities.

Pharmacovigilance (PV)

Innovent, as the Marketing Authorization Holder for pharmaceutical products, strictly adheres to regulatory requirements and has developed corresponding drug safety risk management plans for all marketed drugs. Ensuring patient medication safety is the core mission of its PV work. The Company has established a comprehensive Pharmacovigilance system and set up a dedicated department to be fully responsible for global post-marketing safety monitoring of its products.

The Company strictly complies with regulations such as the *"Good Pharmacovigilance Practice (GVP)"* (<藥物警戒質量管理規範>). It systematically conducts the collection, analysis and evaluation of safety data from clinical trials and post-marketing activities, so as to identify and evaluate drug risk signals in a timely manner. During the Reporting Period, the Company strictly followed the annual update requirement for the "Pharmacovigilance System Master File" (<藥物警戒體系主文件>) and completed the update of system documents on schedule. This ensures the continuous improvement of the PV system, the timely identification and correction of system deficiencies, and the orderly implementation of all PV activities. Based on scientific assessments of the safety characteristics of marketed products, the Company ensures that routine PV activities meet risk management requirements, and prepares and submits various safety reports in accordance with regulations. This provides a continuous scientific basis and decision support for the product lifecycle management.

Adverse Reaction Information Collection	A dedicated hotline has been established to receive reports of adverse reactions. Employee reporting responsibilities are standardized to ensure timely notification to the Pharmacovigilance Department. Literature is regularly searched to monitor product safety information. The Company's website and multimedia accounts are monitored to identify reports of adverse reactions. Adverse reaction reports received from regulatory authorities are promptly processed. Post-marketing studies and programs are managed to ensure the timely reporting of adverse reactions.
Adverse Reaction Report Management	The Pharmacovigilance Department promptly enters received adverse reaction reports into the safety database. These reports are then evaluated and submitted to regulatory authorities in a timely manner in accordance with regulatory requirements.
Adverse Reaction Report Analysis and Risk Control	Individual adverse reaction reports received are subjected to case analysis and assessment. Regular analyses and evaluations are conducted to detect and identify new safety signals. Identified safety signals are evaluated to determine their potential impact on the patient risk-benefit balance. Where necessary, appropriate risk control measures are implemented, such as updating the product labeling. Prepare and submit Periodic Safety Update Reports (PSURs) for products to regulatory authorities.
Pharmacovigilance & Compliance	Continuously improve the pharmacovigilance system. Implement Good Pharmacovigilance Practice (GVP) requirements to ensure medication safety. Develop SOPs covering Safety Committee management, cluster event handling, clustered signal response, responses to regulatory inquiries, and contingency plans.

Post-Market PV Measures

To continuously enhance the quality of PV work, the Company has established a dynamically updated quality control indicator system. This system sets clear quality indicators targeting key activities in PV and implements necessary updates and optimizations based on actual operational performance and regulatory requirements to ensure the standardized and normalized operation of monitoring work.

Pharmacovigilance Training

To ensure the high-quality operation of the PV system, Innovent prioritizes personnel training. By organizing a combination of general awareness training for all staff and specialized training for key positions, the Company continuously enhances the pharmacovigilance awareness and professional capabilities of its entire workforce.

Onboarding Training	On-the-job training	Pharmacovigilance Physician Training	Training for Clinical Research Projects
For new hires, the Department has established a three-month systematic business practice training program tailored to role-specific requirements. This program is further customized based on each staff's prior experience and background to ensure rapid integration and mastery of core workflows.	During their tenure in the PV department, every employee receives continuous training, including the prescribed annual training plan and regular departmental topic-based training.	Specialized capacity-building training was conducted for pharmacovigilance physicians and medical reviewers, with a focus on strengthening capabilities in medical assessment, risk evaluation, and signal detection to ensure professional analysis of safety data and scientific decision-making.	Customized training at the project level is conducted for all personnel participating in clinical trial projects. The content covers the protocol, Investigator's Brochure, risk management plan, and PV system operations to ensure that every participant complies with both project-specific and regulatory requirements.

PV Training System

Specialized Training on Business Skills and Regulatory Knowledge

During the Reporting Period, the PV department continued to strengthen its professional capabilities by enhancing the team's international operations and regulatory practice standards through systematic internal and external training. The department organized a series of thematic training sessions focused on international PV regulations and cutting-edge practices. These sessions included *"Sharing Experience on PV Operation Management for Clinical Trials in Japan"* (<日本臨床試驗 PV 運營管理經驗分享>), *"Pharmacovigilance Requirements for Drug Marketing Authorization in the EU"* (<藥品在歐盟上市的藥物警戒要求>) and *"Regulatory Requirements and Practical Guidelines for Safety Reporting in Canada"* (<加拿大安全性報告遞交法規要求與實操指南>). The department also actively participated in authoritative courses such as the *"Advanced Training Program on Core Pharmacovigilance Technologies"* (<藥物警戒核心技術研修班>) hosted by regulatory authorities. Through targeted learning and seminars, the team further enhanced its compliance execution and risk management capabilities within the global PV system.



PV Training

3.2 Animal Welfare

Innovent consistently adheres to research ethics guidelines. Throughout the entire drug development process, the Company strictly follows ethical norms and scientific standards for animal welfare protection. By establishing a comprehensive ethical review mechanism for experimental animals and implementing rigorous welfare safeguard measures, Innovent effectively protects the welfare and rights of experimental animals.

3.2.1 Our Governance

Innovent strictly complies with national standards such as the *"General Principles for Animal Welfare in Experimental Animals"* (<實驗動物福利通則>) and has systematically established an animal welfare management system covering organizational structure, policy processes, and daily supervision. The Company has established an Ethics Committee for Experimental Animals and a Management Committee for experimental animals, and formulated comprehensive internal management policies to ensure that all animal experiments comply with regulations such as *the "Regulations on the Administration of Experimental Animals"* (<實驗動物管理條例>) and ethical requirements.

At the level of policy implementation, the Company reinforces ethical training and management refinement for laboratory personnel by strictly enforcing operational standards such as the *"Animal Facility User Manual"* (<動物房使用手冊>). During the Reporting Period, all relevant trials were conducted in a standardized manner under the supervision of the Committee, effectively safeguarding and continuously enhancing animal welfare levels.

3.2.2 Our Actions

In the management of animal welfare and experimental ethics, Innovent consistently adheres to and strictly enforces the '3R' principle: Reduction, Replacement, and Refinement. To systematically enhance the standardization and traceability of animal experiment management, the Company officially launched an electronic system for managing laboratory animals during the Reporting Period. This system has fully digitized the IACUC review process. It enables real-time deduction and dynamic monitoring of animal usage in experiments. When usage approaches the limit, it automatically triggers an email alert. This effectively supports real-time supervision and execution management of animal use, prevents overuse through mechanism design, and ensures the implementation of the 3R principles.

Furthermore, the management of experimental animal orders has been fully digitized, covering the entire lifecycle from procurement and usage to disposal. The system synchronously constructs electronic health records for animals, enabling one-click access to certificates of conformity, health inspection records, and daily patrol information. This significantly enhances management efficiency and the precision level of animal welfare assurance.



Add Environmental Enrichment Items to Ensure Animal Welfare and Safeguard the Physical and Mental Health of Mice



Animal Welfare Assurance Measures

To systematically enhance employee awareness of animal welfare, standardize experimental procedures, and mitigate potential risks to both animals and personnel, the Company continues to implement a multi-tiered animal welfare training system. For new staff participating in animal-related work, we have established specialized onboarding training to help them quickly establish ethical awareness and compliance consciousness. At the same time, the Company encourages and arranges for relevant staff to participate in external professional training to learn advanced industry practices.

Starting from 2025, the Animal Center further established a quarterly training mechanism, organizing thematic training sessions for frontline animal experiment personnel each quarter. The training covers key aspects of animal ethics, model selection, breeding management, experimental operations, and cross-disciplinary research applications. External senior experts were invited to provide customized professional sharing based on the background and needs of the participants.

Photos of Frontline Staff Animal Experiment Training

Starting in 2025, Innovent actively initiated organoids platform development to replace certain animal experiments, effectively implementing the '3R' principle of Reduction, Replacement, and Refinement.

3.3 Clinical Research

Innovent prioritizes the health and safety of trial subjects. Ensuring subject safety and timely identification and management of safety risks associated with products and clinical trials are the core objectives of its pharmacovigilance (PV) work. The Company consistently adheres to the highest international regulatory standards and ethical guidelines by establishing and implementing a comprehensive quality and ethics review system throughout the entire process. Through systematic risk prevention and control measures, the Company effectively safeguards the rights and interests of trial subjects.

3.3.1 Our Governance

Innovent has established a dedicated pharmacovigilance (PV) department responsible for coordinating and supervising clinical research activities, systematically building relevant policies, processes, and protocols, and providing technical support for the rapid assessment and reporting of safety information in clinical trials. The Clinical Quality Department of Innovent led the establishment of the PDP Quality Management Committee. The Head of Product Development serves as the Chairperson, Heads of Level-1 Departments within the Clinical Division serve as Vice-Chairpersons, and management representatives from various clinical departments serve as committee members. The PDP Quality Management Committee upholds the clinical quality mission of 'patient-centricity with quality as the foundation' and convenes meetings at least quarterly, with emergency sessions held as necessary.

Primary Responsibilities of the PDP Quality Management Committee

- Integrate quality resources across all departments within the clinical sector to facilitate efficient cross-departmental collaboration.
- Proactively identify key clinical quality risks and assess and formulate quality control measures.
- Regularly review quality data, assess quality trends and risks, and make decisions.
- Review the suitability, adequacy, and effectiveness of the PDP quality management system to promote its optimization and upgrade.
- Build and promote a quality culture to enhance PDP quality outcomes.

The Company established the GCP Compliance Committee to oversee and manage the compliance of all trials and personnel in the clinical sector, ensuring that clinical trials strictly adhere to relevant regulations and safeguard clinical development.

Building on this foundation, we strictly comply with regulations and ethical requirements such as *"Good Clinical Practice"* (<藥物臨床試驗質量管理規範>). We have established comprehensive internal policies and operating procedures to standardize the conduct of researchers and the entire research process, thereby constructing a systematic risk monitoring and control mechanism that covers all stages of clinical research.

3.3.2 Our Actions

Risk Management and Safety in Clinical Research

In the global development of innovative drugs, we establish international regulatory and ethical standards as our foundation. By constructing a forward-looking quality system and implementing dynamic control mechanisms throughout the entire R&D lifecycle, we systematically identify, assess, and manage various risks in clinical trials. This ensures the reliability of research data and the standardization of processes, ultimately safeguarding the safety and rights of every trial participant.

To support Multi-regional Clinical Trials (MRCT) and actively respond to the ICH E6 R3 principle of 'risk-based and proportionate risk management', Innovent systematically upgraded its clinical quality and risk management system during the Reporting Period. The Company has established a controlled document system and risk management plan templates covering the entire lifecycle of clinical trials. From the trial initiation phase, risks at both the trial level and system level are systematically identified. Through graded assessment, formulation of mitigation measures, and development of emergency plans, dynamic tracking and continuous control of risks are achieved. This upgrade optimized ten core modules, including system architecture, project management, monitoring, data monitoring, blind maintenance, and computerized system management. Approximately 165 documents were updated and revised, establishing the policy foundation for the consistency of research quality and international compliance.

The Company has established a dual system encompassing drug safety management throughout the entire R&D lifecycle and QC for clinical research. In terms of safety monitoring, we strictly adhere to the *"Good Pharmacovigilance Practice"* (<藥物警戒質量管理規範>) and ICH E2 series guidelines. We have established a comprehensive set of management documents and templates covering the entire process, from study design and safety information collection to individual case report processing, periodic safety evaluation, and the submission of Development Safety Update Reports (DSUR). Regarding the execution monitoring of research, it is explicitly required that any potential major violations or deviations be reported within 24 hours, with immediate temporary control measures implemented. Concurrently, a Root Cause Analysis and Corrective and Preventive Actions (CAPA) process must be initiated to establish a closed-loop management cycle of 'Identification-Reporting-Control-Correction', thereby continuously ensuring the compliance of clinical research, data reliability, and the rights of subjects.

Protection of Subject Rights

Protecting the safety and rights of subjects and adhering to ethical standards for clinical research are the fundamental principles guiding all drug clinical trials conducted by Innovent. To ensure full compliance and behavioral traceability throughout the research process, the Company has established a closed-loop ethical supervision mechanism spanning the entire trial lifecycle. All studies strictly fulfilled regulatory and ethical pre-approvals. Safety reports, protocol deviations, and progress reports were submitted regularly during the trials as required. Upon completion of the trials, summary documents were promptly submitted, ensuring that the entire research process remained under the continuous supervision of the Ethics Committee.

The Company embeds the core protection of participants' rights throughout the entire informed consent process. informed consent forms of all versions clearly elaborate on key information such as trial risks and benefits, compensation, privacy protection, and the right to withdraw. They are used only after approval by the Ethics Committee, ensuring that investigators fully inform participants and obtain their signed consent for archiving. In 2025, to support the business needs of Multi-regional Clinical Trials (MRCT) and respond to the ICH E6 R3 guidelines, the Company prioritized the optimization of informed consent templates. By refining language expression, strengthening privacy clauses, and simplifying processes, the Company effectively alleviated the burden on trial subjects. In the future,

Innovent will continue to monitor the development of domestic and international regulations and ethical standards, promptly incorporate new requirements into internal policies and operational documents, and ensure that clinical practices consistently adhere to the highest standards.

Extension of the Dosing Process Following Clinical Studies

Based on each subject, determine whether the predetermined treatment specified in the protocol has been completed and assess whether the subject continues to derive benefit from the continued use of the investigational drug. If benefit is derived, this point shall be designated as the start of the gift medication.

The Clinical Project Manager prepares drug-related processes and documents and continuously collects serious adverse reactions, reporting them promptly to the pharmacovigilance (PV) department.

Assess based on the specific condition of each subject, obtain informed consent, and apply for medication dispensation.

All documents generated during the post-trial access phase following the conclusion of clinical trials shall be organized by the clinical project manager or an authorized clinical research associate and stored separately in a document distinct from the original clinical trial.

Clinical Research Culture

To continuously enhance staff's professional capabilities and standardize clinical trial operations while safeguarding the safety, rights, and well-being of subjects, Innovent has established a comprehensive internal training management system. This system is oriented towards job requirements to develop personalized training plans. It is implemented through diverse formats to ensure that staff possess and continuously meet the qualifications and competency requirements related to clinical trials.

Company-wide Training	Coordinated by the Human Resources department, training is delivered through various formats including classroom sessions, online meetings, and the iTalent system, covering company policies, corporate culture, and general compliance requirements.
Clinical Training	Innovent's clinical research training system ensures timely distribution of updated documents through its systematic platform, with cumulative training participations exceeding 61,000 in 2025. The Clinical Quality Department coordinates regular weekly cross-functional training sessions, completing 42 sessions throughout the year, covering topics such as blinding practices, dose escalation, system operations, and trial design. For the 16 SOPs updated to meet MRCT requirements, 10 dedicated training sessions were organized. In addition, each department executes its internal annual training plan, and in 2025, a unified training and assessment on "*Good Clinical Practice*" *(<藥物臨床試驗質量管理規範>)* was completed for all personnel involved in clinical trials.
Clinical Trial Training	Prior to the initiation of each trial, the clinical project manager develops a project-specific training plan and coordinates the delivery of training sessions, either in-person or online. Team members must complete all required training before assuming their duties. All training records are filed in the trial master file. In 2025, the Company updated its operating procedures related to project training, implementing a phased training model with both mandatory and optional components. An assessment mechanism was also introduced to better ensure understanding and proper application of the training material.

3.4 Responsible Marketing

We adhere to scientific, standardized, and responsible marketing guidelines. Product promotion is conducted based on authentic data and clinical evidence to effectively safeguard the rights and interests of customers and patients. The Company has established a comprehensive marketing compliance management system. Through continuous and in-depth employee training, it has embedded integrity and compliance awareness into the corporate culture and daily operations, dedicated to promoting the healthy development and virtuous cycle of the industry ecosystem.

3.4.1 Our Governance

Innovent strictly complies with the laws, regulations, and industry standards applicable to its operations. The Company has promulgated the *"Responsible Marketing Policy"* (<負責任營銷政策>)[4] as a guiding document. Based on this policy, Innovent has established a series of internal policies, including the *"External Material Release Review Process"* (<對外材料發布審核流程>) and the *"Process Guidelines on Promotional and Educational Materials"* (<推廣和教育材料流程指引>) which clearly define the requirements for the entire process of creating, reviewing, and releasing all educational and promotional materials. To ensure the effective implementation of policies, the Company has established a rigorous multi-level review mechanism requiring that all marketing materials be approved by authorized management personnel before being released to the public. In terms of policy implementation and culture building, the Company has integrated responsible marketing as a core module of compliance training. Systematic explanations of relevant requirements are provided in new employee compliance training and annual compliance training, while clear communication is made regarding disciplinary measures for violations to continuously strengthen all staff's compliance awareness and behavioral boundaries.

3.4.2 Our Actions

Innovent strictly prohibits any form of false advertising or misleading conduct and has established a tiered review and supervision mechanism spanning the entire lifecycle of marketing materials to ensure the authenticity and compliance of all external communications. For different types of materials, the Company implements a classified audit process. Corporate promotional materials are strictly reviewed in accordance with the *"External Material Release Approval Process"* (<對外材料發布審核流程>) led by the Corporate Communications Department and jointly examined by multiple departments including Business, Medical, Intellectual Property, Investor Relations (IR), Legal, and Compliance. Education and promotional materials follow the *"Process Guidelines on Promotional and Educational Materials"* (<推廣和教育材料流程指引>) undergoing professional review by functions including Marketing, Medical, Legal, Intellectual Property, and Corporate Communications. These materials are centrally archived by the Compliance Department, with continuous monitoring and inspection implemented to establish a complete management closed loop encompassing review, archiving, and supervision.

Responsible Marketing Training

In 2025, Innovent established a robust compliance framework for responsible marketing for all staff through institutionalized, comprehensive, and routine training. The Company has established "Responsible Marketing" as a core module within its compliance training system and explicitly requires all staff to complete relevant training at least once annually. During the Reporting Period, the Company organized and conducted a total of 27 compliance training sessions for new staff and 1 annual training session for all staff, covering 7,248 attendances.

4 For details regarding the Responsible Marketing Policy, please refer to the Company's official ESG website.

In addition, Innovent conducts irregular compliance spot checks on promotional materials to ensure all advertising and marketing content is accurate and compliant. The Company also regularly performs responsible marketing audits covering all business units, product lines, and functional departments to proactively identify, alert, and correct potential violations. During the Reporting Period, we implemented a comprehensive, data-driven audit and supervision program covering all business processes to strictly monitor the entire marketing chain, including academic promotion, distributor management, and third-party terminals. This ensures that all commercial activities adhere to the highest ethical standards and comply with domestic and international regulations.

Audit of Direct Marketing Activities	For the national commercial team, we conduct audits focusing on various direct commercial activities, and the departure of key commercial personnel to ensure that all commercial activities are conducted within a compliance framework.
Audit of Indirect Marketing Channels	To ensure marketing compliance among distributors and partners, we mandatorily include anti-corruption and compliance clauses in cooperation agreements. Based on monthly data analysis, high-risk partners are identified and subjected to both scheduled and unscheduled on-site audits to review their marketing activities.
Audit of Key Marketing Formats	Compliance auditing of medical education and promotional activities has been integrated into both commercial team audits and marketing department expense audits. These audits examine expenses, programs, budgets, and content to ensure activities are authentic, science-based, and transparent.

At the same time, leveraging the market launch of major new products such as Mazdutide, we have expanded audit supervision from single nodes to the entire product lifecycle, implementing full-chain coverage encompassing "pre-event prevention, in-process control, and post-event evaluation". During the Reporting Period, no administrative penalties or litigation cases occurred due to violations in marketing activities.

Prior to	Participate in establishing channel customer screening criteria and developing the AEPC (Anti-bribery, Ethics, and Compliance) process framework prior to product launch, and audit sales policy compliance.
During	During the launch and promotion phase, conduct concurrent monitoring and analysis of early sales data, expense allocation, and channel behavior.
Following	In the stable sales phase, include these areas in routine quarterly and annual specialized audits for systematic review.

Full-Chain Marketing Compliance Audit

3.5 Supply Chain Management

Innovent fully recognizes that sound Supply Chain Management is critical to the stable operation of the Company's business. We are committed to deeply integrating sustainable development concepts into our supply chain system and practicing responsible business conduct throughout the entire procurement process. We collaborate with supplier partners to build a responsible and sustainable supply chain ecosystem.

3.5.1 Our Actions

Innovent places high importance on supplier management and the construction of supply chain stability, continuously improving a comprehensive management mechanism that covers supplier access, performance evaluation, quality audits, and supply assurance. Focusing on core objectives such as compliance control, quality assurance, and stable supply, the Company continuously strengthens the systematic and forward-looking nature of Supply Chain Management. It advances supplier management from basic access to full-process supervision and collaborative optimization, providing robust support for product quality stability and continuous business operations.

Supplier Onboarding

Innovent regards supply chain access management as a critical component for ensuring supply stability and sustainability. The Company has established a policy framework centered on the *"Supplier Access Management Procedures"* (<供應商准入管理規程>) and the *"Supplier EHS Audit Management Procedures"* (<供應商 EHS 審計管理規程>). During the access assessment, the Company comprehensively evaluates suppliers' quality, cost, delivery, technology, risk resilience, and ESG performance to control cooperation quality and compliance foundations at the source.

In 2025, we systematically revised the *"Supplier Access Management Procedures"* (<供應商准入管理規程>) to further raise the entry threshold. The new regulations have expanded the scope of on-site supplier audits and clarified 9 core qualification standards, including years in operation, registered capital, employee social security contributions, ESG performance and clean records, thereby reducing supply chain compliance risks.

Supplier Evaluation and Assessment

Building upon a rigorous entry screening process, the Company has further strengthened dynamic management of supplier collaboration. In accordance with the *"Supplier Performance Evaluation"* (<供應商績效考核>) evaluations are conducted on a quarterly, semi-annual, or annual basis. Additionally, differentiated performance indicator weights have been established for different types of suppliers to ensure that assessments are scientific and effective.

Following the assessment, we promptly provided feedback to suppliers and offered specific recommendations and corrective guidance to those requiring improvement. This established a closed-loop management mechanism of 'as sessment-feedback-improvement', driving their continuous optimization. As of the end of the Reporting Period, the Company had established a daily performance management system covering more than 700 suppliers on the qualified list and achieved 100% assessment coverage for strategic suppliers. Concurrently, we conducted over 20 high-level communication sessions with suppliers to systematically review and deeply discuss their performance across multiple dimensions, including commercial terms, quality, and delivery. These efforts continue to drive business synergy and focus on building long-term, stable strategic partnership relationships that are mutually beneficial.

Supplier Quality Management

Innovent deeply integrates quality supervision into the full lifecycle management of suppliers. Through policies and systematic audits, the Company systematically builds and continuously strengthens supply chain quality assurance capabilities. The Company has established core policies, including the *"Material Supplier Management Procedures"* (<物料供應商管理規程>) which clearly define requirements for the screening, admission, evaluation, audit, and review of material, service, and outsourced production suppliers. These policies provide clear guidance for the full-process quality management of suppliers. Building on this foundation, the Company has established a supplier quality management system covering all categories and conducts audits strictly in accordance with the *"Global Quality and Compliance Audit Master Process"* (<全球質量與合規審計主流程>).

Collect Supplier Quality Documentation	• Verify the legality of suppliers' business qualifications and production licenses. • Confirm that production suppliers maintain a sound production environment and a comprehensive quality management system. • Ensure that the products and services provided comply with applicable regulations and the Company's technical requirements.
Collect Supplier Survey Documents	• Gain a comprehensive understanding of the supplier's overall operational status and quality management practices. • Identify potential quality, delivery, and compliance risks, and develop corresponding control and response measures.
Execute Quality Audit	• On-site or document-based quality audits are conducted for suppliers classified as A, B, S1, or S2 with higher risk levels. • Audit confirmation ensures its continued compliance with regulatory requirements and Innovent's quality standards.
Sign the Quality Agreement	• Sign binding quality agreements with A/B/S1/S2 category suppliers. • Clearly define the responsibilities of both parties, scope of services, technical quality requirements, and compliance obligations in the agreement to ensure the implementation of consensus and clarity of accountability.

Based on supplier risk levels and the nature of materials or services provided, Innovent implements differentiated tiered management strategies for key suppliers in accordance with its *"Procedure for Grading Material Suppliers, Service Providers, and Contract Research and Manufacturing Organizations"* (<物料供應商、服務商以及合同研發生產商分級>). For suppliers of Category A and B materials, the Company establishes binding constraints through quality agreements. In the event of any changes that may affect material quality, suppliers are required to notify us promptly to enable a rapid assessment of their potential impact on product quality. The Company conducts quality audits on relevant suppliers on a regular basis, with a frequency of once every two or four years. Issues identified during the audit will drive suppliers to formulate and implement corrective and preventive actions. We will continuously monitor the rectification progress to achieve closed-loop management of these issues.

During the Reporting Period, the Company systematically completed quality audits of all key and major material suppliers, service providers, CDMOs, and primary pharmaceutical distributors in accordance with the "Global Quality and Compliance Audit Master Process" (<全球質量與合規審計主流程>).

Audit of Key Material Suppliers/Service Providers/CDMO Suppliers				GDP Distributor Audit
Qualification Confirmation Audit	Routine Audit	Audit with Cause	Tracking Audit	Qualification Confirmation Audit
64	63	8	1	6
Total: 136 quality audits				**Total: 6 quality audits**
Audit Pass Rate: 99%				**Audit Pass Rate: 100%**

Furthermore, as a proactive measure to deepen control, the Company extended its audit scope to key tier-2 service providers and incorporated them into S1-class suppliers – the highest risk category – for biennial re-review management. This approach has achieved deeper quality supervision of the supply chain and closed-loop risk control.

Supplier Training

To systematically enhance the comprehensive capabilities of suppliers, we have established a multi-level training and empowerment system covering the entire lifecycle. We regularly conduct quality and capability building training for all suppliers, covering basic modules such as product delivery quality and system operations. Building on this foundation, approximately 150 one-on-one specialized guidance sessions are provided annually to newly onboarded suppliers. These sessions assist them in quickly mastering key aspects of the registration, questionnaire completion, and quotation processes, ensuring their efficient integration into the management system.

For key material suppliers and CDMO partners, we further implement an in-depth on-site coaching mechanism. During the Reporting Period, a total of 500 person-times of on-site supervision, guidance, and training were conducted, significantly enhancing the technical implementation capabilities and GMP compliance levels of relevant suppliers. Meanwhile, in response to weak links identified in specific projects, we organized special quality improvement initiatives. By combining mechanism establishment, process supervision, and on-site assistance, we effectively promoted a comprehensive improvement in suppliers' quality awareness and system operational capabilities, thereby ensuring the smooth progress of key project milestones.

In addition, we conducted over 20 on-site communications with senior supplier executives to review their performance across multiple dimensions, including commercial terms, quality, and delivery. These efforts aim to continuously enhance supplier performance and establish robust long-term partnerships. The entire system, spanning from foundational training to deep empowerment and from issue rectification to strategic alignment, has established a continuous closed loop that collectively supports the overall advancement of supply chain capabilities.

Specialized Coaching for Supplier Capability Enhancement

In 2025, the Company launched a specialized quality coaching and improvement initiative to address issues exposed during the advancement of CDMO projects, including weak quality systems, pressure on project schedules, and insufficient quality awareness among personnel. By combining mechanism establishment, process supervision, and on-site assistance, the Company promoted the continuous enhancement of suppliers' quality management capabilities. By continuously advancing the project through key milestones such as APS, Engineering Batch, and PPQ, and successfully passing relevant audits, personnel quality awareness and system operational capabilities have been significantly enhanced.

Supply Chain Stability

To strengthen supply chain resilience, our Suzhou facility operates 60,000L antibody capacity and ADC production lines, and our Hangzhou site has 80,000L of built antibody capacity (with a second phase of 90,000L planned). During the Reporting Period, the Hangzhou production base completed commercial-scale validation for multiple products, establishing a fully functional dual-site production backup system between Hangzhou and Suzhou. Based on medium- to long-term sales forecasts and growth potential, Innovent has identified its product priorities and advanced strategic capacity planning.

We continue to implement a dual-source supply strategy and conduct supply chain risk assessments. During the supplier selection phase, we comprehensively evaluated risk factors such as geopolitical issues, tariffs, and supply continuity, while taking corresponding risk control measures. Materials are classified by their impact on products and managed through a tiered system. The Company further ensured the reliability of logistics transportation services by increasing the number of cooperating logistics suppliers. As of the end of the Reporting Period, Innovent has implemented dual-source supply for all its self-manufactured commercialized products. Innovent will continue to optimize its dual-source supply strategy to mitigate supply chain risks.

Sustainable Supply Chain

Innovent is committed to the sustainable development of its supply chain and actively builds a green and responsible management system. During the procurement process, we prioritize suppliers with strong ESG performance and collaborate with partners to advance a virtuous cycle within the supply chain ecosystem. During the Reporting Period, we further integrated ESG requirements into the full lifecycle management of suppliers. At the new supplier onboarding stage, we conducted systematic assessments across key areas including safety management, environmental protection, employee health, and business ethics. In accordance with the "Supplier EHS Audit Management Procedure" (<供應商EHS審計管理規程>), we continuously conduct audits on key suppliers regarding occupational health and safety, compliance in the control of three wastes, and emission reduction. Furthermore, based on different product categories and suppliers, we have signed EHS or quality agreements to clarify relevant performance requirements.

During the Reporting Period, we conducted EHS audits on 27 key suppliers, covering key dimensions such as whether they have obtained ISO 14001 environmental management system certifications, ISO 45001 occupational health and safety management system certifications, and ISO 50001 energy management system certifications; whether they have implemented energy-saving and emission-reduction measures; whether they have undertaken ESG improvement initiatives; as well as their recent compliance performance and safety records. Through these specialized audits, we identify, cultivate, and rotate high-performing suppliers, enhancing the stability of our supply chain. Regarding safety performance, there were no major environmental pollution incidents in the past year.

Strategic Core Suppliers	General Suppliers	New Suppliers
Strategic core suppliers are required to regularly provide ESG reports and ESG Rating results from mainstream ESG rating agencies to ensure their ESG practices align with the Company's requirements.	Encourage general suppliers to continuously improve and meet the majority of our ESG requirements, and submit annual ESG progress and improvement reports.	We will conduct ESG assessments for new suppliers to ensure they meet the Company's basic ESG requirements.

Innovent deeply integrates integrity and compliance management into its supply chain system, striving to build a transparent and open business environment. During the supplier onboarding phase, we implemented a specialized questionnaire incorporating anti-corruption and anti-commercial bribery provisions to comprehensively assess suppliers' business ethics and compliance foundations. Meanwhile, by requiring suppliers to sign the *"Anti-Corruption Pledge"* (<反腐敗承諾書>) and *the "Integrity Pledge"* (<誠信廉潔承諾書>) we further clarify the responsibilities of both parties, disseminate integrity standards, and systematically mitigate corruption risks within the supply chain. During the Reporting Period, both the signing rate of relevant commitment letters and the completion rate of anti-corruption questionnaires reached 100%.

In terms of green procurement, we continue to advance the construction of a green supply chain by integrating environmental performance as a core dimension of supplier management. In accordance with the "*Supplier Access Management Policy*" (<供應商准入管理程序>), we prioritize evaluating suppliers' environmental management capabilities during the selection process. Under equivalent conditions, partners demonstrating superior environmental performance or providing eco-friendly products are given priority. Meanwhile, the Company actively encourages suppliers to establish energy conservation and emission reduction targets, refine environmental management strategies, and implement environmental protection measures and system certifications. This collaborative effort aims to continuously enhance the overall environmental performance of the supply chain and jointly build a sustainable green supply chain ecosystem.

04
PEOPLE FIRST

Innovent has always regarded talent as the core driver of development. We are committed to building a diverse, equitable, and inclusive workplace and supporting every employee's growth through comprehensive remuneration and benefits and continuous care. We not only provide platforms and support, but also strive to be a partner for employees to realize their dreams and achieve continuous progress, fostering a journey in which the Company and employees move forward together to create a shared future.

This chapter is in response to the sustainable development goals (SDGs) of the United Nations

4.1 Compliant Employment

Innovent has always adopted a "people first" approach as the core philosophy of its development. By establishing a comprehensive employee system, the Company safeguards employees' legitimate rights and interests while continuously optimizing the employment experience.

4.1.1 Our Governance

Innovent strictly complies with domestic and international laws and regulations applicable to its operations, including the "Labor Law of the People's Republic of China" (<中華人民共和國勞動法>), the "Labor Contract Law of the People's Republic of China" (<中華人民共和國勞動合同法>), the "Social Insurance Law of the People's Republic of China" (<中華人民共和國社會保險法>), the "Universal Declaration of Human Rights" (<世界人權宣言>), and the International Labor Organization Convention (<國際勞工組織公約>). The Company has established human resources management policies, such as the "Recruitment and Onboarding Management Procedures" (<招聘入職管理辦法>), to ensure the compliant conduct of employee recruitment.

In addition, we have formulated and publicly released the "Human Rights and Diversity Policy" (<人權與多元化政策>)[5]. The Board's Compensation Committee oversees the protection of employee rights and the advancement of diversity objectives. We are committed to upholding internationally recognized human rights standards, fostering a workplace culture of diversity and inclusion, creating an equal employment environment for stakeholders, and fully safeguarding the rights of employees from our own organization, suppliers, contractors, and partners.

4.1.2 Our Goals

Innovent has established employee diversity goals and regularly tracks their progress. As of the end of the Reporting Period, we have successfully achieved our diversity management goals. Female employees account for 51% of the workforce, while female managers represent 45.2%.

Diversity Targets	Maintaining at least 40% female representation among employees and executives
	Ensuring female candidates for key positions constitute more than 40% of the pool

4.1.3 Our Actions

Talent Recruitment

Innovent has established a comprehensive recruitment system. Through regular strategic talent reviews and demand assessments, the Company formulates precise talent acquisition plans aligned with its sustainable development goals. During the Reporting Period, we completed the annual talent review and formulated the 2025 recruitment plan based on our business development strategy. By establishing an intelligent talent database and deepening strategic cooperation with top global talent institutions, the Company is reserving high-quality talent resources for its international development.

During the Reporting Period, the Company successfully recruited near 3,000 talented individuals and attracted approximately 40 international professionals from overseas. Meanwhile, the Company places high importance on the recruitment and development of local talent to better adapt to the characteristics and needs of various markets. Approximately 300 local employees have been successfully recruited in operational locations such as Beijing, Shanghai, Suzhou, and Hangzhou, resulting in a localization rate of 30%. The Company achieved a recruitment completion rate of 95%, with strategic roles exceeding 96%. This includes several senior executives and technical experts possessing experience in multinational pharmaceutical companies. These efforts ensure that our organization is coordinated and advanced in alignment with the Company's development strategy, realizing synergistic development between strategy and talent.

5 Please refer to Innovent's ESG website for "Human Rights and Diversity Policy"(<人權與多元化政策>).

Innovent places high importance on talent pipeline development and continuously optimizes its talent structure by building a diversified recruitment system. In campus recruitment, we actively participated in talent development through joint training programs, off-campus mentor initiatives, university-enterprise visits, career guidance salons, the modern apprenticeship system, and internship training centers. These efforts enhanced our employer brand influence and cumulatively provided over 2,200 job opportunities for fresh graduates. In 2025, the Company further deepened its collaboration between industry and academia. Innovent conducted its campus recruitment program for the fourth consecutive year, holding online and offline information sessions and job fairs in nearly 20 provinces across China and at over 50 institutions. The program offered more than 500 positions and recruited over 400 new graduates from the Class of 2026.

Campus Recruitment Poster

Academia-Innovent Dialogue

Tsinghua University Recruitment Fair

Academia-Innovent Visits

Career Salon – Zhejiang University

In 2025, we visited Zhejiang University to organize a career guidance salon for our employees who are alumni of the university. We shared insights on career planning and industry development prospects with students from the School of Medicine at Zhejiang University, to attract top talent to join Innovent.

Career Salon of the School of Medicine, Zhejiang University

Off-Campus Mentorship Program – Xi'an Jiaotong-Liverpool University

Innovent actively promotes deep integration among industry, academia, and research by inviting multiple senior experts from Innovent, including Dr. Chen Bingliang, to serve as external mentors at Xi'an Jiaotong-Liverpool University. This program provides a practical platform for current students in the field of innovative drug development, offering professional guidance from corporate executives and hands-on opportunities at Innovent to foster composite talents in the biopharmaceutical sector.

Xi'an Jiaotong-Liverpool University External Mentor Program

Protection of Human Rights

Innovent has always adhered to the principles of respecting human rights and compliant employment. The Company firmly opposes child labor and forced labor, and strictly prohibits any acts that violate laws or infringe upon human rights during recruitment and operations. We implement a rigorous vetting mechanism during the recruitment process and utilize identity verification procedures to eliminate the risk of child labor. The Company strictly enforces the provisions of the "Labor Law of the People's Republic of China" (<中華人民共和國勞動法>) by implementing a standard working hour system to ensure that employees' weekly working hours do not exceed the statutory limit. During the Reporting Period, no incidents of child labor or forced labor occurred at Innovent.

At the same time, Innovent strictly complies with the "Law of the People's Republic of China on Trade Unions" (<中華人民共和國工會法>), supports trade union development, and encourages employees to join the trade union. The Company has established a normalized employee communication mechanism to fully listen to employee demands and effectively safeguard their rights and interests. In building diversity and inclusion, the Company has established a systematic training system. Annually, it conducts specialized training on the "Human Rights and Diversity Policy" (<人權與多元化政策>) for all employees to continuously strengthen their understanding and identification with diversity concepts, promoting the construction of an equal, diverse, and inclusive work environment. During the Reporting Period, we conducted a specialized training session on "Human Rights and Diversity Policy" (<人權與多元化政策>) for 100% of new hires.

4.1.4 Our Performance

During the Reporting Period, no non-compliant events related to employment occurred at the Company. As of the end of the Reporting Period, the Company recruited 2,718 new employees, bringing the total workforce to 7,502 employees.

4.2 Employee Development

We have established a systematic talent development framework. Through tiered and categorized training programs, a scientific performance management system, and clear career advancement pathways, we provide comprehensive support to employees across all levels and stages of their professional growth. Innovent upholds the talent development philosophy of "empowering those who strive to succeed" by establishing a comprehensive career progression pathway and a fair competitive mechanism. The Company continuously optimizes its talent evaluation criteria of "valuing integrity, dedication, and impact", while conducting regular 360-degree performance assessments and feedback sessions to enhance employee capabilities and optimize organizational effectiveness.

4.2.1 Our Actions

Employee Compensation System

Innovent strictly adheres to the principle of fair compensation and has established a diversified compensation system. This system comprises core components including fixed pay, performance-based bonuses, and long-term equity incentives. We regularly conduct industry compensation benchmarking analyses. Through systematic market research, we continuously optimize our compensation and benefits policies to ensure that the overall employee compensation level remains at a leading position within the industry.



Employee Compensation System

Employee Performance Evaluation and Feedback Mechanism

Innovent has established a comprehensive performance management system. Through the formulation of differentiated performance objectives and the implementation of annual and semi-annual assessment mechanisms alongside continuous feedback processes, the Company systematically evaluates employee work performance. In this process, employees' line managers will conduct in-depth one-on-one discussions based on the assessment results, providing detailed and targeted feedback and improvement suggestions to support employees' career development.

Performance target setting

- Strategy decoding
- Departmental targets
- Personal targets

Performance implementation and process coaching

- Process monitoring and coaching
- Phase review and summary

Performance assessment and feedback

- Semi-annual and annual performance assessment
- Performance ranking
- Performance feedback

Application of performance results

- Annual bonus
- Annual salary adjustment
- Equity incentives
- Recognition
- Promotion
- Training
- Rotation or transfer

Innovent Performance Management System

Employee Incentives

Innovent has established an equity incentive policy and an R&D talent incentive policy. This policy strictly adheres to the principles of fairness and impartiality. Based on a multi-dimensional performance evaluation system, it implements differentiated economic incentives for high-performing employees. Equity incentives are granted based on a comprehensive assessment of job value contribution and individual performance; all employees have the opportunity to participate in the equity incentive program. During the Reporting Period, the number of employees participating in the equity incentive plan accounted for 20% of the total number of regular employees.

Equity Incentive Mechanism

- Equity incentives include stock option plans and restricted stock plans for key position personnel and employees with annual performance rankings of A/A+, which are approved annually by the Remuneration Committee and the Board of Directors. All employees have the opportunity to receive equity incentives.
- Vesting of equity incentives is linked to the achievement of individual annual targets and the achievement of company targets, which includes ESG-related indicators.
- Equity incentives vest 75% in the third year and 25% in the fourth year after the date of grants. Taxation on vested equity is handled by the Company.

R&D Talent Incentive Policy

- Developed and implemented the "Innovation Incentive Management Guidelines" (<創新激勵管理規程>), which provide phased incentives at key milestones in R&D and commercialization. This covers key employees involved in molecular design and screening, early-stage development, and business development (BD), injecting sustained momentum into early-stage R&D.
- An "Inventor" reward system has been established to provide additional rewards for outstanding R&D personnel and employees who achieve significant innovative results.
- An honor recognition mechanism called "Science Star" and "Dream Chaser" has been established to encourage R&D personnel who make outstanding contributions.

Employee Incentive System

Employee Promotion System

Innovent has established a comprehensive career development system. The Company formulated and implemented the "Promotion Management Measures" (<晉升管理辦法>), constructing a dual-track promotion mechanism comprising "Management Track" and "Professional Track". This policy provides employees with diverse career development opportunities, fully respects their right to make career choices, and supports them in selecting suitable development paths based on their individual career aspirations. In talent selection, we adhere to the principle of prioritizing internal candidates. When a position becomes vacant, we prioritize promotion and transfer opportunities for existing employees to foster a positive synergy between employee career growth and organizational development.

In 2025, a total of 722 promotions were made within Innovent. Among them, 151 individuals were promoted to management positions through internal recruitment.



"Dual Channel" Promotion Paths

In addition, we established a professional competency assessment system and incorporated professional competency assessments into the promotion process for commercial teams.

In 2025, we assessed 184 individuals in the commercial team through this professional competency evaluation system, resulting in the promotion of 62 people.

Talent Development through Diversification

The Company has established a comprehensive employee training and development system. Through the design of tiered and categorized training programs, it provides customized learning solutions for employees at different levels and in various positions. We not only focus on enhancing employees' professional skills but also prioritize leadership development and comprehensive capability growth. Through a diversified learning platform combining online and offline approaches, we ensure that every employee receives resource support aligned with their career development path.

Training System

In accordance with internal regulations such as the "Training Management System" (<培訓管理制度>) and the "Regulations on Regular Employee Education Management"(<在職員工教育管理辦法>), the Company has established a comprehensive employee development system. We have established a tiered and categorized training mechanism. Focusing on key dimensions such as foundational skills, professional capabilities, and innovative thinking, we achieve an in-depth integration of theory and practice. We have designed differentiated leadership development programs for employees at various levels to support their career growth.

In internal knowledge management, we have established a professional system for cultivating internal trainers. By selecting outstanding employees as corporate internal instructors, we continuously refine business practical experiences and develop training courses with distinctive corporate characteristics.

Talent Training System

New Employee Training

Innovent places high importance on talent development and employee integration, having established a systematic onboarding training system tailored for new employees at different levels. We innovatively launched specialized training programs including "Executive Landing", "Innovent Beginning – Newcomer Integration 100-Day Program", and the "Overseas New Employee Program". Through phased and systematic curriculum design, these initiatives comprehensively cover the professional knowledge and core skills required for new employees' career development, effectively facilitating rapid integration and growth.

New Senior Executives

- Senior Executive Landing and Integration Program
  - Scope: Within 6 months of joining
  - Stages: 6 stages
  - Method: Online + Offline
  - Content:
    - Integration into Innovent's Culture
    - Completion of Key Tasks

Domestic New Employee

- Innovent Beginning – Newcomer Integration 100-Day Program
  - Scope: Within 6 months of joining
  - Stages: 3 stages
  - Method: Online + Offline
  - Content:
    - Step 1 – Sensing Innovent
    - Step 2 – Experiencing Innovent
    - Step 3 – Integrating into Innovent

Overseas New Employee

- Scope: Within 6 months of joining
- Method: Online Learning
- Content:
  - Innovent DNA
  - Innovent First Experience
  - Innovent Regulations

New Hire Training System

For fresh graduates, Innovent continues to deepen the "Innovative New Talent Program" by establishing a three-in-one training system comprising "professional development guidance + dual-mentorship model + intensive practical training," thereby creating a comprehensive career development platform for fresh graduates.

"Innovent Beginning"- New Employee Training Program

During the Reporting Period, we launched the "Innovent Beginning" training series for all new employees. Through this three-stage program, new hires will progressively learn about the corporate culture, values, corporate development history, strategic objectives, internal regulations, and professional knowledge across different divisions, facilitating their rapid integration into the Company. Additionally, new employees in commercial roles receive extra training in disease knowledge, product knowledge and communication techniques. In 2025, "Innovent Beginning" conducted 33 offline training sessions, covering 100% of new employees.

"Innovent Beginning" Series Training

Training for Current Employees

Innovent has developed differentiated training programs for its core business departments, including sales, production and quality, as well as research and development and clinical operations. Through a systematic curriculum of professional courses, the Company continuously enhances employees' professional skills and occupational competence.

Training for Commercial Personnel

We launched the "Innovent Beginning", "Innovent Future", and "Innovent Impetus" training programs for grassroots employees and cadres newly promoted or joining in commercial roles, as well as for middle-level managers. Targeted training courses were designed for personnel at different levels to help them adapt to their new positions and acquire the necessary knowledge and skills.

In 2025, the "Xin" series of training programs cumulatively involved over 2,526 participants, with an average satisfaction rate of 100%.

"Xin" Series Training

"Xin" Series Training

Pipeline Training

Pipeline-related training was conducted for all sales personnel, covering disease and product knowledge, marketing promotion strategies, academic promotion practical cases, and communication techniques. Knowledge assessments were subsequently administered based on the learning content to ensure employees fully mastered the material, thereby continuously strengthening their professional skills and knowledge. In 2025, a total of 41 offline training sessions were organized for all employees in the sales sector, with 1,470 participants. Additionally, 162 online pipeline training sessions were conducted, covering 69,083 participants.

Training for Production and Quality related Personnel

During the Reporting Period, the Company organized a total of 7 annual GMP training sessions, covering more than 6,500 participants. In addition, various departments organized over 650 offline training sessions on relevant topics for GMP department employees, led by technical experts from the respective sectors. See the "Product Quality and Safety" section.

GMP Training

GMP Department Training

Training for R&D related Personnel

To continuously enhance the professional competence of the R&D team, the Company organizes cross-disciplinary academic exchange activities every two weeks. These sessions invite internal project leads, industry experts, and external experts and scholars to jointly discuss the latest research developments. This ensures that R&D personnel stay abreast of cutting-edge technological advancements, providing a solid knowledge foundation for innovative drug development. In 2025, we organized a total of 20 Journal Club sessions.

Journal Club Activity

Journal Club Activity

Training for Clinical Personnel

Medical Statistics Regulatory Forum	Regularly organize medical statistics regulatory forums to share knowledge on drug lifecycle management, thereby enhancing the skills and knowledge of the PDP segment and relevant personnel. In 2025, we organized and conducted four forum activities.

Management and Leadership Development Training

For management personnel at all levels, we have designed and implemented a systematic leadership development program. Through diversified training methods such as case studies, visits to benchmark enterprises, and practical exercises, we comprehensively enhanced the professional capabilities and leadership standards of the management team, effectively transforming knowledge and skills into actual management competencies. In addition, we have developed customized training programs for high-potential talents, such as the "Bamboo Class".

In 2025, a total of 121 management and leadership training sessions were conducted across all levels, covering the Company's management personnel in every tier.

High-Potential Talent Management and Leadership Training

Innovent "Lieutenant" program adopts a tiered cultivation model. The "CEO 'Lieutenant' Program", targeting the executive team, focuses on strategic leadership development to cultivate industry-leading talent. Meanwhile, the "Lieutenant" program for department heads enhances management capabilities through diversified scenarios such as practical drills and case studies.

In 2025, the Company precisely designed training programs based on talent development needs. A total of six special activities were conducted throughout the year, covering diverse formats such as leadership development courses, management experience sharing sessions, and thematic seminars. Thanks to the effective implementation of this project, four outstanding trainees were successfully promoted to department heads within the year.

The "Lieutenant" Program

Senior and Middle Management Development Program

The Company is committed to cultivating talents among senior and middle-level management by establishing two flagship programs, the "Cedar Class" and the "Picea Class". These initiatives aim to solidify the talent foundation for sustainable development, empower managers to maximize their value in their roles, and drive the Company's long-term growth.

"Cedar Class"

The "Cedar Class" program targets senior management to systematically enhance the strategic thinking and global perspective of the core management team. In 2025, the Cedar Class held eight events covering internal integration, external exchange, collaborative leadership learning, outdoor team-building training, and class seminars to promote the integration and growth of the senior management team.

The "Picea Class" focuses on middle management, concentrating on management practices and business challenges. Through strategic workshops and business discussions, it enhances team capabilities in real-world scenarios.

Senior and Middle Management Development Program (Continued)

Commercial Team "Picea Class"

The commercial team "Picea Class" aims to cultivate a core workforce deeply embodying the "Innovent Spirit" and to develop trainees into senior executives for Innovent's future, thereby reserving commercial management talent for the Company's sustainable development. In 2025, the class organized one offline intensive seminar, two online thematic learning sessions, and twelve online group co-creation activities.

Commercial Team "Picea Class"

CMC "Picea Class"

To build a top-tier middle-management team for CMC that embodies the "Innovent Spirit" and pursues excellence, thereby facilitating strategic implementation, the first cohort of the CMC "Picea Class" was officially launched in March 2025. Through methods such as learning, writing, research, and practice, the project focuses on defining the middle-management role, implementing corporate culture, and enhancing leadership capabilities. It systematically empowers middle-level executives with the aim of forging a resilient, excellent, and strategically aligned management team to solidify the talent foundation for the Company's sustainable development. In 2025, the class organized four offline study tours.

CMC "Picea Class"

Senior and Middle Management Development Program (Continued)

R&D "Picea Class"

In 2025, the Company launched a new R&D "Picea Class" Program aimed at cultivating an international team of mid-level management and cadre personnel in research and development who embody the "Innovent Spirit", pursue excellence, prioritize innovation, and demonstrate resilience. The project was launched in November, focusing on the Company's strategic intent. Through practical exercises in strategic decoding, it solidified trainees' capabilities in R&D implementation and execution.

R&D "Picea Class"

Training Program for Newly Appointed and High-potential Middle and Junior Management Personnel

In 2025, based on the Company's management philosophy and business experience, we updated 8 training courses for middle and junior managers. We also conducted multiple management and leadership development training sessions for newly appointed junior managers, high-potential junior managers, newly appointed middle managers, and high-potential middle managers.

Training for Newly Appointed and High-potential Middle and Junior Management Personnel

High-Potential Frontline Staff Leadership Development Program

In 2025, the Company launched the "Bamboo Class" Program across multiple business sectors to provide high-potential frontline employees with additional platforms for growth and development.

CMC Sector

The first phase of the "Bamboo Class" talent development program in the CMC sector was launched in August 2024. Over a 15-month training cycle, the program conducted 10 collective learning seminars, more than 20 offline group discussions, and visits to benchmark enterprises, while generating over 300 online knowledge-sharing entries. After two years of operation, the program achieved a participant retention rate of 97% and a promotion rate of 51% over the past two years, fully demonstrating the effectiveness of the Company's investment in talent development. In October 2025, Phase I of the program was successfully completed, and Phase II was officially launched.

CMC Sector "Bamboo Class" Program

High-Potential Frontline Staff Leadership Development Program (Continued)

Commercialization Sector

The commercialization sector's "Bamboo Class" officially launched in April 2024. The program encompassed seven competency themes, featuring five offline intensive training sessions, three phased comprehensive capability assessments for all participants, two post-training practical case assignments, and multiple rounds of online group discussions. Following 12 months of mentorship and coaching by 12 mentors, a total of 11 "Bamboo" students have been successfully promoted, representing 30% of the entire class.

Commercialization Sector "Bamboo Class"

Employee Continuing Education Programs and External Collaborations

We provide degree advancement programs and professional certification support for all employees and facilitate the enhancement of their professional skills through diversified external training projects. Meanwhile, the Company has established a comprehensive mechanism for guiding professional technical qualification certification to provide all-around support for employee career development.

Graduate Workstation Jointly Established with the School of Pharmacy, Soochow University

Within the framework of deepening industry-academia-research integration and talent development strategies, Innovent actively expanded its high-level talent cultivation cooperation with universities. Since 2019, the Company has jointly promoted a joint training program for professional degree graduate students with Soochow University, aiming to systematically enhance the academic literacy and innovation capabilities of scientific research and technical talents. In 2025, two frontline employees were awarded Master of Medicine degrees. This project not only facilitates effective collaboration between Innovent and universities in talent development but also reflects the Company's long-term strategy to support employees' continuous learning and empower the professional growth of its teams. In the future, the Company will continue to broaden such cooperation channels and build a more systematic and open ecosystem for cultivating high-level talents, thereby reserving solid intellectual resources for corporate innovation and industry development.

External Cooperative Training

In January 2025, to expand the pool of internal trainers and enhance their instructional skills and public speaking capabilities, we engaged external professional instructors to deliver a course on facilitation techniques.

In January 2025, we engaged an external senior instructor to deliver training on presentation skills for high-potential middle managers.

In February 2025, senior and middle-level management personnel of Innovent visited Alibaba's Hupan University for study and exchange.

Internal Trainer Training Skills Course

Visit to Hupan University

External Cooperative Training (Continued)

In April 2025, we invited Mr. Liu Lan, a renowned expert in leadership development, to conduct a specialized training session on "The Ten Cultivations of Leadership" to enhance the leadership capabilities of management cadres.

Training Course on "The Ten Cultivations of Leadership"

In July 2025, we invited external professional instructors to conduct a two-day team leadership training program for high-potential middle management.

High-Potential Middle Management Leadership Training

In September 2025, we collaborated with an external training provider to conduct a four-day expansion training program for mid-to-senior level management. The outdoor activities were designed to cultivate teamwork capabilities and foster integration within the management team.

Outdoor Team-building Training Activity

4.2.2 Online Learning Platform

Innovent has established an online learning platform for employees. Employees can access the platform via mobile devices at any time and from anywhere to engage in online learning, attend live training sessions, and take online examinations. To meet the Company's global and intelligent strategic needs, we comprehensively upgraded our learning platform during the Reporting Period, transforming the original online training platform into an AI-powered intelligent learning platform — iTalent.

In 2025, employees of the Company actively participated in platform learning, achieving a coverage rate exceeding 98%.

AI Learning Platform — iTalent

Internal Trainer Policy

To provide employees with enhanced training programs, we established an internal instructor team composed of senior executives from Innovent. Through continuous business summarization, we refined a comprehensive internal training curriculum to convey frontline business cases and practical experience to our employees.

Internal Trainer Program

In 2025, the continued development of a professional internal trainer team were sustainably enhancing organizational capabilities. This year, 11 internal trainers were certified. We organized 12 professional training courses, with a cumulative total of 527 participants and learner satisfaction reaching an excellent level of 98%. Based on employee development needs, we have specifically developed a new course titled the "Financial Management for Non-Financial Managers". The content is closely aligned with actual business operations and has received high recognition from participants.

Internal Trainer Training Program

4.2.3 Our Performance

In 2025, the Company's cumulative training participation reached 7,502 person-times, with a total of 317,694 training hours. The average satisfaction rate among participating employees was 98.95%.

4.3 Staff Care

Innovent has established a comprehensive employee communication mechanism. Through regular activities such as employee satisfaction surveys and open days for management, the Company fully respects and actively responds to employee concerns. At the same time, we continue to optimize our employee benefits system and enhance the employee experience, striving to strengthen employees' sense of belonging.

4.3.1 Our Actions

Democratic Management

Innovent is committed to fostering an open and inclusive communication environment by actively listening to employee feedback through multiple channels, ensuring that their suggestions are given full consideration. To address issues of concentrated concern among employees, we have established a closed-loop mechanism comprising 'Collection, Classification, Feedback, Improvement, and Tracking':

- Common issues will be addressed collectively through management communications or internal announcements;
- Suggestions regarding policies and processes shall be specially evaluated by functional departments to develop improvement plans; and
- Short-term optimization items shall have responsibilities and deadlines clearly defined to facilitate rapid implementation.

In addition, focusing on key business areas and employee concerns, we will organize departmental and cross-departmental symposiums and thematic communication sessions based on actual conditions to encourage small-scale, in-depth exchanges between employee representatives and management.

In 2025, building upon existing employee communication mechanisms, the Company further institutionalized and normalized multi-level communication channels to continuously listen to employee voices. Through 6,593 instances of manual consultation and 12,980 visits to the online self-service consultation platform, all inquiries were addressed and resolved in a timely manner. In addition, we have collected a total of 59 employees' suggestions through the 'Rationalization Suggestions' channel. These primarily focused on workflow and efficiency improvement, optimization of digital systems and tools, and the office environment. Approximately 24% of the rationalization suggestions were adopted and converted into specific improvement measures, driving process optimization, system upgrades, and the refinement of employee support policies.

Online Communication Channels	Offline Communication Channels
• DingTalk Workbench – I Have Something to Say • The Company's consulting platform • Cloud community • Reasonable suggestions • Complaints report • Writing to the chairman	• Employee meetings • Face-to-face communication with executives • Thematic discussion meeting • Summary review meeting • Sharing center communication • Dietary committee • Exit interview • One-on-one employee communication

Innovent Employee Communication Channels

CEO Face-to-Face Event

In 2025, the Company continued to conduct 'CEO Face-to-Face' employee exchange activities, organizing a total of 7 sessions throughout the year. These sessions covered different business lines including R&D, production, commercial operations, and functional support. The initiative employed methods such as on-site interactions, pre-event online surveys, and post-event feedback to comprehensively gather employees' opinions. The content primarily covered key topics including the Company's strategy and business development, career advancement and talent cultivation, organizational processes and cross-departmental collaboration, compensation and benefits and employee care, as well as corporate culture and work atmosphere.

In terms of talent retention, we continue to conduct targeted employee communications, focusing on optimizing the talent experience and reducing turnover among key personnel. For every departing employee member, we conducted a detailed exit interview to gain an in-depth understanding of their reasons for leaving and to collect suggestions from the employees' perspective regarding management practices within the Company and its departments. These insights serve as a reference for relevant teams to improve their work. Meanwhile, HR conducts regular one-on-one communications with key talent to monitor their work status and development needs, ensuring timely responses and effective support.

The Company conducts regular employee satisfaction surveys to comprehensively understand employees' needs and challenges in both their work and personal lives. We conducted the 2025 Employee Satisfaction Survey across multiple dimensions, including work experience and job value, support from supervisors and management, career development and recognition, organizational collaboration and efficiency, work support and workload, and communication atmosphere. A total of 2,825 valid questionnaires were collected in this survey, with an overall employee satisfaction rate of 97.1%.

We have established formal reporting and appeal channels, including email and dedicated hotlines, to ensure that all employees can report or appeal violations anonymously without any conditions. Reporting and appeal channels include: mail, the 400 compliance hotline, public email, DingTalk, and WeChat official account. All matters submitted through reporting and appeal channels are received and processed by the Company's audit team. During the investigation, in accordance with the Whistleblower Protection Policy, we strictly maintained the confidentiality of both the allegations and the whistleblower's information to effectively safeguard the legitimate rights and interests of employees. During the Reporting Period, we received no formal written complaints or reports from employees.

Employee Benefits

Innovent strictly complies with the laws and regulations of all operating locations and provides employees with basic protections such as insurance and housing provident funds in accordance with the law. In addition, we provide comprehensive supplemental benefits, such as supplemental medical insurance and maternity support. We provide a maternity leave of no less than 98 days for all expectant mothers and at least 5 days of parental leave for all employees.

During the Reporting Period, our non-statutory benefit policies achieved full coverage, ensuring that 100% of the Company's employees were able to enjoy the benefits provided by the Company. In 2025, Innovent held a Women's Day event and distributed holiday allowances to all female employees.

Statutory Benefits	• The highest proportion of the five social insurances and one housing fund, including pension insurance, medical insurance, unemployment insurance, work-related injury insurance, maternity insurance, and the housing provident fund.

Non-statutory Benefits	• Welfare benefits for physical and mental health
	  • Paid annual leave and additional service annual leave (One additional day of annual leave for each year of service at Innovent)
	  • Supplementary commercial medical insurance and annual employee health check-ups
	  • Gym for employees
	  • Holiday and birthday benefits
	• Family Benefits
	  • Establish a nursing room and set up a green channel for pregnant employees in the cafeteria.
	• Workplace Benefits
	  • Transportation allowance, communication allowance, and meal allowance
	• Financial Support Benefits
	  • Annual Excellence Awards
	  • 5-Year and 10-Year Long-Service Awards
	• Scientific Research Awards:
	  • Inventor Reward Policy, "Science Star" and "Dream Chaser" award, etc.

Employee Anniversary Culture Badge

In 2025, Innovent innovatively launched the "Anniversary Culture Badge Program," which integrates corporate branding with employees' growth journeys through digital design. Each employee will receive a dedicated badge on their work anniversary to enhance their sense of belonging and organizational identification.

Anniversary Badge

4.3.2 Our Performance

In 2025, Innovent achieved significant results in talent management and retention. The Company's overall employee turnover rate was approximately 13.3%, reflecting a steady downward trend over the past three years.

4.4 Occupational Health and Safety

Innovent is committed to creating a safe and healthy working environment for its staff. The Company continuously optimizes its occupational health management system and implements a systematic risk management mechanism across all operational sites. Through preventive measures such as regular occupational health risk assessments, safety hazard inspections, and emergency drills, we continuously improve occupational health performance indicators to ensure comprehensive protection of the safety rights and interests of staff and relevant parties.

4.4.1 Our Governance

Innovent strictly complies with laws and regulations such as the "Civil Code of the People's Republic of China" (<中華人民共和國民法典>), the "Safety Production Law of the People's Republic of China" (<中華人民共和國安全生產法>), and the Regulations on Prevention and Control of Occupational Diseases. The Company has established management policies including the "Environmental, Safety, and Occupational Health Management Manual" (<環境、安全、職業健康管理手冊>) and the "Occupational Health Management Manual" (<職業健康管理手冊>) to ensure the legality of its operations and the health and safety of its staff. During the Reporting Period, we upgraded and updated our High-Activity Pharmaceutical Management System. We systematically strengthened three core modules: risk assessment, control strategies, and monitoring and surveillance. Additionally, we revised policies regarding the graded management of occupational health risks, engineering control measures, as well as emergency response and training requirements.

During the Reporting Period, we revised and issued policies, including the "Accident Incident Reporting, Investigation, and Handling Procedures" (<事故事件報告、調查和處理規程>), the "Active Pharmaceutical Ingredient Risk Assessment and Management Procedures" (<活性藥物風險評估與管理規程>), and the "Chemical Safety Management Policy" (<化學品安全管理規程>). These measures clarified the reporting timelines and processes for EHS-related incidents at all levels and optimized various active pharmaceutical ingredient risk control procedures by aligning with industry group standards. Based on operational status, the Shanghai R&D Center has newly formulated and issued 19 EHS policies, providing effective assurance for safety management at the current stage. Furthermore, to ensure the smooth commissioning and operation of the Hangzhou production base, the base systematically formulated and implemented 52 EHS policies. These include core documents such as the "EHS Management Manual" (<EHS管理手冊>), the "Procedure for Identification of Environmental Aspects and Control of Significant Environmental Aspects" (<環境因素識別與重大環境因素管控程式>), and the "Emergency Response Management Protocol for Unexpected Incidents" (<突發事件應急響應管理規程>). This initiative has established a scientific and comprehensive framework for the EHS management system.

The Company has established a occupational health and safety management structure with the Board as the highest accountability body, continuously implementing measures for environmental management and the occupational health and safety management system. During the Reporting Period, we successfully passed the spot check for Level II certification of Jiangsu Province's Work Safety Standardization and received official recognition via public announcement on the website of the Emergency Management Department of Jiangsu Province in March 2025.

During the Reporting Period, the Hangzhou base successfully obtained ISO 45001 Occupational Health and Safety Management System certification. As of the end of the Reporting Period, 100% of Innovent's operating production bases have obtained ISO 45001 occupational health and safety management system certification.

bsi.

Certificate of Registration

职业健康安全管理体系 - ISO 45001:2018

兹证明：

夏尔巴生物技术（杭州）有限公司
91330113MA8N7Q6EX2
中国
浙江省
杭州市
临平区
临平街道顺风路266号
邮编：311103

Altruist Biologics (Hangzhou) Co., Ltd.
No. 266, Shunfeng Road, Linping Street
Linping District
Hangzhou
Zhejiang
311103
China

持有证书： OHS 837153

并运行符合 ISO 45001:2018 要求的职业健康安全管理体系，认证范围如下：

临床试验用单克隆抗体类生物药品的生产。
The production of monoclonal antibody biological drugs for clinical trials.

BSI代表：

Michael Lam, Senior Vice President, APAC Assurance

首次发证日期： 2026-01-22
最新发证日期： 2026-01-22

生效日期： 2026-01-22
有效期至： 2029-01-21

Page: 1 of 1

..making excellence a habit."

Hangzhou Plant ISO 45001 System Certification Certificate

4.4.2 Our Goals

The Company has established a systematic set of occupational health and safety objectives and regularly conducts assessments and improvement initiatives to evaluate the achievement of these goals. During the Reporting Period, we successfully achieved all occupational health and safety management targets.

Occupational Health and Safety Production Targets	lost time injury rate per million working hours ≤ 0.3
	timely closure rate for external inspection findings 100%
	0 occupational disease incidents

4.4.3 Our Actions

Occupational Health and Safety Risk Management

Innovent has established a comprehensive "Risk Identification, Assessment, and Control Management Procedure" (<風險識別、評估和控制管理程序>). Adopting an internationally recognized risk management framework, the Company systematically categorizes occupational health and safety risks into four levels – low, general, high, and major – through a scientific risk assessment matrix and a four-color hazard identification visualization tool. The Company implements a three-tier control mechanism and establishes closed-loop management processes specifically for high and major risks, continuously optimizing prevention and control measures through the Plan-Do-Check-Act (PDCA) cycle.

Safety Production Informatization Index System

Innovent has established an intelligent safety production information index system and created a comprehensive safety monitoring mechanism covering dimensions such as safety awareness and behavior, hazard identification, accident status, and emergency plan drills. We regularly conduct systematic observation and analysis of safety warning indices and implement targeted control measures based on data insights. We continuously enhance our work safety management level to create a safe and healthy working environment for staff.

2025 Safety Production Informatization Index Diagram



Safety Production Informatization Index System Diagram

To strengthen occupational health and safety risk management, the Company has formulated a series of risk response measures to comprehensively enhance its risk prevention and control capabilities.

Establish occupational health and safety objectives	Establish a systematic safety goal tracking and assessment system to implement the responsibility system for all staff.
Develop a safety training program	Established an annual training plan and completed 20 online courses and 29 offline sessions to strengthen staff's safety skills.
Reduce workplace hazards	Continuously improve the working environment, monitor staff's occupational health status, and provide appropriate personal protective equipment.
Establish and improve mechanisms for accident prevention and emergency response	A detailed emergency drill plan has been formulated, necessary emergency supplies and first-aid medicines have been equipped, and regular inspections are conducted.

Innovent actively builds a digital EHS management system by applying its self-developed "safety hazard" intelligent management platform to achieve intelligent hazard monitoring and closed-loop management. This platform supports enterprise-wide participatory safety management. Staff can report potential risks in real time. The system automatically generates rectification work orders and tracks processing progress, significantly improving hazard response efficiency.

Safety Inspection

Innovent conducts regular internal and external safety inspections to comprehensively eliminate potential health and safety risks for staff. During the Reporting Period, we underwent 28 external inspections. All identified items requiring rectification have been fully addressed.

Comprehensive Safety Inspection:

Area supervisors shall conduct a comprehensive safety inspection once per month.

Pre-holiday Special Inspection:

A focused inspection is conducted before major holidays, covering fire safety measures, equipment conditions, holiday duty rosters, warehouse materials, and the implementation status of emergency response plans.

Professional Inspection:

A professional inspection of electrical facilities is conducted quarterly.

Seasonal Inspection:

A preventive inspection is conducted each quarter based on seasonal weather patterns, focusing on fire/explosion prevention, rain/flood control, lightning protection, heatstroke prevention, and wind damage prevention.

High-risk Area Self-inspection:

A self-inspection for potential hazards in high-risk areas of the plant is organized monthly. During the Reporting Period, we carried out systematic hazard identification and rectification across all facilities and departments, effectively reducing on-site operational risks.

Occupational Health Status Inspection:

Regular assessments of the occupational health environment are performed. In 2025, a total of 365 occupational hazard factors were monitored. All monitoring results were qualified, and risk assessments for all monitoring results were completed.

External Inspection:

Inspections by regulatory authorities are received on an ad hoc basis.

Safety Inspection Type

Occupational Health and Safety Protection Measures

To ensure the safety of daily production and operations, Innovent has established a series of strict occupational safety regulations as well as procedures for managing hazardous chemicals and special equipment. In addition, we regularly conduct EHS training and occupational disease prevention training for staff to continuously enhance their awareness of health and safety protection.

Personal Protective Equipment

Innovent has established the "Regulations on the Management of Labor Protective Articles" (<勞動防護用品管理規定>) and the "Occupational Health Management Procedures" (<職業健康管理程序>), and has provided comprehensive personal protective equipment to frontline production staff. These include helmets, face shields, respirators, gas masks, work uniforms, and protective gloves, ensuring comprehensive health and safety protection for staff throughout their work processes.

Personal Protective Equipments

The Company conducts specialized occupational health inspections on a quarterly basis. These inspections focus on verifying the proper use of personal protective equipment (PPE) by on-site personnel, ensuring ventilation facilities and protective equipments are utilized in compliance with requirements, and confirming that all warning labels are present. The objective is to promptly identify and rectify potential safety hazards, thereby ensuring the work environment meets occupational health standards.

Occupational Disease Prevention

Innovent strictly complies with laws and regulations such as the "Occupational Disease Prevention and Control Law of the People's Republic of China" (<中華人民共和國職業病防治法>) and the "Regulations on the Quality Management of Drug Operations" (<藥品經營質量管理規範>). The Company regularly arranges medical examinations for staff engaged in work involving occupational disease risks and provides professional occupational health training to enhance relevant personnel's occupational health risk awareness and prevention capabilities. During the Reporting Period, we completed a total of 834 pre-employment, on-the-job, and post-employment medical examinations.

At the same time, we established a policy for informing staff of positions exposed to occupational hazards, improved the management system for occupational health records, and achieved risk control throughout the entire process. During the Reporting Period, we completed the electronic file establishment for 'one person, one file' for 719 personnel in occupational hazard positions.

In addition, we conduct specialized occupational disease prevention examinations for staff on an irregular basis as needed. In 2025, to protect employee health, the Company introduced tubeless weighing hoods for positions involving potential exposure to active pharmaceutical ingredients and conducted equipment containment performance testing (CPT) assessments, effectively reducing occupational exposure risks.

Management of Special Equipment

Based on applicable regulations, Innovent has established the "Regulations for the Management of Special Equipment/ Special Operations" (<特種設備／特種作業管理規程>), which clarifies the types of special operations and categories of personnel. The Company manages equipment throughout its entire lifecycle via a cloud-based platform for special equipment. The Company strictly complies with regulatory requirements, conducts regular maintenance and upkeep of equipment, and calibrates assets on schedule to ensure safe operations.

All operators of special equipment hold valid professional operation certificates. At the same time, the Company regularly organizes training and assessments for these operators to continuously enhance their professional skills and safety awareness. As of the end of the Reporting Period, the Company had 376 special operation personnel, achieving a 100% certification rate among such personnel. In addition, all personnel awaiting re-examination have completed the review on schedule.

Management of Hazardous Chemicals

Innovent has established policies such as the "Hazardous Chemicals Management Regulations" (<危險化學品管理規程>) to standardize the entire process of procurement, storage, usage, and disposal of hazardous chemicals.

Engineering Measures	Management Measures	Labor Protection Measures	Emergency Measures
Install ventilation and grounding for the explosion-proof cabinet and set up an electrostatic discharge ball.	Safety inspections are conducted regularly. A special contingency plan for hazardous chemical accidents and an on-site emergency response drill plan have been formulated and implemented. Regular training on Chemical Safety Management is also carried out.	Labor protection equipment such as acid and alkali-resistant gloves and protective face shields shall be provided on-site.	Emergency response cards are posted on-site, and emergency spill response materials and fire-fighting equipment are provided.

Measures for Hazardous Chemical Management

Development of Occupational Health and Safety Culture

Innovent places high importance on the construction of its occupational health and safety management system. Through systematic implementation of specialized training courses on identifying and controlling occupational hazards, it continuously enhances the occupational health and safety literacy of all staff.

Innovent has established a comprehensive EHS training system and achieved full coverage for all staff through a digital learning platform. We strictly enforce the three-level safety education policy to ensure that new staff complete company-level, department-level, and position-level safety training upon onboarding. This initiative comprehensively enhances all staff's safety awareness and on-site risk management capabilities while continuously reducing the number of lost-time incidents[6]. In 2025, Innovent conducted various occupational health and safety training programs, including 20 online courses and 29 offline sessions, collectively reaching over 18,000 participants. We achieved a year with zero work-related fatalities, with only one lost-time injury involving an ankle sprain occurring while going down stairs.

AED Practical Training

In 2025, we provided hands-on training on Automated External Defibrillators (AED) for staff, enabling relevant staff to master first aid skills using AEDs. This initiative aims to enhance staff's ability to respond to emergency incidents.

AED Practical Training

6 A lost-time accident refers to an accident in which an employee is injured due to work-related reasons during the course of work, which results in the employee being unable to work normally on the next working day.

Series of Thematic Activities for the Safety Production Month

In 2025, Innovent successfully organized a series of safety production month theme activities, actively responding to the 2025 National Safety Month theme: "Everyone talks about safety, everyone knows how to respond — identify safety hazards around you".



Series of Thematic Activities for Safety Production Month

Series of Thematic Activities for the Safety Production Month (Continued)

Safety Knowledge Competition

In 2025, we organized a safety knowledge competition with over 300 staff participating. This initiative promoted learning through competition and continuously strengthened staff's safety awareness.

Safety Knowledge Competition

Special Lecture on Emergency First Aid

Innovent invited the Director of the Emergency Department from a Grade III Class A hospital to conduct professional emergency skills training. This training adopted an interactive teaching model combining "theoretical instruction" and "practical drills", cumulatively covering staff from key positions including R&D and manufacturing. Participants systematically mastered core first-aid skills through simulated scenarios such as cardiopulmonary resuscitation and trauma bandaging, significantly enhancing their emergency response capabilities for unexpected incidents.



Emergency and First Aid Knowledge Lecture

"Safety Eagle Eyes" Campaign

To encourage all staff to proactively identify safety hazards in their vicinity, we launched the "Safety Eagle Eyes" campaign. This initiative invites staff to report potential hazards. Members of the EHS Committee then score each report based on its severity and likelihood. Outstanding cases are recognized and incentivized, fostering a collaborative effort across our Suzhou, Shanghai, and Hangzhou locations.

Safety Month Thematic Event

EHS Knowledge Classroom

Innovent regularly delivers EHS knowledge sessions to its staff, continuously strengthening the dissemination of environmental, health, and safety-related knowledge. In 2025, a total of 24 EHS knowledge sessions and 6 sharing sessions on typical internal and external accident cases were conducted, achieving a 100% coverage rate among staff for the series of training programs.

EHS Knowledge Sharing Session

During the Reporting Period, we organized and conducted specialized drills including fire evacuation exercises, hazardous chemical incidents, forklift accidents, Class A warehouse incidents, special equipment accidents, confined space incidents, gas leak incidents, and food poisoning incidents. Across all bases, a total of 50 sessions were held with 2,100 participants, continuously enhancing staff's awareness of accident prevention and emergency response capabilities.

Fire Evacuation Drill

Practical Firefighting Drills for Volunteer Firefighters

Special Emergency Plan Drill for Elevator Entrapment Incidents

Boiler Accident Emergency Drill

Emergency Drill for Confined Space Accidents

Emergency Drill for Theft and Robbery Prevention of Highly Toxic Substances

Supplier and Contractor Safety Management

We have established the "EHS Management Procedures for Contractors and Suppliers" (<承包商供應商 EHS 管理程序>). Through measures including establishing strict entry standards, implementing full-process safety supervision, and conducting regular assessments, we systematically enhance the safety management capabilities of suppliers and contractors. In 2025, we revised the "Contractor Safety Management Regulations"(<承包商安全管理規程>), optimized the approval process for high-risk work permits, and refined contractor site entry training content across different business scenarios, significantly enhancing the practical applicability of the policy.

During the Reporting Period, we conducted over 60 safety inspections at contractor work sites and issued 8 rectification notices for contractors' non-compliance with construction regulations. All involved contractors have completed the required safety rectifications in accordance with our standards. No safety incidents involving contractors occurred throughout the year.

4.4.4 Our Performance

During the Reporting Period, Innovent did not experience any major work safety accidents. Only one lost-time accident occurred, caused by an ankle sprain while going down stairs.

In 2025, Innovent demonstrated outstanding performance in environmental protection and work safety management, receiving letters of appreciation from the local Emergency Management Bureau and the Ecology and Environment Bureau. At the same time, the Company also received high recognition for its chemical management and was awarded a letter of appreciation from the Municipal Precursor Chemical Association.

Letter of Appreciation

05
EMBRACING ECOLOGY

Against the backdrop of global efforts to address climate change and the accelerating green transformation of the pharmaceutical industry, pharmaceutical R&D enterprises, as key participants in technological innovation and sustainable development, bear the mission of driving green transformation and fulfilling low-carbon responsibilities. Innovent fully recognizes the potential environmental impacts of its R&D, manufacturing, and operational activities. The Company integrates environmental responsibility into corporate governance and daily operations, continuously improves mechanisms for addressing climate change, advances energy conservation and resource efficiency, actively practices green office initiatives and eco-friendly practices, and is committed to achieving harmony between the enterprise and nature.

This chapter is in response to the sustainable development goals (SDGs) of the United Nations

5.1 Responding to Climate Change

As a leading biopharmaceutical enterprise in the industry, Innovent has consistently focused on climate change issues and actively responds to the initiatives of the "Paris Agreement"(<巴黎协定>). To scientifically and effectively disclose the Company's efforts in addressing climate change, Innovent follows the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) to report its climate change risk management system and response actions across four dimensions: governance, strategy, risk management, and metrics and targets. We continuously explore solutions to respond to climate change by planning emission reduction pathways, applying energy-saving and emission-reduction technologies, and utilizing renewable energy sources to achieve sustainable low-carbon development.

5.1.1 Governance

A sound and effective climate governance structure serves as a critical strategic foundation for the Company to systematically identify, assess, manage, and respond to climate-related risks and opportunities, thereby achieving its climate goals. Innovent continues to refine its climate governance system and deeply integrates it into the EHS governance framework. The Company has clearly defined division of responsibilities, process designs, and execution mechanisms for climate action, ensuring that climate factors are comprehensively incorporated into strategic decision-making and daily operations. The Company has established a climate governance structure led by the Board of Directors. Relying on the EHS Management Committee for overall coordination, the Company advances climate governance work through collaborative efforts involving the EHS Executive Committee, the EHS Coordinator Team, and various functional departments. The Company conducts 2 dedicated climate change reporting sessions annually to continuously monitor the progress of climate goals and the effectiveness of governance.

Board of Directors

EHS Management Committee	EHS Executive Committee	EHS Coordinator Team
• Coordinate and supervise the overall EHS performance of The Company • Ensure that the factory operations comply with the EHS requirements of Innovent and local regulations • Review and approve the factory's EHS policies, objectives, procedures, budgets, reports, and plans	• Regularly review the department's EHS-related performance • Develop corrective measures for significant hazards or issues and track their implementation • Regularly review laws and regulations, and develop optimization measures in adherence to compliance requirements	• Implement EHS routine workflows and promote EHS cultural development • Supervise departmental activities to ensure compliance with EHS requirements • Participate in and assist with the department's EHS incident investigation and handling • Effectively communicate EHS policies, track and promote EHS action improvements, and collect departmental suggestions and feedback

Innovent's EHS Governance Framework

To continuously enhance the Company's climate change management capabilities, we regularly provide training on climate-related topics to the Board of Directors, the EHS Management Committee, and heads of relevant functional departments. This ensures they possess the necessary professional expertise, stay informed about applicable climate laws and regulations and response strategies, and are fully capable of fulfilling their oversight responsibilities regarding climate change matters.

Innovent has incorporated the achievement of climate change-related targets into the performance appraisal system of the management team to promote the steady achievement of climate risk and opportunity management goals. We established a management mechanism that balances positive incentives with accountability constraints by integrating key environmental performance indicators into the assessment of management personnel. The Company has incorporated energy management performance into the annual performance appraisal for the CMC head of manufacturing and head of engineering, accounting for 5% of their overall performance. Executives who do not meet annual energy consumption targets will incur a 5% reduction in their performance evaluation, while those who achieve the targets will receive a 5% performance bonus increase.

5.1.2 Strategy

Incorporating the Company's long-term strategic planning and current operational management status, the Company has defined strategies to address climate change. It regularly conducts comprehensive assessments of the financial impacts and dependencies of climate risks and opportunities, and takes targeted actions from dimensions such as its own operations and supply chain collaboration to actively respond to climate challenges and seize green opportunities.

The Company referred to Part D of Appendix C2 of the "Environmental, Social and Governance Reporting Code" (<環境、社會及管治報告守則>) of the "Listing Rules"(<上市規則>) of the Hong Kong Stock Exchange, selected the Representative Concentration Pathways (RCP) 4.5 and the IEA[7] 2050 Net Zero Emissions (NZE) scenario from the Intergovernmental Panel on Climate Change (IPCC) as green scenarios, and RCP 8.5 and the IEA APS as brown scenarios to assess the potential impact of climate change risks and opportunities on the Company's future operations, while continuously improving response measures. At the same time, we have established corresponding time dimensions based on the Company's development strategy and emission reduction plan: short-term (within 3 years), medium-term (3-10 years), and long-term (10-25 years).

Currently, our updated risk and opportunity register includes 3 physical risks, 3 transition risks, and 2 opportunities. To further clarify the priorities of climate change response measures, we assessed the impact level of various risks and opportunities to establish a ranking of risk and opportunity impacts, thereby identifying key climate-related risks and opportunities. The table below details the climate change risks and opportunities identified by Innovent, their scope, risk levels, the anticipated impact on the Company's operations, and the measures taken by the Company to address them.

7 IEA: International Energy Agency

Risk Category		Risk Name	Risk Description	Financial Impact	Risk Response Measures	Climate Scenarios	Impact levels across different time horizons		
							Short-term	Mid-term	Long-term
Physical Risk	Acute Risks	Typhoon	• Risk of Asset Damage: If the severity and frequency of extreme weather events increase, the Company may need to incur additional capital expenditures for repairing damaged assets, including asset maintenance, restoration, relocation, and increased insurance premiums, to ensure asset safety and continuous operations. • Impact on Production and Operations: An increased frequency of typhoons, floods, blizzards, and other extreme weather events may cause damage to production equipment or necessitate repairs, resulting in interruptions or delays to the production process. This could lead to disruptions in product supply and distribution, thereby impacting revenue and market share. • Logistics Disruptions and Delays: Extreme weather events such as typhoons, floods, and blizzards may cause transportation interruptions, communication failures, and damage to power transmission lines, thereby affecting the Company's production and supply chain.	Operating costs increased Loss on Fixed Assets	• Emergency Response Plan and Protective Measures: Innovent has developed "Emergency Plans" (<應急預案>), which includes specific measures to mitigate the impact of extreme weather events (such as typhoons). By designating on-duty personnel, we ensure rapid response and the implementation of emergency measures during extreme weather events to minimize losses to production and facilities. • Risk Management Standard Operating Procedure (SOP): The Company has established relevant risk management SOPs to identify, assess, and manage risks associated with extreme weather. Through standardized processes and measures, the Company ensures it can systematically address potential risks posed by various extreme weather events. • Clinical Trial Emergency Response: For clinical trials, we provide a grace period for subjects and offer remote communication options during extreme weather events. By adopting remote assessment and management, the impact of extreme weather on clinical trial progress is minimized to ensure subject safety and the smooth conduct of the trials.	RCP4.5	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
						RCP8.5	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
		Flood		Operating costs increased. Loss on Fixed Assets Increased cost of default		RCP4.5	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
						RCP8.5	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
	Chronic Risks	Rising average temperatures	• Impact on Logistics and Transportation: As global average temperatures rise, the distribution and transportation of certain raw materials and pharmaceutical products may be affected. High temperatures may affect the quality of raw materials and pharmaceuticals, requiring enterprises to implement additional temperature control measures and incur increased operating costs. • Increased Energy Consumption: In regions with persistently rising temperatures, the Company may need to implement additional ventilation and cooling measures to ensure the suitability of production and office environments. This will lead to increased energy consumption, thereby driving up operating costs.	Increase in operating costs	• Backup Power Systems and Diversification of Electricity Supply: Innovent ensures power supply through dual-circuit power supply to mitigate the risk of power outages. • For transportation and storage within the supply chain, the Company has equipped a temperature control system. Upon detecting any temperature anomalies, the system immediately issues alerts to ensure timely handling. During the transportation validation process, we conducted simulations for both minimum and maximum temperatures to ensure that temperature control requirements are met under extreme high or low temperature conditions. • Adjust working hours during high-temperature periods to safeguard staff's occupational health and safety.	RCP4.5	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
						RCP8.5	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*

Risk Category		Risk Name	Risk Description	Financial Impact	Risk Response Measures	Climate Scenarios	Impact levels across different time horizons		
							Short-term	Mid-term	Long-term
Transition Risks	Risks related to policies and regulations	Impact of Carbon Pricing Mechanisms and Carbon Tax Policies	• As global and regional carbon pricing systems expand their coverage, rising costs associated with greenhouse gas emissions in the future will lead to increased operating expenses. • Geopolitical developments may lead to green trade barriers such as carbon border taxes, impacting the Company's value chain and international competitiveness. • Differences in carbon emission policies across different countries and regions may lead to increased operating costs and heightened financial uncertainty.	Operating costs increased	• Routine monitoring of carbon pricing policies and market dynamics: The Company continuously monitors and analyzes changes in carbon pricing policies across all operating regions and key product markets to ensure timely awareness of relevant policies and market developments. • Develop flexible response strategies: Adjust product pricing, production processes, and supply chain management based on information feedback to optimize resource efficiency and reduce carbon emissions, thereby mitigating cost pressures arising from policy changes. • Strengthen Carbon Emission Compliance Management: Establish a comprehensive carbon emission monitoring and management system to ensure the Company's compliance under carbon pricing policies and secure potential tax incentives or subsidies through such compliance. • Establishing Long-Term Goals Related to Carbon Emissions: The Company has established goals related to carbon emissions and will further adjust and strengthen these goals in accordance with future market regulatory requirements and business development, ensuring that the Company maintains a leading position in sustainable development. • Increase Investment in Green Technologies: Actively invest in low-carbon and environmentally friendly technologies to drive the green transformation of products and production processes, reduce carbon emissions, and thereby minimize future expenditures on carbon trading and carbon taxes.	NZE	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
						IEA APS	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*

Risk Category		Risk Name	Risk Description	Financial Impact	Risk Response Measures	Climate Scenarios	Impact levels across different time horizons		
							Short-term	Mid-term	Long-term
	Technological Risk	Costs of Low-Carbon Technology Transition	• As market demands and regulatory requirements continue to rise, pharmaceutical companies face increasingly stringent environmental standards, particularly regarding carbon emissions and energy efficiency during the production process. To adapt to this change, pharmaceutical companies need to extensively develop and apply green technologies, including green design, automated production, energy-saving equipment, and green processes, to replace existing high-energy-consumption and high-emission production and operation models. • The development and deployment of low-emission technologies involve significant technological innovation risks. Uncertainties regarding timing selection and final outcomes may affect the Company's expected returns on investments in these technologies. These uncertainties include technology maturity, market acceptance, and cost-effectiveness in practical applications.	Operating costs increased	• Promote the use of clean energy and expand the application coverage of new energy facilities such as solar panels and photovoltaic power stations. • Introducing Green Design and Automated Production: Innovent has strengthened the application of green design concepts by implementing more energy-efficient and environmentally friendly design solutions in product development and manufacturing processes. By introducing automated production technologies, we reduce energy consumption from manual operations and carbon emissions generated during the production process. • Process Optimization: The Company has further improved production efficiency and reduced carbon emissions per unit of product by updating and iterating research schemes and optimizing the production and R&D processes. • Development of Green Processes and Equipment: Increase R&D investment in green processes and environmentally friendly equipment, explore low-carbon emission alternative processes to reduce energy consumption and carbon emissions from the source during product manufacturing, and ensure products comply with green certification standards. • Strengthen green collaboration with suppliers: Collaborate with suppliers to jointly develop and procure raw materials and equipment that meet green standards, ensuring that the entire lifecycle of products from source to terminal complies with environmental protection requirements.	NZE	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
						IEA APS	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*

Risk Category	Risk Name	Risk Description	Financial Impact	Risk Response Measures	Climate Scenarios	Impact levels across different time horizons		
						Short-term	Mid-term	Long-term
Market Risk	Increase in raw material costs	• The raw materials used by the Company encompass various types. Extreme weather events (such as heavy rainfall and drought) may directly impact the production activities of raw material suppliers, leading to reduced output or production stoppages. This, in turn, increases supply risks and procurement costs for raw materials. Due to supply instability and significant fluctuations in raw material costs, which will impact production costs, the Company's financial management has faced increased pressure.	Operating costs increased. Administrative expenses rose.	• Localized Procurement: To mitigate transportation disruptions or cost increases caused by factors such as extreme weather, we continue to promote the localized procurement of raw materials. By selecting suppliers located in closer proximity, we reduce logistics costs while lowering carbon emissions generated during transportation. • Diversified Supplier Management: To address the instability of raw material supply, the Company will mitigate risks arising from single-supplier disruptions by enhancing supplier diversity, establishing long-term partnerships, and maintaining adequate safety stock. Innovent has implemented dual-source supply for all its self-manufactured commercialized products. • Establish a green supply chain by strengthening research on upstream suppliers and actively developing green suppliers. • Monitor market changes and forecast demand: By tracking raw material market dynamics in real time, forecasting price fluctuations, and making timely procurement decisions, the Company reduces cost risks arising from market volatility.	NZE	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
					IEA APS	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*

Opportunity Category	Opportunity Description	Response Measures	Climate Scenarios	Impact levels across different time horizons		
				Short-term	Mid-term	Long-term
Resource Utilization	We are progressively promoting the transformation of low-carbon technologies and processes by adopting more automated and intelligent production and R&D models. This enhances resource allocation efficiency within the Company, contributing to long-term cost savings and improved production efficiency.	• Enhance Resource Efficiency: Implement measures to improve energy efficiency and resource utilization, reduce consumption of water resources and packaging materials, strengthen resource recycling, minimize environmental footprint, and lower operating costs. • Adoption of New Energy Vehicles for Transportation: Encourage transportation service providers to utilize new energy vehicles for logistics operations to reduce carbon emissions generated during the transportation process. • Through process optimization, equipment and facility upgrades, and technical improvements, energy efficiency is enhanced.	NZE	Low *(Expected financial impact: <1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: <1% of total assets)*
			IEA APS	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*
Energy Sources	Exploring alternatives to fossil fuels by installing distributed photovoltaic power generation and procuring green electricity to increase the proportion of renewable energy use, reduce carbon emissions during production, optimize the Company's energy structure, and enhance the Company's resilience in energy supply.	• Gradually transition to low-carbon energy and expand application scenarios for clean energy sources such as solar and wind power. • Increase the proportion of procurement and application of renewable energy, including green electricity and green certificates. • Expand the application scope of distributed photovoltaic power generation: Provide electricity supply for office areas through distributed photovoltaic power generation to reduce greenhouse gas emissions generated by office operations.	NZE	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: <1% of total assets)*
			IEA APS	Low *(Expected financial impact: < 1% of total assets)*	Low *(Expected financial impact: <1% of total assets)*	Low *(Expected financial impact: < 1% of total assets)*

During the Reporting Period, we integrated our business layout, asset structure, and existing management measures to statistically aggregate the financial impacts of identified climate change-related risks and opportunities, conducting quantitative analysis of both current and expected financial impacts. After assessment, it has been determined that current climate-related risks and opportunities have not had a material impact on the Company's financial position, results of operations, or cash flows. In the absence of extreme and severe climate disasters or significant changes in policies and markets, no material risks are expected that would result in significant adjustments to the carrying amounts of assets and liabilities in the relevant financial statements for the next reporting year.

Measurement and Verification of Greenhouse Gas Emissions

During the Reporting Period, Innovent engaged an internationally recognized third-party certification body to conduct greenhouse gas emissions verification for Scope 1 (direct emissions), Scope 2 (energy indirect emissions), and Scope 3 (other indirect emissions in the value chain) across all operating entities in accordance with the ISO 14064 international standard, ensuring the integrity and accuracy of emission data.

Regarding Scope 3 emission verification, the Company has established a systematic mechanism for emission source identification and quantitative assessment. Based on the characteristics of the value chain, quantitative data analysis was prioritized in this year for Category 3 (Purchased Goods and Services) and Category 4 (Upstream Transportation and Distribution). In the future, building upon the existing verification framework, the Company will continue to expand Scope 3 emission accounting dimensions to provide data support for achieving carbon targets.

Promoting energy efficiency improvements

Ensuring the safety and compliance of R&D and production activities, the Company continues to improve energy use efficiency. Through a systematic review of equipment operation modes, usage scenarios, and actual requirements, we identified multiple energy-saving potentials. We advanced technical upgrades and operational optimizations, implementing energy-saving technical retrofit projects at each base tailored to local conditions, which effectively reduced energy consumption per unit of product. During the Reporting Period, through a series of energy-saving optimization projects, the Company's energy consumption per unit of product decreased by 27.74% compared to 2024, and energy efficiency level continued to improve.

Across production areas at various bases, the Company has implemented multiple energy-saving technical upgrades and operational optimization measures, tailored to geographical locations and operational conditions, focusing on cooling supply, power supply, lighting, ventilation, and auxiliary system operations.

Suzhou Site	Hangzhou Site	Shanghai Site
• Optimization of cooling method for the water system: Converted the original independent cooling equipment into a centralized cooling system, improving cooling efficiency and saving approximately 195,000 kWh of electricity annually.	• Shutdown of idle facilities: Closed workshops without production plans and vacant warehouses to reduce unnecessary energy consumption. • Optimization of equipment operation: Implemented cold storage system retrofits, variable frequency equipment upgrades, and energy-saving optimization of air conditioning systems. • Upgrade of lighting systems: Introduced smart lighting and sensor-based controls to enable on-demand operation and reduce lighting energy consumption. • Through the above measures, the Hangzhou Site has cumulatively achieved annual electricity savings of over 5 million kWh.	• Intelligent lighting control: Optimized lighting modes in underground parking garages, achieving 60% energy savings; installed sensor switches for basement lighting to reduce standby power consumption.

Energy-saving Initiatives in the Productional Sites

While continuously advancing energy-saving optimization at production bases, the Company has also extended its energy conservation and consumption reduction philosophy to office areas. By integrating intelligent management with behavioral energy saving, the Company is creating a green and low-carbon working environment.

Central air conditioning in general areas operates at low frequency and is shut down during non-production periods.	Optimization and retrofit of underground parking garage lighting: reduced quantity and replaced with sensor-based controls.	Power supply for electric water heaters in the gym is equipped with timer control.

Energy-saving Initiatives in Office Areas

5.1.3 Energy Transition Planning

Innovent focuses on the impact of energy structure adjustments on the Company's long-term operations and cost stability. In alignment with the requirements for energy continuity and safety in pharmaceutical R&D and production, while ensuring stable operations and research activities, the Company has identified and capitalized on transformation opportunities arising from renewable energy development. The Company is advancing the planning and implementation of clean energy projects, such as photovoltaic power generation, exploring the transition from traditional to green energy sources, and reducing reliance on conventional energy.

Application of Photovoltaic Power Generation Projects in R&D and Productional Sites

Shanghai R&D Center

The photovoltaic power generation system at the Shanghai R&D Center was completed and officially put into use. Located on the rooftop of the Innovent Global R&D Center, it covers an area of approximately 600 square meters. Operating under a "self-generation for self-use with surplus power fed to the grid" model, the generated electricity is prioritized for internal use within the park, thereby enhancing energy self-sufficiency. The project generates approximately 30,000 kWh of electricity annually, providing a reliable clean energy supplement for the daily operations of the R&D Center.

Suzhou Site

The Suzhou site has completed the preliminary planning for the rooftop photovoltaic power station. Currently, the Company is evaluating the impact of photovoltaic construction on construction safety and production continuity by integrating it with the operational status of existing workshops. While ensuring that existing production activities and electrical safety are not compromised, the Company will steadily advance the preparatory work for project implementation.

Photovoltaic Site Photo

5.1.4 Risk Management

Innovent has established a comprehensive mechanism for managing climate-related risks and opportunities and integrated it into the Company's overall risk management process. This mechanism covers four key stages: identification, assessment, response, and monitoring of risks and opportunities. It aims to enhance the Company's ability to adapt to climate risks and its business resilience.

Prepare the list of climate risks

- Based on relevant policies issued by regulatory authorities, peer benchmarking, interviews with business departments, and external information retrieval, a preliminary list of climate risks and opportunities is compiled.
- Interviews and discussions are conducted with heads of relevant business departments to further gather input, and the Company's list of climate risks and opportunities is finalized to ensure the comprehensiveness and applicability of climate risk management.

Conduct climate risk assessment

- Using public climate database including WRI Water Risk Atlas, WRI Floods, and Climate Impact Explorer for physical risk screening, the potential impacts of climate change on the Company's operations are analyzed and assessed. This includes understanding the likelihood of each risk occurring, the severity of its impact, and the resilience under different scenarios and timeframes, thereby determining the risk level of each listed item.
- Based on climate change policies analysis across operating locations, industry development trends analysis, and interviews with heads of key departments, we assessed the transition risks that may impact Innovent and determined the risk levels for corresponding risk items.

Formulate response measures

- Based on the results of the climate risk assessment, the EHS department and relevant business departments jointly discuss and formulate targeted response measures. After approval and confirmation by the EHS Management Committee, the EHS department and relevant business departments are responsible for implementation.

Monitor and inspect

- The EHS department and relevant business departments, in adherence to the Company's risk monitoring and inspection processes, regularly summarize and review the implementation of climate risk response measures. Reports are submitted to the EHS Committee, and response measures are adjusted as necessary based on actual conditions to ensure the orderly and efficient advancement of climate risk management.

Innovent's Climate Risk Management Process

5.1.5 Metrics and Targets

To actively fulfill its corporate social responsibility and deeply implement its sustainable development strategy, the Company has established carbon reduction targets. The Company is promoting the achievement of carbon neutrality through diverse pathways, including the installation of photovoltaic power generation and the advancement of energy-saving technical upgrades, while tracking and monitoring the progress of these targets in real time.

Our climate targets are achieving a 5% annual reduction in energy consumption per production unit by 2030 and reducing greenhouse gas emissions (Scope 1 and Scope 2) per unit of production by 10% in 2030 compared to 2020. These targets apply to entities under Innovent's operational control.

Target metrics	Target	Target status in 2025	
Energy Consumption	Achieving a 5% annual reduction in energy consumption per production unit by 2030	Achieved	Reduced by 28% (3,096 KWH/Kvials) in 2025 as compared with 2024 (4,285 KWH/Kvials)
Greenhouse Gas Emissions	Reducing greenhouse gas emissions per unit of production by 10% in 2030 compared to 2020	Achieved	Reduced by 73% (3.82 T/Kvials) as in 2025 compared with 2020 (13.97 T/Kvials)

5.2 Environmental Management

Innovent upholds the concept of sustainable development and actively responds to the national "Dual Carbon" strategy by deeply integrating green and low-carbon development into all aspects of corporate operations and production. We continue to optimize our environmental management system and strengthen environmental compliance management. We are committed to building an environmentally friendly enterprise and working with all sectors of society to promote ecological civilization construction, contributing to a green future.

5.2.1 Our Governance

Innovent strictly complies with environmental laws and regulations such as the "Environmental Protection Law of the People's Republic of China"(<中華人民共和國環境保護法>) and the "Law of the People's Republic of China on Environmental Impact Assessment" (<中華人民共和國環境影響評價法>), as well as relevant industry standards. The Company has formulated and published the "Environmental Management Policy"(<環境管理政策>)[8] on our official website, covering all key areas of environmental management (e.g., energy conservation, emission reduction, resource management, waste management and environmental training). In accordance with the ISO 14001 Environmental Management System standard, the Company has established 66 management procedures, including the "EHS Management Manual" (<EHS 管理手冊>) and the "Procedures for the Identification of Environmental Factors and Management of Important Environmental Factors" (<環境因素識別與重要環境管理程序>) as well as 24 environmental policies. These documents provide clear and detailed guidance for all environmental management activities. Furthermore, the Company has completed the signing of a full staff responsibility system to enhance safety awareness among personnel at all levels.

In 2025, the Company established a comprehensive EHS management policy in its new facilities, encompassing requirements for environmental protection. An annual review of existing policies was completed, confirming that the environmental protection policy framework has matured with no major adjustments. At the same time, we continue to advance the signing of environmental responsibility commitments by all staff and enhance environmental awareness and safety consciousness across all levels. During the Reporting Period, 100% of Innovent's production sites in operation (including newly established site) were certified under the ISO 14001 Environmental Management System.

8 Please refer to Innovent's ESG website for "Environmental Management Policy"(<環境管理政策>).


bsi.

Certificate of Registration

EMS 837152

...making excellence a habit.

Hangzhou Base ISO 14001 Environmental Management System Certification

Innovent has established a top-down EHS governance structure to effectively ensure the implementation of environmental policies and systems. The Audit Committee serves as the ultimate oversight body for environmental management, responsible for reviewing and supervising issues related to environmental management (see "5.1 Responding to Climate Change").

5.2.2 Our Actions

Environmental Compliance Audit

We are committed to ensuring the effectiveness and compliance of environmental management, continuously improving our environmental management standards, and strictly implementing internal and external environmental audit and inspection policies. We regularly conduct internal environmental compliance audits and actively cooperate with external regulatory authorities to carry out external environmental compliance audits. Based on audit findings, we promptly address and rectify identified issues while continuously optimizing management measures. We conduct annual environmental compliance audits covering 100% of sites in operation. The audit scope mainly includes the validity of environmental permits, the operational stability of pollutant treatment facilities, the status of wastewater, waste gas and solid waste emissions, and compliance with the Environmental Management System (EMS). During the Reporting Period, Innovent conducted 4 environmental management system audits, including 2 internal audits and 2 external audits.

In addition, prior to the construction of new facilities or the initiation of projects, we conduct environmental impact assessments to ensure that projects comply with environmental regulations at the design stage. After projects commence operations, we carry out regular environmental monitoring in accordance with the latest pollutant discharge permit requirements, continuously track emissions of pollutants such as wastewater and waste gas, and ensure that all emission indicators consistently meet applicable standards. As of the end of the Reporting Period, in line with pollutant discharge permit requirements and the annual environmental monitoring plan, we conducted 21 environmental impact assessments covering all operational sites, and all results complied with applicable emission standards.

Environmental Risk Management

Innovent adheres to the principle of prevention first and combining prevention with control, continuously improving its environmental risk identification and response mechanisms to enhance capabilities for preventing and managing sudden environmental incidents. We strictly comply with documents such as the "Measures for Emergency Management of

Environmental Emergencies" (<突發環境事件應急管理辦法>) and the "Measures for the Administration of Emergency Plans for Environmental Emergencies in Enterprises and Institutions (Trial)"(<企業事業單位突發環境事件應急預案管理辦法(試行)>). Based on these regulations, we have established internal policies including the "Emergency Plans for Environmental Emergencies" (<突發環境事件應急預案>), the "Emergency Response Management Procedures" (<應急管理程序>), the "Hidden Hazard Investigation and Governance Procedures" (<隱患排查管治程序>), the "EHS Incident Management Regulations" (<環境健康安全事故管理規定>) and the "Hidden Hazard Investigation Regulations" (<隱患排查制度>), the Company's bases regularly conduct inspections to identify and eliminate environmental risk hazards. Based on the actual findings of these inspections, the Company has formulated and refined internal policies, including the "Regulations on Safety Management of Gas Cylinders and Special Gases" (<氣瓶與特氣安全管理規定>), the "Procedures for Reporting, Investigation and Handling of Incidents and Accidents" (<事故事件報告、調查和處理規程>), the "Procedures for Risk Assessment and Management of Active Pharmaceuticals" (<活性藥物風險評估與管理規程>) and the "Chemical Safety Management Procedures" (<化學品安全管理規程>). These measures further optimize risk control processes for high-activity pharmaceuticals and chemicals, thereby enhancing the overall level of environmental risk management.

We have established an environmental and legal compliance assessment mechanism led by the EHS Laws and Regulations Assessment Committee to continuously conduct compliance evaluations of relevant environmental protection laws and regulations. By collecting environmental protection laws and regulations on a weekly basis and conducting systematic identification and evaluation by the assessment team on a quarterly basis, we ensure that the Company's policies and operational activities remain compliant with the latest regulatory requirements. In 2025, the Company collected a total of 54 environmental protection laws and regulations documents and implemented five improvement measures based on assessment results, effectively ensuring operational compliance.

We actively identify potential environmental risks across various activities and related stages, including drug development requirements, procurement, R&D testing, pollutant emission control, resource conservation and utilization, and waste classification management. We conduct in-depth assessments of these identified risks to ensure that all operational activities comply with environmental regulations.



Environmental Management Measures

In terms of daily supervision, the Company has established the "Environmental and Occupational Health and Safety Monitoring and Measurement Control Management Procedure" (<環境和職業健康安全監視測量控制管理程序>). In accordance with the "2025 Annual Environmental Monitoring Plan" (<2025年度環境監測計劃>), the Company conducts routine environmental monitoring and special environmental protection inspections to strengthen risk control at key stages. During the Reporting Period, Innovent organized eight on-site environmental protection special inspections, with a focus on the operation and management of environmental protection equipment and facilities, as well as operational risks in environmental protection management within R&D laboratories. All issues identified during the inspection have been incorporated into follow-up management to ensure the implementation of relevant rectification and improvement measures.

In addition, to enhance practical capabilities in responding to sudden environmental incidents, the Company organized and conducted environmental emergency drills in accordance with its annual plan.

Environmental Emergency Drill

In 2025, Innovent conducted multiple environmental emergency drills, including drills for hazardous waste leakage incidents, contingency plan exercises for abnormal failures of environmental facilities, and biological safety accident drills. The relevant drill plan is reasonably configured. The drill process was orderly, enhancing staff's familiarity with emergency response procedures and their response capabilities.

Drill Report Slides

5.2.3 Our Performance

Innovent conducted environmental protection training on various topics for all staff. Additionally, specialized skills training was provided to staff in positions requiring relevant competencies and professional qualifications to enhance their capabilities in environmental risk prevention and control.

Training Topic	Number of relevant staff trained in 2025	Proportion of relevant employee training in 2025
Waste Classification and Management	576	100%
Waste Operation Procedures	38	100%
Environmental Awareness Training for New Staff	652	100%
Identification and Management of Environmental Factors	18	100%

5.3 Resource Conservation and Emission Reduction

Innovent has always regarded resource conservation and waste reduction as a vital component of its sustainable development strategy. We are committed to continuously reducing the consumption of various resources by optimizing production processes, enhancing equipment efficiency, and strengthening waste management, while decreasing emissions of pollutants such as wastewater, exhaust gases, and solid waste.

5.3.1 Our Goals

Innovent has established a series of resource reduction and emission targets and continues to track the progress of annual target achievement. The Company is committed to continuously improving resource utilization efficiency and reducing its environmental footprint while ensuring business growth.

Target Indicators	Targets	Status of Achievement in 2025	
Fresh Water Usage	Achieving a 5% reduction in annual fresh water use per production unit by 2030.	Achieved	In 2025, the Company's freshwater consumption per unit of product was 37 T/Kvials, which reduced by 42% as compared with 2024 (64 T/Kvials)
Hazardous Waste Generation	Achieving an annual 5% reduction in hazardous waste generation per unit of product by 2030 as compared to 2022.	Achieved	In 2025, the hazardous waste per unit of product was 27 KG/Kvials, representing a reduction of 43.75% compared to 48 KG/Kvials in 2024; compared to 80 KG/Kvials in 2022, an average annual reduction of 17.67% per unit of product was achieved.
Air Emission Reduction (VOCs)	Achieving a 30% reduction in air emission generation by 2030 as compared to 2022.	In Progress	In 2025, waste gas emissions totaled 398 kilograms, which reduced by approximately 4% as compared with 2022 (414 KG).

5.3.2 Our Actions

Reduction of Wastewater, Waste Gas and Solid Waste

Emission Management Policy

Innovent strictly adheres to the three-waste emission standards and has formulated and optimized internal policies such as the "Waste Management Regulations" (<廢棄物管理規程>) and the "Hazardous Waste Operation Procedures" (<危險廢棄物操作規程>). Each site has established internal waste management measures, such as the "Operating Procedures for Wastewater and Waste Gas Treatment Systems" (<污水及廢氣處理系統操作規程>) tailored to our specific operational characteristics. These measures standardize wastewater and waste gas treatment processes to ensure compliance with emission standards.

Solid Waste Management

Innovent has established and adheres to internal policies such as the "Waste Management Procedures "(<廢棄物管理規程>) and the "Hazardous Chemicals Management System" (<危險化學品管理制度>), and the "Suzhou Base Hazardous Waste Operation Procedures" (<蘇州基地危險廢棄物操作規程>). These policies clearly define management requirements for various types of solid waste, mandating their classification, collection, storage, and disposal. We continue to advance the classification management and resource utilization of solid waste, strictly distinguishing between general solid waste and hazardous waste, while optimizing processes to reduce waste generation. Meanwhile, each site carried out standardized improvements to hazardous waste storage facilities and enhanced management compliance based on actual conditions.

Waste Gas and Wastewater Management

Innovent continues to refine internal policies for waste gas and wastewater management, including the "Standard Operating Procedures for Sewage Treatment Systems"(<污水處理系統標準操作規程>) and the "Standard Operating and Maintenance Procedures for the Exhaust Gas Treatment System"(<廢氣處理系統標準操作維護規程>), ensuring standardized and regulated governance of waste gas and wastewater. The Company is committed to reducing the environmental impact of waste gas and wastewater emissions through technological innovation and management optimization, ensuring compliance with discharge standards, and continuously advancing related emission reduction efforts.

Wastewater Management

- Implement classified collection and standardized treatment for production wastewater and domestic sewage. Production wastewater is collected and pre-treated as necessary before entering the wastewater treatment system, where compliance discharge is achieved through processes such as regulation, reaction, and sedimentation.
- Relevant discharge outlets are equipped with online monitoring devices to enable real-time monitoring of water quality. Each base continuously strengthens the maintenance and management of internal monitoring equipment to ensure the accuracy and reliability of monitoring data.

Waste Gas Management

- Conduct regular inspection and maintenance of waste gas treatment facilities, and replenish reagents and replace consumables in a timely manner based on operational conditions to ensure stable operation of treatment systems.
- For key equipment, the Company strengthens preventive maintenance on top of routine inspections to enhance the continuity and reliability of waste gas treatment systems.

During the Reporting Period, based on standardized management practices, Innovent implemented a series of facility optimization and process improvement projects to enhance the stability and controllability of pollutant disposal while reducing emissions of waste and potential toxic substances.

Strengthening Monitoring of Wastewater Treatment and Risk Control of Abnormal Discharges

To mitigate environmental risks during the wastewater treatment process and enhance water quality control, Suzhou site has implemented a series of optimization measures in the operation and management of its wastewater treatment facilities. Specifically, the automatic sampling frequency of internal monitoring increased from once every six hours to once every two hours. This enhancement significantly improves responsiveness to fluctuations in influent and effluent water quality, facilitates timely detection and control of abnormal conditions, and effectively reduces potential toxic substance emissions.

Meanwhile, the base has added new collection and filtration pools for domestic wastewater to enhance the pre-treatment of sewage. This further ensures the stability of the total effluent quality at the plant outlet, guarantees continuous compliance with discharge standards, and reduces the impact on the receiving water body.

Facility Construction Site

Optimization Project of Wastewater and Waste Gas Treatment Systems

The Hangzhou base has achieved open-pipe collection of production wastewater in wastewater management and implemented closed management of sewage treatment facilities to effectively collect waste gases generated during the treatment process. In terms of waste gas management, the base has established supporting waste gas treatment systems in production workshops, laboratories, and related auxiliary areas. By adopting a combined treatment processes involving water spraying, demisting and activated carbon adsorption, the facility ensures that treated waste gases are discharged in stable compliance with applicable standards.

Environmental Protection Facility Site

Meanwhile, the Company conducted special inspections and remediation of rainwater and wastewater pipeline networks within its production facilities to promptly identify and address potential issues, ensuring effective collection and disposal of wastewater.

Specialized Investigation of Rainwater and Sewage Pipeline Networks in the Industrial Zone

In 2025, Innovent collaborated with the industrial park's water utility unit to conduct special inspections and remediation of the plant's rainwater and sewage pipe networks. Potential issues were identified and addressed in a timely manner to ensure the integrity and effectiveness of the wastewater collection and treatment systems.

Special Investigation Site

Hazardous Waste Management

Innovent places high importance on the full-process management of hazardous waste. A Hazardous Waste Reduction Committee has been established to coordinate the generation, storage, and disposal of hazardous waste across all bases. We continue to advance the standardization and normalization of hazardous waste management. Each base strictly implements regulatory requirements by enforcing measures such as classified storage, standardized labeling, and record-keeping. By improving warehousing conditions, strengthening on-site controls, and collaborating with qualified professional third-party units, we ensure compliant disposal of hazardous waste and effectively mitigate environmental risks.

Raw Materials	We prioritize the use of non-toxic or low-toxic chemicals and add activated carbon adsorption devices in hazardous waste warehouses to reduce the generation of hazardous waste from the source, ensuring that the environmental impact during the production process is minimized.
Management	Integrating with the hazardous waste life-cycle monitoring system to achieve full-process tracking and management of hazardous waste. Through real-time monitoring of waste generation, transportation, and disposal, the system ensures standardized waste treatment and improves the transparency and efficiency of waste management.
Transportation	During the transportation of waste, we collaborate with professional third parties to effectively reduce the volume and emissions of hazardous waste through methods such as compression, packaging, and other means, further reducing the environmental burden during the transportation process.

Hazardous Waste Management Measures

Standardized Renovation of Hazardous Waste Warehouses

The Hangzhou Site implemented standardized improvements to its hazardous waste storage facilities, including anti-seepage and anti-corrosion treatment of the floor, classified and zoned storage, and information disclosure measures. These actions further enhanced the standardization of hazardous waste storage and management.

Optimized Hazardous Waste Warehouse

We actively implement various hazardous waste reduction projects across all operational sites to explore the minimization of hazardous waste generation at the source and enhance resource utilization efficiency. By implementing source reduction measures for hazardous waste in core operational areas of production and R&D, the Company has reduced the intensity of hazardous waste generation and its potential impact on the environment.

Optimization and Reduction Project for Re-testing Sample Volume in R&D Laboratories

Based on standardized disposal practices, Innovent identified opportunities for reduction in the production and R&D processes to decrease the generation of hazardous waste per unit of product. In 2025, we advanced the optimization of retest sample volumes in our R&D phase. Through scientific assessment of testing requirements and reasonable adjustment of retest sample usage, we reduced unnecessary sample preparation and testing frequency. This project covers 11 categories of finished products and injectable solutions, which shorten the testing cycle and enhance R&D efficiency.

Homogenization Treatment of Production Wastewater

To enhance wastewater treatment efficiency and reduce the volume of hazardous waste requiring off-site disposal, Innovent optimizes the pre-treatment approach for production wastewater through thorough mixing and homogenization treatment. This ensures better compatibility with subsequent treatment processes, thereby minimizing the quantity of waste necessitating outsourced disposal. In 2025, the Company reduced hazardous waste off-site disposal by approximately 175 tons through this measure, effectively mitigating potential environmental impacts and demonstrating our concrete actions to reduce emissions during core operations.

Water Resource Management

Innovent regards water conservation as a critical component of daily operations management. The Company continuously promotes the application of water-saving technologies and management optimization. Each operating site has formulated water-saving measures based on its specific water usage characteristics to enhance water resource utilization efficiency. During the Reporting Period, municipal water supply was the primary source of water for Innovent's production and operations. The Company did not encounter any issues regarding water resource withdrawal. In 2025, the total volume of recycled water used by the Company reached 51,100 tons.

In the production phase, we optimized the solution preparation process and reasonably controlled water usage to reduce unnecessary water consumption, achieving effective savings in annual tap water use. Regarding park operations, some bases constructed rainwater collection systems based on site conditions to utilize collected rainwater for non-production purposes such as landscape irrigation, effectively reducing reliance on fresh tap water and enhancing the level of water resource recycling.

Water-saving Optimization in Production Processes	• In 2025, Innovent optimized the solution preparation processes in key production stages. Through precise control of usage and reduction of redundant operations, annual tap water savings of approximately 629 tons were achieved.
Construction of Rainwater Resource Utilization Systems	• Hangzhou Site: Constructed two sponge city systems to enable rainwater collection and reuse, saving approximately 1,500 tons of fresh tap water annually, mainly used for landscape irrigation. • Shanghai R&D Center: Deployed one sponge city system to collect rainwater for landscape irrigation, saving approximately 1,000 tons of fresh tap water annually.

Water Conservation Project

5.4 Green Operations

During pharmaceutical research and development as well as production operations, daily operational practices also influence the Company's environmental performance, in addition to resource and emission management within the production phase. Innovent integrates green principles into office management, facility construction, and park operations. Through measures such as optimizing office environments, promoting green travel, improving packaging methods, and focusing on ecological environmental protection, the Company continues to reduce the impact of daily operations on the environment.

5.4.1 Our Actions

Green Office

In its daily operations and park management, Innovent actively promotes a green office culture through infrastructure development and employee engagement, advocating for low-carbon, energy-efficient, and environmentally friendly working practices.

Green Travel and Charging Infrastructure Construction

Innovent has equipped all its operational sites with charging stations for both automobiles and electric bicycles to support staff's green commuting.

- In 2025, the Suzhou base operated four electric vehicle charging stations and 180 non-motorized vehicle charging stations, serving over 4,000 employee uses in total with a cumulative charging volume of 90,000 kilowatt-hours.
- The Hangzhou base has established 12 electric vehicle charging piles and 100 non-motorized vehicle charging piles, serving 4,608 employee uses with a total charging volume of 80,000 kilowatt-hours.
- The Shanghai R&D Center is equipped with 85 electric vehicle charging piles and 40 non-motorized vehicle charging piles, serving 5,528 employee uses with a total charging volume of 135,800 kWh, effectively guiding staff to choose clean energy transportation modes.

Charging Pile Configuration

Energy Conservation Promotion and Behavioral Advocacy

Innovent regularly publishes energy-saving briefs and promotes key equipment energy-saving points through channels such as bulletin boards and internal platforms. Meanwhile, security personnel conduct nightly energy-saving inspections to ensure that lighting, air conditioning, and other equipment are promptly turned off.

In 2025, the Company organized and carried out the environmental protection theme activity 'Beautiful China, I Lead First — A Joyful Journey to Reduce Plastic Life' at Dushu Lake Ecological Park. Through plastic reduction publicity and environmental cleanup actions, the Company enhanced staff's environmental awareness and fulfilled its social responsibility.

Night Inspection Check-in Record

Group Photo of the Environmental Protection Event

Green Packaging

Innovent is committed to reducing resource consumption at the source and promoting the sustainable transformation of packaging materials. The Company continues to explore ways to minimize plastic usage and enhance material recyclability.

R&D Processes

Reuse consumables such as pipette tips and straws to effectively reduce the use of single-use plastic products

Production Processes

Introduced automated packaging production lines to enable functions such as automatic assembly, labeling, boxing, and weight checking.

Adopt environmentally friendly design concepts by using all-paper packaging technologies to replace traditional PET/PVC plastic packaging materials

Green Packaging Practices

Biodiversity Conservation

Innovent recognizes the critical importance of biodiversity for ecosystem stability and human health, and has integrated biodiversity conservation into our sustainable development strategy. We are committed to assessing the impact of our operational activities on the surrounding ecosystem. By optimizing site selection, minimizing land disturbance, and preserving green spaces, we strive to reduce interference with natural habitats.

- We used low-toxicity greening agents to efficiently safeguard birds and other wildlife.
- We collected testing waste liquids generated in the laboratory that may be harmful to aquatic organisms, avoiding possible adverse effects on aquatic organisms and the environment.
- We updated the "Management Procedure of Pest Control" (<蟲害控制管理流程>), clarifying the responsibility of pest-control equipment suppliers. We also conducted 2 pest control trainings.

Biodiversity Conservation Measures

Appendix I: HKEX ESG Reporting Code Index

Environmental, Social and Governance Areas, General Disclosures and Key Performance Indicators (KPIs)		Section
A. Environmental		
A1: Emissions		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste. *Note: Waste gas emissions include nitrogen oxides, sulfur oxides, and other pollutants regulated by national laws and regulations. Hazardous waste refers to that defined by national regulations.*	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
Key Performance Indicator A1.1	The types of emissions and respective emissions data.	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator A1.2	Repealed 1 January 2025	/
Key Performance Indicator A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator A1.5	Description of emissions target(s) set and steps taken to achieve them.	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
Key Performance Indicator A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
A2: Use of Resources		
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials. *Note: Resources may be utilized for production, storage, transportation, buildings, and electronic equipment.*	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
Key Performance Indicator A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	5 Embracing Ecology: 5.1 Responding to Climate Change Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility)	Appendix IV: 2025 Statistical Data Tables

Environmental, Social and Governance Areas, General Disclosures and Key Performance Indicators (KPIs)		Section
Key Performance Indicator A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	5 Embracing Ecology: 5.1 Responding to Climate Change
Key Performance Indicator A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
Key Performance Indicator A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Appendix IV: 2025 Statistical Data Tables
A3: The Environment and Natural Resources		
General Disclosure	Policies on minimising the issuer's significant impact on the environment and natural resources.	5 Embracing Ecology: 5.2 Environmental Management 5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
Key Performance Indicator A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	5 Embracing Ecology: 5.2 Environmental Management 5.3 Resource Conservation and Emission
A4: Climate Change	Repealed 1 January 2025	\
Key Performance Indicator A4.1	Repealed 1 January 2025	\
B. Social		
Employment and Labor Practices		
B1: Employment		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	4 People First: 4.1 Compliant Employment
Key Performance Indicator B1.1	Total workforce by gender, employment type (for example, full – or part-time), age group and geographical region.	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B1.2	Employee turnover rate by gender, age group and geographical region.	Appendix IV: 2025 Statistical Data Tables

Environmental, Social and Governance Areas, General Disclosures and Key Performance Indicators (KPIs)		Section
B2: Health and Safety		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	4 People First: 4.4 Occupational Health and Safety
Key Performance Indicator B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B2.2	Lost days due to work injury.	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	4 People First: 4.4 Occupational Health and Safety
B3: Development and Training		
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. *Note: Training refers to vocational training, which may include internal and external courses paid for by the employer.*	4 People First: 4.2 Employee Development
Key Performance Indicator B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B3.2	The average training hours completed per employee by gender and employee category.	Appendix IV: 2025 Statistical Data Tables
B4: Labor Standards		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	4 People First: 4.1 Compliant Employment
Key Performance Indicator B4.1	Description of measures to review employment practices to avoid child and forced labour.	4 People First: 4.1 Compliant Employment
Key Performance Indicator B4.2	Description of steps taken to eliminate such practices when discovered.	4 People First: 4.1 Compliant Employment

Environmental, Social and Governance Areas, General Disclosures and Key Performance Indicators (KPIs)		Section
Operating Practices		
B5: Supply Chain Management		
General Disclosure	Policies on managing environmental and social risks of the supply chain.	3 High Quality As Key: 3.5 Supply Chain Management
Key Performance Indicator B5.1	Number of suppliers by geographical region.	Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	3 High Quality As Key: 3.5 Supply Chain Management
Key Performance Indicator B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	3 High Quality As Key: 3.5 Supply Chain Management
Key Performance Indicator B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	3 High Quality As Key: 3.5 Supply Chain Management
B6: Product Responsibility		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labeling and privacy matters relating to products and services provided and methods of redress.	3 High Quality 3.1 Product Quality and Safety 3 High Quality As Key: 3.4 Responsible Marketing
Key Performance Indicator B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	3 High Quality 3.1 Product Quality and Safety Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B6.2	Number of products and service related complaints received and how they are dealt with.	3 High Quality 3.1 Product Quality and Safety Appendix IV: 2025 Statistical Data Tables
Key Performance Indicator B6.3	Description of practices relating to observing and protecting intellectual property rights.	1 Excellent Governance: 1.5 Intellectual Property Protection
Key Performance Indicator B6.4	Description of quality assurance process and recall procedures.	3 High Quality As Key: 3.1 Product Quality and Safety
Key Performance Indicator B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	1. Excellent Governance: 1.4 Customer Privacy Protection and Information Security

Environmental, Social and Governance Areas, General Disclosures and Key Performance Indicators (KPIs)		Section
B7: Anti-Corruption		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	1. Excellent Governance: 1.2 Compliance Operations
Key Performance Indicator B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	1. Excellent Governance: 1.2 Compliance Operations
Key Performance Indicator B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	1. Excellent Governance: 1.2 Compliance Operations
Key Performance Indicator B7.3	Description of the anti-corruption training provided to directors and employees.	1. Excellent Governance: 1.2 Compliance Operations
Community		
B8: Community Investment		
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	2. Enjoying Good Health: 2.2 Public Welfare and Charity
Key Performance Indicator B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	2. Enjoying Good Health: 2.2 Public Welfare and Charity
Key Performance Indicator B8.2	Resources contributed (e.g. money or time) to the focus area.	2. Enjoying Good Health: 2.2 Public Welfare and Charity

Part D: Climate-related Disclosures				
Climate-related Disclosure Requirements				**Chapter**
(I) Governance	1. An issuer shall disclose information about:			
	(a) the governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities. Specifically, the issuer shall identify that body(s) or individual(s) and disclose information about:			
		(i)	how the body(s) or individual(s) determines whether appropriate skills and competencies are available or will be developed to oversee strategies designed to respond to climate-related risks and opportunities;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(ii)	how and how often the body(s) or individual(s) is informed about climate-related risks and opportunities;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(iii)	how the body(s) or individual(s) takes into account climate-related risks and opportunities when overseeing the issuer's strategy, its decisions on major transactions, and its risk management processes and related policies, including whether the body(s) or individual(s) has considered trade offs associated with those risks and opportunities;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(iv)	how the body(s) or individual(s) oversees the setting of, and monitors progress towards, targets related to climate-related risks and opportunities (see paragraphs 19 to 22), including whether and how related performance metrics are included in remuneration policies (see paragraph 17); and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b) management's role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities, including information about:			
		(i)	whether the role is delegated to a specific management-level position or management-level committee and how oversight is exercised over that position or committee; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(ii)	whether management uses controls and procedures to support the oversight of climate related risks and opportunities and, if so, how these controls and procedures are integrated with other internal functions.	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements			Chapter
(II) Strategy	**Climate-related risks and opportunities**		
	2. An issuer shall disclose information to enable an understanding of climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, its access to finance or cost of capital over the short, medium or long term. Specifically, the issuer shall:		
		(a) describe climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, its access to finance or cost of capital over the short, medium or long term;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(b) explain, for each climate-related risk the issuer has identified, whether the issuer considers the risk to be a climate-related physical risk or climate related transition risk;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(c) specify, for each climate-related risk and opportunity the issuer has identified, over which time horizons – short, medium or long term – the effects of each climate-related risk and opportunity could reasonably be expected to occur; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(d) explain how the issuer defines 'short term', 'medium term' and 'long term' and how these definitions are linked to the planning horizons used by the issuer for strategic decision-making.	5 Embracing Ecology: 5.1 Responding to Climate Change
	Business model and value chain		
	3. An issuer shall disclose information that enables an understanding of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain. Specifically, the issuer shall disclose:		
		(a) a description of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(b) a description of where in the issuer's business model and value chain climate-related risks and opportunities are concentrated (for example, geographical areas, facilities and types of assets).	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements			Chapter
Strategy and decision-making			
4.	An issuer shall disclose information that enables an understanding of the effects of climate-related risks and opportunities on its strategy and decision-making. Specifically, the issuer shall disclose:		
	(a)	information about how the issuer has responded to, and plans to respond to, climate related risks and opportunities in its strategy and decision-making, including how the issuer plans to achieve any climate-related targets it has set and any targets it is required to meet by law or regulation. Specifically, the issuer shall disclose information about:	
		(i) current and anticipated changes to the issuer's business model, including its resource allocation, to address climate-related risks and opportunities;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(ii) current and anticipated adaptation and mitigation efforts (whether direct or indirect);	5 Embracing Ecology: 5.1 Responding to Climate Change
		(iii) any climate-related transition plan the issuer has (including information about key assumptions used in developing its transition plan, and dependencies on which the issuer's transition plan relies), or an appropriate negative statement where the issuer does not have a climate-related transition plan; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(iv) how the issuer plans to achieve any climate related targets (including any GHG emissions targets (if any)), described in accordance with paragraphs 19 to 22; and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b)	information about how the issuer is resourcing, and plans to resource, the activities disclosed in accordance with paragraph 4(a).	5 Embracing Ecology: 5.1 Responding to Climate Change
5.	An issuer shall disclose information about the progress of plans disclosed in previous Reporting Periods in accordance with paragraph 4(a).		5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements			Chapter
Financial position, financial performance and cash flows **Current financial effect** 6. An issuer shall disclose qualitative and quantitative information about:			
	(a)	how climate-related risks and opportunities have affected its financial position, financial performance and cash flows for the Reporting Period; and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b)	the climate-related risks and opportunities identified in paragraph 24(a) for which there is a significant risk of a material adjustment within the next annual Reporting Period to the carrying amounts of assets and liabilities reported in the related financial statements.	5 Embracing Ecology: 5.1 Responding to Climate Change
Financial position, financial performance and cash flows **Anticipated financial effect** 7. The issuer shall provide qualitative and quantitative disclosures about:			
	(a)	how the issuer expects its financial position to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities, taking into consideration:	
		(i) its investment and disposal plans; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(ii) its planned sources of funding to implement its strategy; and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b)	how the issuer expects its financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities.	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements				Chapter
Climate resilience				
8.	An issuer shall disclose information that enables an understanding of the resilience of the issuer's strategy and business model to climate-related changes, developments and uncertainties, taking into consideration the issuer's identified climate-related risks and opportunities. An issuer shall use climate-related scenario analysis to assess its climate resilience using an approach that is commensurate with an issuer's circumstances. In providing quantitative information, the issuer may disclose a single amount or a range. Specifically, the issuer shall disclose:			
	(a)	the issuer's assessment of its climate resilience as at the reporting date, which shall enable an understanding of:		
		(i)	the implications, if any, of the issuer's assessment for its strategy and business model, including how the issuer would need to respond to the effects identified in the climate-related scenario analysis;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(ii)	the significant areas of uncertainty considered in the issuer's assessment of its climate resilience; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(iii)	the issuer's capacity to adjust, or adapt its strategy and business model to climate change over the short, medium or long term;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b)	how and when the climate-related scenario analysis was carried out, including:		
		(i)	information about the inputs used, including:	5 Embracing Ecology: 5.1 Responding to Climate Change
			(1) which climate-related scenarios the issuer used for the analysis and the sources of such scenarios;	
			(2) whether the analysis included a diverse range of climate-related scenarios;	
			(3) whether the climate-related scenarios used for the analysis are associated with climate-related transition risks or climate-related physical risks;	
			(4) whether the issuer used, among its scenarios, a climate-related scenario aligned with the latest international agreement on climate change;	
			(5) why the issuer decided that its chosen climate related scenarios are relevant to assessing its resilience to climate-related changes, developments or uncertainties;	
			(6) time horizons the issuer used in the analysis; and	
			(7) what scope of operations the issuer used in the analysis (for example, the operation, locations and business units used in the analysis);	
		(ii)	the key assumptions the issuer made in the analysis; and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(iii)	the Reporting Period in which the climate related scenario analysis was carried out.	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements				Chapter
(III) Risk Management	9.	An issuer shall disclose information about:		
		(a)	the processes and related policies it uses to identify, assess, prioritise and monitor climate-related risks, including information about:	
			(i) the inputs and parameters the issuer uses (for example, information about data sources and the scope of operations covered in the processes);	5 Embracing Ecology: 5.1 Responding to Climate Change
			(ii) whether and how the issuer uses climate related scenario analysis to inform its identification of climate-related risks;	5 Embracing Ecology: 5.1 Responding to Climate Change
			(iii) how the issuer assesses the nature, likelihood and magnitude of the effects of those risks (for example, whether the issuer considers qualitative factors, quantitative thresholds or other criteria);	5 Embracing Ecology: 5.1 Responding to Climate Change
			(iv) whether and how the issuer prioritises climate-related risks relative to other types of risks;	5 Embracing Ecology: 5.1 Responding to Climate Change
			(v) how the issuer monitors climate-related risks; and	5 Embracing Ecology: 5.1 Responding to Climate Change
			(vi) whether and how the issuer has changed the processes it uses compared with the previous Reporting Period;	5 Embracing Ecology: 5.1 Responding to Climate Change
		(b)	the processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities (including information about whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related opportunities); and	5 Embracing Ecology: 5.1 Responding to Climate Change
		(c)	the extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer's overall risk management process.	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements			Chapter
(IV) Metrics and Targets	**GHG emissions**		
	10. An issuer shall disclose its absolute gross GHG emissions generated during the Reporting Period, expressed as metric tons of CO_2 equivalent, classified as:		
	(a)	Scope 1 GHG emissions;	5 Embracing Ecology: 5.1 Responding to Climate Change Appendix IV: 2025 Statistical Data Tables
	(b)	Scope 2 GHG emissions; and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(c)	Scope 3 GHG emissions.	Appendix IV: 2025 Statistical Data Tables
	11. An issuer shall: (a) measure its GHG emissions in accordance with the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004) unless required by a jurisdictional authority or another exchange on which the issuer is listed to use a different method for measuring GHG emissions;		
	(b)	disclose the approach it uses to measure its GHG emissions including:	
		(i) the measurement approach, inputs and assumptions the issuer uses to measure its GHG emissions;	Appendix IV: 2025 Statistical Data Tables
		(ii) the reason why the issuer has chosen the measurement approach, inputs and assumptions it uses to measure its GHG emissions; and	Appendix IV: 2025 Statistical Data Tables
		(iii) any changes the issuer made to the measurement approach, inputs and assumptions during the Reporting Period and the reasons for those changes;	Appendix IV: 2025 Statistical Data Tables
	(c)	for Scope 2 GHG emissions disclosed in accordance with paragraph 10(b), disclose its location-based Scope 2 GHG emissions, and provide information about any contractual instruments that is necessary to enable an understanding of the issuer's Scope 2 GHG emissions; and	Appendix IV: 2025 Statistical Data Tables
	(d)	for Scope 3 GHG emissions disclosed in accordance with paragraph 10(c), disclose the categories included within the issuer's measure of Scope 3 GHG emissions, in accordance with the Scope 3 categories described in the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011).	Appendix IV: 2025 Statistical Data Tables

Climate-related Disclosure Requirements		Chapter
Climate-related transition risks		
12.	An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks.	5 Embracing Ecology: 5.1 Responding to Climate Change
Climate-related physical risks		
13.	An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks.	5 Embracing Ecology: 5.1 Responding to Climate Change
Climate-Related Opportunities Targets		
14.	An issuer shall disclose the amount and percentage of assets or business activities aligned with climate-related opportunities.	5 Embracing Ecology: 5.1 Responding to Climate Change
Capital deployment		
15.	An issuer shall disclose the amount of capital expenditure, financing or investment deployed towards climate-related risks and opportunities	5 Embracing Ecology: 5.1 Responding to Climate Change
Internal carbon prices		
16.	An issuer shall disclose:	
	(a) an explanation of whether and how the issuer is applying a carbon price in decision-making (for example, investment decisions, transfer pricing, and scenario analysis); and	The Company has not yet adopted an internal carbon pricing mechanism. We will continue to monitor relevant policy developments and industry practices and assess the feasibility of introducing such a mechanism when appropriate.
	(b) the price of each metric tonne of GHG emissions the issuer uses to assess the costs of its GHG emissions; or an appropriate negative statement that the issuer does not apply a carbon price in decision-making.	The Company has not yet adopted an internal carbon pricing mechanism. We will continue to monitor relevant policy developments and industry practices and assess the feasibility of introducing such a mechanism when appropriate.
Remuneration		
17.	An issuer shall disclose whether and how climate-related considerations are factored into remuneration policy, or an appropriate negative statement. This may form part of the disclosure under paragraph 1(a)(iv).	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements			Chapter
Industry-based metrics			
18.	An issuer is encouraged to disclose industry based metrics that are associated with one or more particular business models, activities or other common features that characterise participation in an industry. In determining the industry-based metrics that the issuer discloses, an issuer is encouraged to refer to and consider the applicability of the industry-based metrics associated with disclosure topics described in the IFRS S2 Industry-based Guidance on implementing Climate-related Disclosures and other industry-based disclosure requirements prescribed under other international ESG reporting frameworks.		5 Embracing Ecology: 5.1 Responding to Climate Change
Climate-related targets			
19.	An issuer shall disclose (a) the qualitative and quantitative climate-related targets the issuer has set to monitor progress towards achieving its strategic goals; and (b) any targets the issuer is required to meet by law or regulation, including any GHG emissions targets. For each target, the issuer shall disclose:		
	(a)	the metric used to set the target;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b)	the objective of the target (for example, mitigation, adaptation or conformance with science-based initiatives);	5 Embracing Ecology: 5.1 Responding to Climate Change
	(c)	the part of the issuer to which the target applies (for example, whether the target applies to the issuer in its entirety or only a part of the issuer, such as a specific business unit or geographic region);	5 Embracing Ecology: 5.1 Responding to Climate Change
	(d)	the period over which the target applies;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(e)	the base period from which progress is measured;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(f)	milestones or interim targets (if any);	5 Embracing Ecology: 5.1 Responding to Climate Change
	(g)	if the target is quantitative, whether the target is an absolute target or an intensity target; and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(h)	how the latest international agreement on climate change, including jurisdictional commitments that arise from that agreement, has informed the target.	5 Embracing Ecology: 5.1 Responding to Climate Change

Climate-related Disclosure Requirements			Chapter
	20.	An issuer shall disclose information about its approach to setting and reviewing each target, and how it monitors progress against each target, including:	
		(a) whether the target and the methodology for setting the target has been validated by a third party;	The Company has not separately disclosed the specific methodology for target setting and revision details; however, it has systematically presented the synergistic logic between climate-related targets and business decisions through Strategic Planning documents and financial forecasting models. Furthermore, quantitative core indicators related to climate change have been incorporated into the ESG performance management system to ensure that targets remain dynamic and aligned with industry regulations and sustainable development requirements.
		(b) the issuer's processes for reviewing the target;	The Company has not separately disclosed the specific methodology for target setting and revision details; however, it has systematically presented the synergistic logic between climate-related targets and business decisions through Strategic Planning documents and financial forecasting models. Furthermore, quantitative core indicators related to climate change have been incorporated into the ESG performance management system to ensure that targets remain dynamic and aligned with industry regulations and sustainable development requirements.

Climate-related Disclosure Requirements			Chapter
	(c)	the metrics used to monitor progress towards reaching the target; and	The Company has not separately disclosed the specific methodology for target setting and revision details; however, it has systematically presented the synergistic logic between climate-related targets and business decisions through Strategic Planning documents and financial forecasting models. Furthermore, quantitative core indicators related to climate change have been incorporated into the ESG performance management system to ensure that targets remain dynamic and aligned with industry regulations and sustainable development requirements.
	(d)	any revisions to the target and an explanation for those revisions.	The Company has not separately disclosed the specific methodology for target setting and revision details; however, it has systematically presented the synergistic logic between climate-related targets and business decisions through Strategic Planning documents and financial forecasting models. Furthermore, quantitative core indicators related to climate change have been incorporated into the ESG performance management system to ensure that targets remain dynamic and aligned with industry regulations and sustainable development requirements.

Climate-related Disclosure Requirements			Chapter
21.	An issuer shall disclose information about its performance against each climate-related target and an analysis of trends or changes in the issuer's performance.		5 Embracing Ecology: 5.1 Responding to Climate Change
22.	For each GHG emissions target disclosed in accordance with paragraphs 19 to 21, an issuer shall disclose:		
	(a)	which GHGes are covered by the target;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(b)	whether Scope 1, Scope 2 or Scope 3 GHG emissions are covered by the target;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(c)	whether the target is a gross GHG emissions target or a net GHG emissions target. If the issuer discloses a net GHG emissions target, the issuer is also required to separately disclose its associated gross GHG emissions target;	5 Embracing Ecology: 5.1 Responding to Climate Change
	(d)	whether the target was derived using a sectoral decarbonisation approach; and	5 Embracing Ecology: 5.1 Responding to Climate Change
	(e)	the issuer's planned use of carbon credits to offset GHG emissions to achieve any net GHG emissions target. In explaining its planned use of carbon credits, the issuer shall disclose:	
		(i) the extent to which, and how, achieving any net GHG emissions target relies on the use of carbon credits;	The Company currently has no plans to utilize carbon credits. We will continue to closely monitor the development of relevant policies and industry practices and assess the feasibility of implementing such a plan when appropriate.
		(ii) which third-party scheme(s) will verify or certify the carbon credits;	The Company currently has no plans to utilize carbon credits. We will continue to closely monitor the development of relevant policies and industry practices and assess the feasibility of implementing such a plan when appropriate.

Climate-related Disclosure Requirements			Chapter
	(iii)	the type of carbon credit, including whether the underlying offset will be nature-based or based on technological carbon removals, and whether the underlying offset is achieved through carbon reduction or removal; and	The Company currently has no plans to utilize carbon credits. We will continue to closely monitor the development of relevant policies and industry practices and assess the feasibility of implementing such a plan when appropriate.
	(iv)	any other factors necessary to enable an understanding of the credibility and integrity of the carbon credits the issuer plans to use (for example, assumptions regarding the permanence of the carbon offset).	The Company currently has no plans to utilize carbon credits. We will continue to closely monitor the development of relevant policies and industry practices and assess the feasibility of implementing such a plan when appropriate.
Applicability of cross-industry metrics and industry-based metrics 23. In preparing disclosures to meet the requirements in paragraphs 3 to 8 and 19 to 20, an issuer shall refer to and consider the applicability of cross-industry metrics (see paragraphs 10 to 17) and (ii) industry-based metrics (see paragraph 18).			After a prudent assessment, it has been determined that the applicability of the relevant cross-industry and industry-specific indicators to the Group is limited; therefore, no specific disclosure has been made.

Appendix II: GRI Standards Guidance Index

GRI Standard	Disclosure	Location
GRI 1: Foundation 2021		
GRI 2: General Disclosures 2021		
The organization and its reporting practices		
2-1	Organizational details	About Innovent
2-2	Entities included in the organization's sustainability reporting	About This Report
2-3	Reporting period, frequency and contact point	About This Report
2-4	Restatements of information	About This Report
2-5	External Assurance	/
Activities and Workers		
2-6	Activities, value chain and other business relationships	3 High Quality As Key: 3.5 Supply Chain Management
2-7	Employees	Appendix IV: 2025 Statistical Data Tables
2-8	Workers who are not employees	Appendix IV: 2025 Statistical Data Tables
Governance		
2-9	Governance structure and composition	1. Excellent Governance: 1.1 ESG Governance
2-10	Nomination and selection of the highest governance body	/
2-11	Chair of the highest governance body	/
2-12	Role of the highest governance body in overseeing the management of impacts	1. Excellent Governance: 1.1 ESG Governance
2-13	Delegation of responsibility for managing impacts	1. Excellent Governance: 1.1 ESG Governance
2-14	Role of the highest governance body in sustainability reporting	1. Excellent Governance: 1.1 ESG Governance
2-15	Conflicts of interest	/
2-16	Communication of critical concerns	1. Excellent Governance: 1.1 ESG Governance
2-17	Collective knowledge of the highest governance body	5 Embracing Ecology: 5.1 Responding to Climate Change
2-18	Evaluation of the performance of the highest governance body	/
2-19	Remuneration policies	/

GRI Standard	Disclosure	Location
2-20	Process to determine remuneration	/
2-21	Annual total compensation ratio	/
Strategy, Policies, and Practices		
2-22	Statement on sustainable development strategy	1. Excellent Governance: 1.1 ESG Governance
2-23	Policy commitments	4 People First: 4.1 Compliant Employment
2-24	Embedding policy commitments	4 People First: 4.1 Compliant Employment
2-25	Processes to remediate negative impacts	/
2-26	Mechanisms for seeking advice and raising concerns	4 People First: 4.3 Employee Care
2-27	Compliance with laws and regulations	No significant violations occurred.
Stakeholder Engagement		
2-29	Approach to stakeholder engagement	1. Excellent Governance: 1.1 ESG Governance
2-30	Collective bargaining agreements	/
GRI 3: Material Topics 2021		
3-1	Process to determine material topics	1. Excellent Governance: 1.1 ESG Governance
3-2	List of material topics	1. Excellent Governance: 1.1 ESG Governance
Economy		
GRI 201: Economic Performance 2016		
201-1	Directly generated and distributed economic value	/
201-2	Financial impacts of climate change and other risks and opportunities	5 Embracing Ecology: 5.1 Responding to Climate Change
Material Issues		
202-1	Ratios of standard entry level wage by gender compared to local minimum wage	These data are currently outside the scope of the Company's ESG data management. The Company will gradually expand the scope of data in the future and consider disclosing this information upon its inclusion.
202-2	The proportion of executives hired from the local community	

GRI Standard	Disclosure	Location
Procurement Practices		
204-1	Proportion of expenditure sourced from local suppliers	These data are currently outside the scope of the Company's ESG data management. The Company plans to gradually expand the scope of data collection in the future and will consider disclosing this information upon its inclusion.
GRI 205: Anti-corruption 2016		
205-1	Operations assessed for risks	1. Excellent Governance: 1.2 Compliance Operations
205-2	Communication and training about anti-corruption policies and procedures	1. Excellent Governance: 1.2 Compliance Operations 3 High Quality As Key: 3.5 Supply Chain Management
205-3	Confirmed incidents of corruption and actions taken	Appendix IV: 2025 Statistical Data Tables
GRI 206: Anti-competitive Behavior 2016		
206-1	Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	No legal proceedings have been initiated regarding anti-competitive conduct, antitrust violations, or monopolistic practices.
Environment		
GRI 301: Materials 2016		
301-1	Materials used by weight or volume	Appendix IV: 2025 Statistical Data Tables
GRI 302: Energy 2016		
302-1	Energy consumption within the organization	Appendix IV: 2025 Statistical Data Tables
302-3	Energy intensity	Appendix IV: 2025 Statistical Data Tables
302-4	Reduction of energy consumption	Appendix IV: 2025 Statistical Data Tables

GRI Standard	Disclosure	Location
GRI 303: Water and Effluents 2018		
303-1	Interactions with water as a shared resource	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
303-2	Management of water discharge – related impacts	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
303-4	Water discharge	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
303-5	Water consumption	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction Appendix IV: 2025 Statistical Data Tables
GRI 305: Emissions 2016		
305-1	Direct (Scope 1) GHG emissions	Appendix IV: 2025 Statistical Data Tables
305-2	Energy indirect (Scope 2) GHG emissions	Appendix IV: 2025 Statistical Data Tables
305-4	GHG emissions intensity	Appendix IV: 2025 Statistical Data Tables
305-5	Reduction of GHG emissions	Appendix IV: 2025 Statistical Data Tables
305-7	Nitrogen oxides (NO_x), sulfur oxides (SO_x), and other significant air emissions	Appendix IV: 2025 Statistical Data Tables
GRI 306: Waste 2020		
306-1	Waste generation and significant waste-related impacts	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
306-2	Management of significant waste – related impacts	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
306-3	Waste generated	5 Embracing Ecology: 5.3 Resource Conservation and Emission Reduction
GRI 308: Supplier Environmental Assessment in 2016		
308-1	New suppliers that were screened using environmental criteria	3 High Quality As Key: 3.5 Supply Chain Management
308-2	Negative environmental impacts in the supply chain and actions taken	3 High Quality As Key: 3.5 Supply Chain Management

GRI Standard	Disclosure	Location
Social		
GRI 401: Employment 2016		
401-1	New employee hires and employee turnover	Appendix IV: 2025 Statistical Data Tables
401-3	Parental leave	4 People First: 4.3 Employee Care
GRI 403: Occupational Health and Safety 2018		
403-1	Occupational health and safety management system	4 People First: 4.4 Occupational Health and Safety
403-2	Hazard identification, risk assessment, and incident investigation	4 People First: 4.4 Occupational Health and Safety
403-3	Occupational health services	4 People First: 4.4 Occupational Health and Safety
403-5	Worker training on occupational health and safety	4 People First: 4.4 Occupational Health and Safety
403-8	Workers covered by an occupational health and safety management system	4 People First: 4.4 Occupational Health and Safety
403-9	Work-related injuries	Appendix IV: 2025 Statistical Data Tables
403-10	Work-related health issues	Appendix IV: 2025 Statistical Data Tables
GRI 404: Training and Education 2016		
404-1	Average hours of training per year per employee	Appendix IV: 2025 Statistical Data Tables
404-2	Programs for upgrading employee skills and transition assistance programs	4 People First: 4.2 Employee Development
404-3	Percentage of employees receiving regular performance and career development reviews	4 People First: 4.2 Employee Development
GRI 405: Diversity and Equal Opportunity 2016		
405-1	Diversity of governance bodies and employees	4 People First: 4.1 Compliant Employment
GRI 406: Non-discrimination 2016		
406-1	Incidents of discrimination and corrective actions taken	4 People First: 4.1 Compliant Employment

GRI Standard	Disclosure	Location
GRI 408: Child Labor 2016		
408-1	Operations and suppliers at significant risk for incidents of child labor	These data are currently outside the scope of the Company's ESG data management. The Company will gradually expand the scope of data in the future and consider disclosing this information upon its inclusion.
GRI 409: Forced or Compulsory Labor 2016		
409-1	Operations and suppliers at significant risk for incidents of forced or compulsory labor	These data points are currently outside the scope of the Company's ESG data management. The Company will gradually expand the scope of data collection in the future and consider disclosing this information upon its inclusion.
GRI 413: Local Communities 2016		
413-1	Operations with local community engagement, impact assessments, and development programs	2 Enjoying Good Health: 2.1 Inclusive Healthcare
GRI 414: Supplier Social Assessment 2016		
414-1	New suppliers that were screened using social criteria	3 High Quality As Key: 3.5 Supply Chain Management
414-2	Negative social impacts in the supply chain and actions taken	3 High Quality As Key: 3.5 Supply Chain Management
GRI 416: Customer Health and Safety 2016		
416-1	Assessment of the health and safety impacts of product and service categories	3 High Quality As Key: 3.1 Product Quality and Safety
GRI 417: Marketing and Labelling 2016		
417-1	Requirements for product and service information and labeling	3 High Quality As Key: 3.4 Responsible Marketing
417-2	Incidents of non-compliance concerning product and service information and labeling	These data are currently outside the scope of the Company's ESG data management. The Company will gradually expand the scope of data in the future and consider disclosing this information upon its inclusion.
417-3	Incidents of non-compliance concerning marketing communications	
GRI 418: Customer Privacy 2016		
418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	1 Excellent Governance: 1.4 Customer Privacy Protection and Information Security

Appendix III: SASB Standard Index

Topic	Metric	Code	Chapter
Safety of Clinical Trial Participants	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	HC-BP-210a.1	3 High Quality As Key: 3.3 Clinical Research
	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	HC-BP-210a.2	/
	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	HC-BP-210a.3	
Access to Medicines	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	HC-BP-240a.1	2 Enjoying Good Health: 2.1 Inclusive Healthcare
	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	HC-BP-240a.2	/
Affordability & Pricing	Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	HC-BP-240b.2	/
	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	HC-BP-240b.3	
Drug Safety	Products listed in public medical product safety or adverse event alert databases	HC-BP-250a.1	3 High Quality As Key: 3.1 Product Quality and Safety
	Number of fatalities associated with products	HC-BP-250a.2	
	(1) Number of recalls issued, (2) total units recalled	HC-BP-250a.3	
	Total amount of product accepted for takeback, reuse, or disposal	HC-BP-250a.4	
	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	HC-BP-250a.5	3 High Quality As Key: 3.1 Product Quality and Safety

Topic	Metric	Code	Chapter
Counterfeit Drugs	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	HC-BP-260a.1	/
	Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	HC-BP-260a.2	
	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	HC-BP-260a.3	
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	HC-BP-270a.1	3 High Quality As Key: 3.4 Responsible Marketing
	Description of code of ethics governing promotion of off-label use of products	HC-BP-270a.2	
Employee Recruitment, Development and Retention	Discussion of talent recruitment and retention efforts for scientists and research and development staff	HC-BP-330a.1	4 People First: 4.1 Compliant Employment 4 People First: 4.2 Employee Development
	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	HC-BP-330a.2	Appendix IV: 2025 Statistical Data Tables
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit programme or equivalent third-party audit programmes for integrity of supply chain and ingredients	HC-BP-430a.1	3 High Quality As Key: 3.5 Supply Chain Management
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	HC-BP-510a.1	1. Excellent Governance: 1.2 Compliance Operations
	Description of code of ethics governing interactions with health care professionals	HC-BP-510a.2	3 High Quality As Key: 3.3 Clinical Research

Appendix IV: 2025 Statistical Data Tables

Environmental Data Statistics

Category	KPIs	Unit	2025
Greenhouse gases[9]	Scope 1: Direct GHG emissions	Tons of carbon dioxide equivalent	7,802.76
	Intensity of direct GHG emissions	Tons of carbon dioxide equivalent per million revenue	0.60
	Scope 2: Indirect GHG emissions	Tons of carbon dioxide equivalent	74,685.26
	Scope 3: Indirect GHG emissions	Tons of carbon dioxide equivalent	19,460.43
	Intensity of indirect GHG emissions	Tons of carbon dioxide equivalent per million revenue	7.22
	Total GHG emissions	Tons of carbon dioxide equivalent	101,948.45
	Intensity of total GHG emissions	Tons of carbon dioxide equivalent per million revenue	7.82
Waste	Total hazardous waste produced	Ton	545.29
	Intensity of hazardous waste produced	Ton/million revenue	0.04
	Total non-hazardous waste produced	Ton	529.00
	Intensity of non-hazardous waste produced	Ton/million revenue	0.04
Wastewater	Domestic wastewater discharged	m^3	69,800.00
	Industrial wastewater discharged[10]	m^3	308,984.00
COD	/	m^3	10.79

9 The calculation method is based on market position. The significant increase in related indicators compared to previous years is mainly attributable to the expansion of the reporting boundary in 2025 from previously covering only the Suzhou site to including the Hangzhou site and Shanghai R&D Center (including office areas). In addition, Scope 3 greenhouse gas emissions data have been newly included. Due to these changes in reporting boundary and disclosure scope, comparability with prior years is limited, and the variations do not fully reflect actual operational performance. The Company will continue to adopt this reporting boundary for future disclosure.

10 The significant increase in this indicator is mainly attributable to the expansion of the reporting boundary in 2025 from previously covering only the Suzhou site to including the Hangzhou site and Shanghai R&D Center (including office areas). Due to the boundary adjustment, comparability with prior years is limited, and the changes do not fully reflect actual operational performance. The Company will continue to adopt this reporting boundary going forward.

Environmental Data Statistics

Energy	Electricity	MWh	53.56
	Intensity of electricity consumption	MWh/million revenue	0.004
	Heat[11]	KJ	251,235,000,000.00
	Intensity of heat consumption	KJ/million revenue	19,264,237.77
	Natural Gas	0'000 standard m^3	2.95
	Intensity of natural gas consumption	0'000 standard m^3/million revenue	0.0002
	Comprehensive energy consumption	Tons of standard coal	15,196.86
	Energy consumption intensity	Tons of standard coal/million revenue	1.17
Water Consumption	Tap water	m^3	929,435.00
	Recycled water	m^3	51,100.00
	Intensity of water consumption	m^3/million revenue	71.27
Packaging Materials	Carton	Ton	123.75
	Small box	Ton	186.00
	Others	Ton	49.00
	Total	Ton	358.75
	Intensity	Ton/million revenue	0.03

11 The significant increase in this indicator is mainly attributable to the expansion of the reporting boundary in 2025 from previously covering only the Suzhou site to including the Hangzhou site and Shanghai R&D Center (including office areas). Due to the boundary adjustment, comparability with prior years is limited, and the changes do not fully reflect actual operational performance. The Company will continue to adopt this reporting boundary going forward.

Social Dimension Data Statistics

Category	KPIs	Unit	2025
Company workforce	Total number of employees	Person	7,502
Total number of employees/by gender	Male	Person	3,677
	Female	Person	3,825
Total number of employees/by employment type	Full-time employees	Person	7,502
	Part-time employees	Person	–
Total number of employees/by age	30 years old and below	Person	3,387
	31 to 49 years old	Person	4,046
	50 years old and above	Person	69
Total number of employees/by region	Suzhou	Person	1,833
	Beijing	Person	331
	Shanghai	Person	702
	Other regions	Person	4,636
Total number of employees/by rank	Senior management (Executive Director and above)	Person	71
	Female in senior management	Person	25
	Middle Management	Person	270
	Junior Management	Person	745
	General staff	Person	6,416
Total Number of Employees/By ethnicity	Ethnic minorities employees	Person	321
Average service years of employees/ by gender	Male	Year	15
	Female	Year	14
Total number of new hires/by gender	Male	Person	1,350
	Female	Person	1,368
Total number of new hires/by age	30 years old and below	Person	1,432
	31 to 49 years old	Person	1,267
	50 years of age and above	Person	19

Social Dimension Data Statistics			
Total number of new hires/by region	Suzhou	Person	325
	Beijing	Person	153
	Shanghai	Person	320
	Others (including America and Europe)	Person	1,920
Total number of new hires/by employment type	Full-time employees	Person	2,718
	Part-time employees	Person	–
Total number of new hires/by rank	Senior Management Senior management (Executive Director and above)	Person	14
	Middle Management	Person	62
	Junior Management	Person	185
	General staff	Person	2,457
Number of employee Voluntary turnover/by gender	Male	Person	411
	Female	Person	464
Number of employee Voluntary turnover/by age	30 years old and below	Person	445
	31 to 49 years old	Person	425
	50 years of age and above	Person	5
Number of employee Voluntary turnover/by region	Suzhou	Person	147
	Beijing	Person	55
	Shanghai	Person	87
	Others (including America and Europe)	Person	586
Employee turnover rate	Employee turnover rate (Executive Director and above)	%	13.3
Employee turnover rate/by gender	Male	%	12.74
	Female	%	13.83
Employee turnover rate/by age	30 years old and below	%	14.72
	31 to 49 years old	%	12.15
	50 years old and above	%	8.33
Employee turnover rate/by region	Suzhou	%	8.39
	Beijing	%	19.68
	Shanghai	%	14.97
	Others (including America and Europe)	%	14.77

Social Dimension Data Statistics			
Work injury and work-related deaths	Number of work-related fatalities of employees (from 2023 to 2025)	Person	0
	Rate of work-related fatalities of employees	%	0
	Lost days due to work injury	Day(s)	1
	Number of work-related fatalities of suppliers and contractors	Person	0
	Rate of work-related fatalities of suppliers and contractors	%	0
Employee training percentage/by gender	Male	%	100%
	Female	%	100%
Employee training percentage/by rank	Senior management (Executive Director and above)	%	100%
	Middle management	%	100%
	Junior management	%	100%
	General staff	%	100%
Average hours of employee training/by gender	Male	Hour	43.03
	Female	Hour	41.69
Average hours of employee training/by rank	Senior management (Executive Director and above)	Hour	26.97
	Middle management	Hour	28.19
	Junior management	Hour	37.93
	General staff	Hour	43.63
Number of supplier by region	Eastern China	Unit	743
	Southern China	Unit	34
	Central China	Unit	14
	Northern China	Unit	101
	Northwestern China	Unit	4
	Northeastern China	Unit	3
	Southwestern China	Unit	14
	Outside Mainland China (including Hong Kong, Macau and Taiwan)	Unit	69

Social Dimension Data Statistics			
Number of supplier by type	Materials	Unit	222
	Fixed assets	Unit	345
	Engineering	Unit	138
	R&D	Unit	129
	Clinical	Unit	89
	Ordinary	Unit	241
Customer Complaints	Product and service complaints	Case	1,280
	Safety and health-related recalls percentage	%	0
Anti-Corruption	Number of corruption cases brought against the Company or its employees	Case	0
	Anti-corruption training	Time	189
	Number of anti-corruption training participants	Person-times	8,236
	Participation rate in anti-corruption training	%	100
Number of patent, trademark, copyright and domain name applications in 2025	Number of patent applications domestically	Unit	49
	Number of trademark applications domestically	Unit	111
	Number of copyright applications domestically	Unit	24
	Number of domain name applications domestically	Unit	12
	Number of patent applications internationally	Unit	85
	Number of trademark applications internationally	Unit	43
Number of patents, trademarks, copyrights and domain names approved in 2025	Number of patents granted	Unit	29
	Number of trademarks registered	Unit	121
	Number of copyrights registered	Unit	23
	Number of domain names registered	Unit	12

Social Dimension Data Statistics			
Cumulative number of patent and trademark applications	Number of patent applications domestically	Unit	498
	Number of trademark applications domestically	Unit	1,263
	Number of patent applications internationally	Unit	981
	Number of trademark applications internationally	Unit	188
Cumulative number of copyright registrations	Number of copyright registrations domestically	Unit	54
Cumulative number of patents and trademarks approved	Number of patents granted	Unit	270
	Number of trademarks registered	Unit	1,113
Social welfare	Capital investment of public welfare[12]	RMB 1 million	150
	Time investment of public welfare	Hour	2,120
	Number of volunteers	Person	312

12 The data presented herein represent the Company's charitable donation amount for 2025, calculated in accordance with the methodology used in the Annual Report of the Company dated 28 April 2026. The drug donation amount disclosed in this Report has not been included within the scope of this indicator due to differences in statistical methodology.

Appendix V: External Assurance Report

Your partner in progress

Verification Opinion

Verified as Satisfactory	
Based on the process and procedures conducted, the GHG statement contained in "Greenhouse Gas Emissions in 2025" produced by Innovent Biopharmaceutical Group	• is materially correct and is a fair representation of GHG data and information. • has been prepared in accordance with ISO 14064-1:2018 and its principles.
With the following caveats	The GHG inventory is limited to direct emissions, indirect emissions from imported electricity, indirect GHG emissions from transportation (upstream transportation, downstream transportation, employee commuting and business travel) and indirect GHG emissions from products used by organization. The GHG accounting is done based on the customer defined template and emission factors. GHG reporting for Scope 2 is done applying Location based approaches as per client (Innovent Biopharmaceutical Group) requirement.
Lead Verifier	Jennifer Cai
Independent Reviewer	Bell Deng
Signed on behalf of BSI	Matt Page, Senior Vice President, Assurance Services EMEA 
Issue Date	13 April 2026
BSI Assurance UK Ltd., Kitemark Court, Davy Avenue, Milton Keynes, MK5 8PP, UK	
NOTE: BSI Assurance UK Ltd. is independent to and has no financial interest in Innovent Biopharmaceutical Group. This 3rd party Verification Opinion has been prepared for Innovent Biopharmaceutical Group only for the purposes of verifying its statement relating to its GHG emissions more particularly described in the scope above. It was not prepared for any other purpose. In making this Statement, BSI Assurance UK Ltd. has assumed that all information provided to it by Innovent Biopharmaceutical Group is true, accurate and complete. BSI Assurance UK Ltd. accepts no liability to any third party who places reliance on this statement.	

CFV 844296

UKAS VALIDATION & VERIFICATION
0003

Information and Contact:
BSI Management Systems Certification (Beijing) Co., Ltd.
Rm. 2008, East Ocean Center, No. 24A, Jianguomenwai Street, Beijing, 100004, P.R. China Tel: +86 10 85073000
A Member of the BSI Group of Companies.

Page: 1 of 6

Your partner in progress

Verification Opinion

Verification Engagement

Organization	Innovent Biopharmaceutical Group
Responsible party	Innovent Biopharmaceutical Group
Verification Objectives	To express an opinion on whether the organizational GHG Statement which is historical in nature: • Is accurate, materially correct and is a fair representation of GHG data and information • Has been prepared in accordance with ISO 14064-1:2018, the criteria used by BSI to verify the GHG Organizational Statement
Materiality Level	5%
Level of Assurance	Reasonable
Verification evidence gathering procedures	• Evaluation of the monitoring and controls systems through interviewing employees, observation & inquiry • Verification of the data through sampling recalculation, retracing, cross checking and reconciliation
The verification activities applied in a limited level of assurance verification are less extensive in nature, timing and extent than in a reasonable level of assurance verification.	
Verification Standards	The verification was carried out in accordance with ISO 14064-3:2019, ISO 14065:2020 and ISO 17029:2019
Note: Innovent Biopharmaceutical Group is responsible for the preparation and fair presentation of the GHG statement and report in accordance with the agreed criteria. BSI is responsible for expressing an opinion on the GHG statement based on the verification.	

Information and Contact:
BSI Management Systems Certification (Beijing) Co., Ltd.
Rm. 2008, East Ocean Center, No. 24A, Jianguomenwai Street, Beijing, 100004, P.R. China Tel: +86 10 85073000
A Member of the BSI Group of Companies.

Your partner in progress

Verification Opinion

Organizational GHG Statement

Organization		Innovent Biopharmaceutical Group
Organizations GHG Report containing GHG Statement		Innovent Biopharmaceutical Group "Greenhouse Gas Emissions in 2025"
Organizational Boundary		Operational Control
Locations included in the Organizational Boundary		No. 168, Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, China, 215123 No. 288, Shunfeng Road, Linping District, Hangzhou City, Zhejiang Province, China, 311100 No. 999, Jinguang Road, Minhang District, Shanghai City, China, 201100
Scope of activities:		Research, development, and production of antibody-based and protein-based drugs, pharmaceuticals, and biopharmaceutical products.
Reporting Boundary	Direct GHG Emissions (Scope 1)	Greenhouse gas emissions from fossil fuels (NPG, diesel, gasoline), Refrigerant leakage, Septic tank methane (CH_4) leakage, Sulphur hexafluoride (SF_6) leakage, carbon dioxide (CO_2) & HFC-227 fire extinguisher
	Indirect GHG Emissions from imported energy (Scope 2)	Purchased electricity, Steam
	Indirect GHG emissions from transportation (Scope 3)	Upstream and downstream transportation, Employee commuting, Business travel
	Indirect GHG emissions from products used by organization (Scope 3)	Purchased material, tap water, upstream of energy products, wastes disposal
	Indirect GHG emissions associated with the use of products from the organization (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
	Indirect GHG emissions from other sources (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
Criteria for developing the organizational GHG Inventory:		ISO 14064-1:2018
Reporting Period		Year 2025 (1-Jan-25 to 31-Dec-25)

2025	$tCO_2(e)$
Direct Emissions (Scope 1) non biomass	7,802.76
Direct Emissions (Scope 1) biomass	0
Removals	0
Indirect Emissions from Imported Energy (Scope 2) - Location Based	74,685.26
Indirect Emissions from Imported Energy (Scope 2) - Market Based	NA
Indirect GHG Emissions from transportation (Scope 3)	5,562.96
Indirect GHG Emissions from products used by organization (Scope 3)	13,897.46
Total (Location Based)	**101,948.45**
Total (Market Based)	**NA**

Information and Contact:
BSI Management Systems Certification (Beijing) Co., Ltd.
Rm. 2008, East Ocean Center, No. 24A, Jianguomenwai Street, Beijing, 100004, P.R. China Tel: +86 10 85073000
A Member of the BSI Group of Companies.

Your partner in progress

Verification Opinion

Organizational GHG Statement

Organization		Innovent Biologics (Suzhou) Co., Ltd.
Organizations GHG Report containing GHG Statement		Innovent Biopharmaceutical Group "Greenhouse Gas Emissions in 2025"
Organizational Boundary		Operational Control
Locations included in the Organizational Boundary		No. 168, Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, China, 215123
Scope of activities:		Research, development, and production of antibody and protein-based drugs, pharmaceuticals, and biopharmaceutical products.
Reporting Boundary	Direct GHG Emissions (Scope 1)	Greenhouse gas emissions from fossil fuels (NPG, diesel, gasoline), Refrigerant leakage, Septic tank methane (CH_4) leakage, Sulphur hexafluoride (SF_6) leakage, carbon dioxide (CO_2) & HFC-227 fire extinguisher
	Indirect GHG Emissions from imported energy (Scope 2)	Purchased electricity, Steam
	Indirect GHG emissions from transportation (Scope 3)	Upstream and downstream transportation, Employee commuting, Business travel
	Indirect GHG emissions from products used by organization (Scope 3)	Purchased materials, tap water, upstream of energy products, wastes disposal
	Indirect GHG emissions associated with the use of products from the organization (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
	Indirect GHG emissions from other sources (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
Criteria for developing the organizational GHG Inventory:		ISO 14064-1:2018
Reporting Period		Year 2025 (1-Jan-25 to 31-Dec-25)

2025	$tCO_2(e)$
Direct Emissions (Scope 1) non biomass	4,911.96
Direct Emissions (Scope 1) biomass	0
Removals	0
Indirect Emissions from Imported Energy (Scope 2) - Location Based	46,199.16
Indirect Emissions from Imported Energy (Scope 2) - Market Based	NA
Indirect GHG Emissions from transportation (Scope 3)	5,519.02
Indirect GHG Emissions from products used by organization (Scope 3)	9,072.32
Total (Location Based)	**65,702.44**
Total (Market Based)	**NA**

Information and Contact:
BSI Management Systems Certification (Beijing) Co., Ltd.
Rm. 2008, East Ocean Center, No. 24A, Jianguomenwai Street, Beijing, 100004, P.R. China Tel: +86 10 85073000
A Member of the BSI Group of Companies.

bsi Your partner in progress

Verification Opinion

Organizational GHG Statement

Organization		Altruist Biotechnology (Hangzhou) Co., Ltd.
Organizations GHG Report containing GHG Statement		Innovent Biopharmaceutical Group "Greenhouse Gas Emissions in 2025"
Organizational Boundary		Operational Control
Locations included in the Organizational Boundary		No. 288, Shunfeng Road, Linping District, Hangzhou City, Zhejiang Province, China, 311100
Scope of activities:		Pharmaceutical production; drug clinical trial services.
Reporting Boundary	Direct GHG Emissions (Scope 1)	Greenhouse gas emissions from diesel, Refrigerant leakage, Septic tank methane (CH_4) leakage, Sulphur hexafluoride (SF_6) leakage, HFC-227 fire extinguisher leakage
	Indirect GHG Emissions from imported energy (Scope 2)	Purchased electricity
	Indirect GHG emissions from transportation (Scope 3)	Downstream transportation, Employee commuting
	Indirect GHG emissions from products used by organization (Scope 3)	Tap water, upstream of energy products, wastes disposal
	Indirect GHG emissions associated with the use of products from the organization (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
	Indirect GHG emissions from other sources (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
Criteria for developing the organizational GHG Inventory:		ISO 14064-1:2018
Reporting Period		Year 2025 (1-Jan-25 to 31-Dec-25)

2025	$tCO_2(e)$
Direct Emissions (Scope 1) non biomass	2,307.88
Direct Emissions (Scope 1) biomass	0
Removals	0
Indirect Emissions from Imported Energy (Scope 2) - Location Based	26,586.07
Indirect Emissions from Imported Energy (Scope 2) - Market Based	NA
Indirect GHG Emissions from transportation (Scope 3)	34.37
Indirect GHG Emissions from products used by organization (Scope 3)	4,562.29
Total (Location Based)	**33,490.62**
Total (Market Based)	**NA**

Information and Contact:
BSI Management Systems Certification (Beijing) Co., Ltd.
Rm. 2008, East Ocean Center, No. 24A, Jianguomenwai Street, Beijing, 100004, P.R. China Tel: +86 10 85073000
A Member of the BSI Group of Companies.

Your partner in progress

Verification Opinion

Organizational GHG Statement

Organization		Innovent Biology Technology Co., Ltd.
Organizations GHG Report containing GHG Statement		Innovent Biopharmaceutical Group "Greenhouse Gas Emissions in 2025"
Organizational Boundary		Operational Control
Locations included in the Organizational Boundary		No. 999, Jinguang Road, Minhang District, Shanghai City, China, 211100
Scope of activities:		Research, and production of antibody and protein-based drugs, pharmaceuticals, and biopharmaceutical products; drug clinical trial services.
Reporting Boundary	Direct GHG Emissions (Scope 1)	Greenhouse gas emissions from NPG, diesel, Refrigerant leakage, Septic tank methane (CH_4) leakage, Sulphur hexafluoride (SF_6) leakage, CO_2 & HFC-227 fire extinguisher leakage
	Indirect GHG Emissions from imported energy (Scope 2)	Purchased electricity
	Indirect GHG emissions from transportation (Scope 3)	Downstream transportation, Employee commuting
	Indirect GHG emissions from products used by organization (Scope 3)	Tap water, upstream of energy products, wastes disposal
	Indirect GHG emissions associated with the use of products from the organization (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
	Indirect GHG emissions from other sources (Scope 3)	Not quantified as the non-significant indirect emissions according to the significance criteria of indirect emission
Criteria for developing the organizational GHG Inventory:		ISO 14064-1:2018
Reporting Period		Year 2025 (1-Jan-25 to 31-Dec-25)

2025	$tCO_2(e)$
Direct Emissions (Scope 1) non biomass	582.93
Direct Emissions (Scope 1) biomass	0
Removals	0
Indirect Emissions from Imported Energy (Scope 2) - Location Based	1,900.03
Indirect Emissions from Imported Energy (Scope 2) - Market Based	NA
Indirect GHG Emissions from transportation (Scope 3)	9.58
Indirect GHG Emissions from products used by organization (Scope 3)	262.85
Total (Location Based)	**2,755.38**
Total (Market Based)	**NA**

Information and Contact:
BSI Management Systems Certification (Beijing) Co., Ltd.
Rm. 2008, East Ocean Center, No. 24A, Jianguomenwai Street, Beijing, 100004, P.R. China Tel: +86 10 85073000
A Member of the BSI Group of Companies.

Innovent
信达生物制药

Innovent Biologics Group
Address: 168 Dongping Street, Industrial Park,
Suzhou, Jiangsu Province